EP0823941A4 - Human antibodies derived from immunized xenomice - Google Patents
Human antibodies derived from immunized xenomiceInfo
- Publication number
- EP0823941A4 EP0823941A4 EP95918935A EP95918935A EP0823941A4 EP 0823941 A4 EP0823941 A4 EP 0823941A4 EP 95918935 A EP95918935 A EP 95918935A EP 95918935 A EP95918935 A EP 95918935A EP 0823941 A4 EP0823941 A4 EP 0823941A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- human antibodies
- antibodies derived
- immunized xenomice
- xenomice
- immunized
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2812—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
- C07K16/1282—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Clostridium (G)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
- C07K16/2854—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72 against selectins, e.g. CD62
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
- C07K16/4283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
- C07K16/4291—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig against IgE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002219486A CA2219486A1 (en) | 1995-04-28 | 1995-04-28 | Human antibodies derived from immunized xenomice |
PCT/US1995/005500 WO1996034096A1 (en) | 1995-04-28 | 1995-04-28 | Human antibodies derived from immunized xenomice |
Publications (2)
Publication Number | Publication Date |
---|---|
EP0823941A1 EP0823941A1 (en) | 1998-02-18 |
EP0823941A4 true EP0823941A4 (en) | 2001-09-19 |
Family
ID=25679770
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP95918935A Withdrawn EP0823941A4 (en) | 1995-04-28 | 1995-04-28 | Human antibodies derived from immunized xenomice |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP0823941A4 (en) |
AU (1) | AU2466895A (en) |
CA (1) | CA2219486A1 (en) |
WO (1) | WO1996034096A1 (en) |
Families Citing this family (1456)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US6713610B1 (en) | 1990-01-12 | 2004-03-30 | Raju Kucherlapati | Human antibodies derived from immunized xenomice |
US7041871B1 (en) | 1995-10-10 | 2006-05-09 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US6300129B1 (en) * | 1990-08-29 | 2001-10-09 | Genpharm International | Transgenic non-human animals for producing heterologous antibodies |
US5770429A (en) * | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US7084260B1 (en) | 1996-10-10 | 2006-08-01 | Genpharm International, Inc. | High affinity human antibodies and human antibodies against human antigens |
US5795966A (en) † | 1995-02-22 | 1998-08-18 | Immunex Corp | Antagonists of interleukin-15 |
US7888466B2 (en) | 1996-01-11 | 2011-02-15 | Human Genome Sciences, Inc. | Human G-protein chemokine receptor HSATU68 |
US7964190B2 (en) | 1996-03-22 | 2011-06-21 | Human Genome Sciences, Inc. | Methods and compositions for decreasing T-cell activity |
US6635743B1 (en) | 1996-03-22 | 2003-10-21 | Human Genome Sciences, Inc. | Apoptosis inducing molecule II and methods of use |
AU2405297A (en) | 1996-04-23 | 1997-11-12 | Chugai Seiyaku Kabushiki Kaisha | Cerebral stroke/cerebral edema preventive or remedy containing il-8 binding inhibitor as active ingredient |
WO1998006431A2 (en) * | 1996-08-16 | 1998-02-19 | Osther Kurt B | Method for treating diabetes |
CA2722378C (en) | 1996-12-03 | 2015-02-03 | Amgen Fremont Inc. | Human antibodies that bind tnf.alpha. |
AU2008200005B2 (en) * | 1996-12-03 | 2012-05-17 | Amgen Fremont Inc. | Transgenic Mammals Having Human Ig Loci Including Plural Vh and Vk Regions and Antibodies Produced Therefrom |
ES2382488T3 (en) | 1997-03-21 | 2012-06-08 | Chugai Seiyaku Kabushiki Kaisha | A preventive or therapeutic agent for diseases mediated by sensitized t cells comprising an il-6 antagonist as an active ingredient |
US20020173629A1 (en) | 1997-05-05 | 2002-11-21 | Aya Jakobovits | Human monoclonal antibodies to epidermal growth factor receptor |
US6235883B1 (en) * | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
DK1004315T3 (en) | 1997-08-15 | 2008-07-21 | Chugai Pharmaceutical Co Ltd | Preventants and / or drugs containing anti-IL6 receptor neutralizing antibodies to reduce urinary protein excretion by systemic lupus erythematosus |
EP1895001B1 (en) | 1998-11-04 | 2011-08-03 | Chugai Seiyaku Kabushiki Kaisha | Novel trypsin family serine proteases |
ATE305506T1 (en) * | 1998-12-09 | 2005-10-15 | Protein Design Labs Inc | USE OF IL-12 ANTIBODIES TO TREAT PSORIASIS |
EE05627B1 (en) | 1998-12-23 | 2013-02-15 | Pfizer Inc. | Human monoclonal antibodies to CTLA-4 |
KR100849443B1 (en) | 1998-12-23 | 2008-07-31 | 화이자 인크. | Human monoclonal antibodies to ctla-4 |
US7109003B2 (en) | 1998-12-23 | 2006-09-19 | Abgenix, Inc. | Methods for expressing and recovering human monoclonal antibodies to CTLA-4 |
EP1161451A4 (en) | 1999-02-26 | 2006-05-17 | Human Genome Sciences Inc | Human endokine alpha and methods of use |
US6914128B1 (en) | 1999-03-25 | 2005-07-05 | Abbott Gmbh & Co. Kg | Human antibodies that bind human IL-12 and methods for producing |
WO2000061744A1 (en) | 1999-04-09 | 2000-10-19 | Chugai Research Institute For Molecular Medicine, Inc. | Novel fetal genes |
EP1642596A3 (en) | 1999-05-07 | 2006-04-12 | Genentech, Inc. | Treatment of autoimmune diseases with antagonists which bind to B cell surface markers |
EE200100651A (en) | 1999-06-01 | 2003-02-17 | Biogen, Inc. | VLA-1 blocking monoclonal antibody and its use in the treatment of inflammation |
WO2000075314A1 (en) | 1999-06-02 | 2000-12-14 | Chugai Research Institute For Molecular Medicine, Inc. | Novel hemopoietin receptor protein nr10 |
US6833268B1 (en) | 1999-06-10 | 2004-12-21 | Abgenix, Inc. | Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions |
ES2277846T3 (en) * | 1999-07-29 | 2007-08-01 | Medarex, Inc. | HUMAN MONOCLONAL ANTIBODIES FOR SPECIFIC PROSTATIC ANTIGEN. |
WO2001013940A1 (en) | 1999-08-23 | 2001-03-01 | Chugai Seiyaku Kabushiki Kaisha | Hm1.24 antigen expression potentiators |
EP1212422B1 (en) * | 1999-08-24 | 2007-02-21 | Medarex, Inc. | Human ctla-4 antibodies and their uses |
AU6871900A (en) | 1999-09-06 | 2001-04-10 | Chugai Seiyaku Kabushiki Kaisha | Tsg-like gene |
WO2001021792A1 (en) | 1999-09-21 | 2001-03-29 | Chugai Seiyaku Kabushiki Kaisha | Transporter genes oatp-b, c, d and e |
MXPA02003278A (en) | 1999-10-01 | 2002-09-02 | Chugai Pharmaceutical Co Ltd | Prevention and treatment of diseases associated with blood coagulation. |
WO2001053484A1 (en) | 2000-01-24 | 2001-07-26 | Haruo Sugiyama | Wt1-interacting protein wtip |
KR20110032012A (en) | 2000-02-10 | 2011-03-29 | 아보트 러보러터리즈 | Antibodies that bind human interleukin-18 and methods of making and using |
US6653448B1 (en) | 2000-03-29 | 2003-11-25 | Curagen Corporation | Wnt-7B-like polypeptides and nucleic acids encoding same |
GB0006398D0 (en) * | 2000-03-16 | 2000-05-03 | Novartis Ag | Organic compounds |
CA2747325A1 (en) | 2000-04-12 | 2001-10-25 | Human Genome Sciences, Inc. | Albumin fusion proteins |
WO2001083755A2 (en) * | 2000-04-28 | 2001-11-08 | La Jolla Institute For Allergy And Immunology | Human anti-cd40 antibodies and methods of making and using same |
US7063845B2 (en) | 2000-04-28 | 2006-06-20 | Gemini Science, Inc. | Human anti-CD40 antibodies |
AU2001272925A1 (en) * | 2000-05-26 | 2001-12-11 | Immunex Corporation | Use of interleukin-4 antagonists and compositions thereof |
US20030031675A1 (en) | 2000-06-06 | 2003-02-13 | Mikesell Glen E. | B7-related nucleic acids and polypeptides useful for immunomodulation |
CA2413160A1 (en) | 2000-06-15 | 2001-12-20 | Human Genome Sciences, Inc. | Human tumor necrosis factor delta and epsilon |
CA2407910C (en) | 2000-06-16 | 2013-03-12 | Steven M. Ruben | Antibodies that immunospecifically bind to blys |
PE20020132A1 (en) | 2000-06-29 | 2002-03-04 | Abbott Lab | DOUBLE SPECIFICITY ANTIBODIES AND METHODS FOR THE PREPARATION AND USE THEREOF |
US7288390B2 (en) | 2000-08-07 | 2007-10-30 | Centocor, Inc. | Anti-dual integrin antibodies, compositions, methods and uses |
US6902734B2 (en) | 2000-08-07 | 2005-06-07 | Centocor, Inc. | Anti-IL-12 antibodies and compositions thereof |
UA81743C2 (en) | 2000-08-07 | 2008-02-11 | Центокор, Инк. | HUMAN MONOCLONAL ANTIBODY WHICH SPECIFICALLY BINDS TUMOR NECROSIS FACTOR ALFA (TNFα), PHARMACEUTICAL MIXTURE CONTAINING THEREOF, AND METHOD FOR TREATING ARTHRITIS |
EP1326896B1 (en) | 2000-10-02 | 2010-11-24 | Novartis Vaccines and Diagnostics, Inc. | Human anti-cd40 antibodies |
EP2412384A1 (en) | 2000-11-28 | 2012-02-01 | MedImmune, LLC | Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment |
ES2727425T3 (en) | 2000-12-12 | 2019-10-16 | Medimmune Llc | Molecules with prolonged half-lives, compositions and uses thereof |
AR032028A1 (en) | 2001-01-05 | 2003-10-22 | Pfizer | ANTIBODIES AGAINST THE RECEIVER OF THE SIMILAR TO INSULIN GROWTH FACTOR |
JP2005510201A (en) * | 2001-01-26 | 2005-04-21 | アブジェニックス インコーポレイテッド | Neutralizing human monoclonal antibodies against HIV-1, their production and use |
EP1364657B1 (en) | 2001-02-07 | 2016-12-28 | Chugai Seiyaku Kabushiki Kaisha | Remedies for myelocytic leukemia |
CN1564826A (en) | 2001-02-09 | 2005-01-12 | 人类基因组科学公司 | Human G-protein chemokine receptor (CCR5) HDGNR10 |
US7087726B2 (en) * | 2001-02-22 | 2006-08-08 | Genentech, Inc. | Anti-interferon-α antibodies |
US8981061B2 (en) | 2001-03-20 | 2015-03-17 | Novo Nordisk A/S | Receptor TREM (triggering receptor expressed on myeloid cells) and uses thereof |
JP2005508608A (en) | 2001-03-22 | 2005-04-07 | アボット ゲーエムベーハー ウント カンパニー カーゲー | Transgenic animals expressing antibodies specific to the gene of interest and uses thereof |
UA80091C2 (en) | 2001-04-02 | 2007-08-27 | Chugai Pharmaceutical Co Ltd | Remedies for infant chronic arthritis-relating diseases and still's disease which contain an interleukin-6 (il-6) antagonist |
WO2002081641A2 (en) | 2001-04-06 | 2002-10-17 | Georgetown University | Gene scc-112 and diagnostic and therapeutic uses thereof |
AU2002303261A1 (en) | 2001-04-06 | 2002-10-21 | Georgetown University | Gene brcc2 and diagnostic and therapeutic uses thereof |
AU2002258728A1 (en) | 2001-04-06 | 2002-10-21 | Georgetown University | Gene brcc-3 and diagnostic and therapeutic uses thereof |
JP2004536579A (en) | 2001-04-13 | 2004-12-09 | ヒューマン ジノーム サイエンシーズ, インコーポレイテッド | Vascular endothelial growth factor 2 |
CN1561345B (en) | 2001-04-13 | 2011-09-14 | 比奥根艾迪克Ma公司 | Antibodies to VLA-1 |
EP2009027B1 (en) | 2001-04-27 | 2014-05-21 | Kyowa Hakko Kirin Co., Ltd. | Anti-CD40 monoclonal antibody |
EP1463522A4 (en) | 2001-05-16 | 2005-04-13 | Einstein Coll Med | Human antipneumococcal antibodies from non-human animals |
US7064189B2 (en) | 2001-05-25 | 2006-06-20 | Human Genome Sciences, Inc. | Antibodies that immunospecifically bind to trail receptors |
US7247304B2 (en) | 2001-08-23 | 2007-07-24 | Genmab A/S | Methods of treating using anti-IL-15 antibodies |
NZ531211A (en) | 2001-08-23 | 2007-04-27 | Genmad As | Human antibodies specific for interleukin 15 (IL-15) |
US7329405B2 (en) | 2001-08-23 | 2008-02-12 | Genmab A/S | Human antibodies specific for interleukin 15 (IL-15) |
US7981863B2 (en) | 2001-09-19 | 2011-07-19 | Neuronova Ab | Treatment of Parkinson's disease with PDGF |
WO2003029296A1 (en) * | 2001-10-02 | 2003-04-10 | Chiron Corporation | Human anti-cd40 antibodies |
AR039067A1 (en) | 2001-11-09 | 2005-02-09 | Pfizer Prod Inc | ANTIBODIES FOR CD40 |
EP1461442B1 (en) | 2001-11-30 | 2017-09-06 | Amgen Fremont Inc. | Transgenic animals bearing human ig lambda light chain genes |
EP1463751B1 (en) | 2001-12-21 | 2013-05-22 | Human Genome Sciences, Inc. | Albumin fusion proteins |
EP3192528A1 (en) | 2002-02-14 | 2017-07-19 | Chugai Seiyaku Kabushiki Kaisha | Formulation of anti-il6r antibody-containing solutions comprising a sugar as a stabilizer |
EP1527100B1 (en) | 2002-03-29 | 2009-07-01 | Schering Corporation | Human monoclonal antibodies to interleukin-5 and methods and compositions comprising same |
JPWO2003083116A1 (en) | 2002-03-29 | 2005-08-04 | 中外製薬株式会社 | Transporter inhibitor screening method |
US7244565B2 (en) | 2002-04-10 | 2007-07-17 | Georgetown University | Gene shinc-3 and diagnostic and therapeutic uses thereof |
US7452535B2 (en) | 2002-04-12 | 2008-11-18 | Medarex, Inc. | Methods of treatment using CTLA-4 antibodies |
EP1499352A4 (en) | 2002-04-12 | 2006-10-11 | Medimmune Inc | Recombinant anti-interleukin-9 antibodies |
CA2429483A1 (en) | 2002-05-17 | 2003-11-17 | Amrad Operations Pty Ltd. | Immunointeractive molecules |
SG145559A1 (en) | 2002-06-06 | 2008-09-29 | Oncotherapy Science Inc | Genes and polypeptides relating to human colon cancers |
ES2361541T3 (en) | 2002-06-06 | 2011-06-17 | Oncotherapy Science, Inc. | GENES AND POLYPEPTIDES RELATED TO HUMAN COLON CANCER. |
US7563882B2 (en) | 2002-06-10 | 2009-07-21 | University Of Rochester | Polynucleotides encoding antibodies that bind to the C35 polypeptide |
US7425618B2 (en) | 2002-06-14 | 2008-09-16 | Medimmune, Inc. | Stabilized anti-respiratory syncytial virus (RSV) antibody formulations |
BR0312738A (en) | 2002-07-15 | 2007-06-26 | Wyeth Corp | processes and compositions for modulating helper t cell development and function (th) |
US7425620B2 (en) | 2002-08-14 | 2008-09-16 | Scott Koenig | FcγRIIB-specific antibodies and methods of use thereof |
JP4489591B2 (en) | 2002-08-27 | 2010-06-23 | 中外製薬株式会社 | Method for stabilizing protein solution formulations |
AU2003267124A1 (en) | 2002-09-09 | 2004-03-29 | Dana-Farber Cancer Institute, Inc. | Bh3 peptides and method of use thereof |
SI1561756T1 (en) | 2002-09-11 | 2016-02-29 | Chugai Seiyaku Kabushiki Kaisha | Method of purifying protein |
TW200413725A (en) | 2002-09-30 | 2004-08-01 | Oncotherapy Science Inc | Method for diagnosing non-small cell lung cancers |
TW200418988A (en) | 2002-09-30 | 2004-10-01 | Oncotherapy Science Inc | Method for diagnosing prostate cancer |
EP1795595A1 (en) | 2002-10-22 | 2007-06-13 | Eisai R&D Management Co., Ltd. | Gene specifically expressed in postmitotic dopaminergic neuron precursor cells |
AU2003280643A1 (en) | 2002-10-30 | 2004-05-25 | Chugai Seiyaku Kabushiki Kaisha | Membrane protein originating in mast cells |
CA2505325C (en) | 2002-11-08 | 2014-02-25 | Ablynx N.V. | Stabilized single domain antibodies |
US9320792B2 (en) | 2002-11-08 | 2016-04-26 | Ablynx N.V. | Pulmonary administration of immunoglobulin single variable domains and constructs thereof |
US20060034845A1 (en) | 2002-11-08 | 2006-02-16 | Karen Silence | Single domain antibodies directed against tumor necrosis factor alpha and uses therefor |
JP4727992B2 (en) | 2002-11-15 | 2011-07-20 | ノバルティス バクシンズ アンド ダイアグノスティックス,インコーポレーテッド | Methods for preventing and treating cancer metastasis and bone loss associated with cancer metastasis |
JP2007531505A (en) | 2002-11-27 | 2007-11-08 | ミネルバ バイオオテクノロジーズ コーポレーション | Techniques and compositions for diagnosis and treatment of cancer (MUC1) |
JP4754219B2 (en) | 2002-12-02 | 2011-08-24 | アムジエン・フレモント・インコーポレイテツド | Antibodies directed against tumor necrosis factor and their use |
ATE490323T1 (en) | 2002-12-29 | 2010-12-15 | Toudai Tlo Ltd | ADIPONECTIN RECEPTOR AND GENE CODING IT |
EP2368578A1 (en) | 2003-01-09 | 2011-09-28 | Macrogenics, Inc. | Identification and engineering of antibodies with variant Fc regions and methods of using same |
DE10303974A1 (en) | 2003-01-31 | 2004-08-05 | Abbott Gmbh & Co. Kg | Amyloid β (1-42) oligomers, process for their preparation and their use |
EP2241330A1 (en) | 2003-02-14 | 2010-10-20 | The Curators Of The University Of Missouri | Contraceptive methods and compositions related to proteasomal interference |
WO2004073656A2 (en) | 2003-02-20 | 2004-09-02 | Seattle Genetics, Inc. | Anti-cd70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders |
ES2537015T3 (en) | 2003-03-19 | 2015-06-01 | Biogen Ma Inc. | NOGO receptor binding protein |
JP2007525434A (en) | 2003-03-19 | 2007-09-06 | アブジェニックス インコーポレイテッド | Antibodies to T cells, immunoglobulin domain and mucin domain 1 (TIM-1) antigen and uses thereof. |
KR20110094361A (en) | 2003-04-11 | 2011-08-23 | 메디뮨 엘엘씨 | Recombinant il-9 antibodies and uses thereof |
EP1615956A1 (en) * | 2003-04-14 | 2006-01-18 | Board Of Regents The University Of Texas System | Methods for ex vivo hybridoma-free production of polyclonal and monoclonal antibodies and generation of immortalized cell populations |
GB2401040A (en) | 2003-04-28 | 2004-11-03 | Chugai Pharmaceutical Co Ltd | Method for treating interleukin-6 related diseases |
US9708410B2 (en) | 2003-05-30 | 2017-07-18 | Janssen Biotech, Inc. | Anti-tissue factor antibodies and compositions |
EP1642971B1 (en) | 2003-06-18 | 2010-07-21 | Chugai Seiyaku Kabushiki Kaisha | Fucose transporter |
AU2004260936B2 (en) | 2003-06-27 | 2010-06-10 | Amgen Fremont Inc. | Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof |
CA2532250A1 (en) | 2003-07-15 | 2005-02-03 | Barros Research Institute | Compositions and methods for immunotherapy of cancer and infectious diseases |
HN2004000285A (en) | 2003-08-04 | 2006-04-27 | Pfizer Prod Inc | ANTIBODIES DIRECTED TO c-MET |
EP2311468B1 (en) | 2003-08-08 | 2014-01-15 | Perseus Proteomics Inc. | Gene overexpressed in cancer |
CN1838968A (en) | 2003-08-08 | 2006-09-27 | 艾伯吉尼斯公司 | Antibodies aimed to parathyroid hormone (PTH) and uses thereof |
EP1654383A1 (en) | 2003-08-08 | 2006-05-10 | Licentia, Ltd. | Materials and methods for colorectal cancer screening, diagnosis, and therapy |
CA2534661A1 (en) | 2003-08-08 | 2005-02-17 | Genenews Inc. | Osteoarthritis biomarkers and uses thereof |
AR045563A1 (en) | 2003-09-10 | 2005-11-02 | Warner Lambert Co | ANTIBODIES DIRECTED TO M-CSF |
WO2005035753A1 (en) | 2003-10-10 | 2005-04-21 | Chugai Seiyaku Kabushiki Kaisha | Double specific antibodies substituting for functional protein |
US20080075712A1 (en) | 2003-10-14 | 2008-03-27 | Kunihiro Hattori | Double Specific Antibodies Substituting For Functional Proteins |
MXPA06004853A (en) | 2003-11-07 | 2006-07-06 | Immunex Corp | Antibodies that bind interleukin-4 receptor. |
US20050100965A1 (en) | 2003-11-12 | 2005-05-12 | Tariq Ghayur | IL-18 binding proteins |
US8454963B2 (en) * | 2003-11-13 | 2013-06-04 | Musc Foundation For Research Development | Tissue targeted complement modulators |
WO2005060520A2 (en) | 2003-11-25 | 2005-07-07 | Dana-Farber Cancer Institute, Inc. | ANTIBODIES AGAINST SARS-CoV AND METHODS OF USE THEREOF |
WO2005054295A2 (en) | 2003-12-05 | 2005-06-16 | Multimmune Gmbh | Therapeutic and diagnostic anti-hsp 70 antibodies |
US7312320B2 (en) | 2003-12-10 | 2007-12-25 | Novimmune Sa | Neutralizing antibodies and methods of use thereof |
SG10201404273QA (en) | 2003-12-23 | 2014-10-30 | Genentech Inc | Novel anti-il 13 antibodies and uses thereof |
HUE026132T2 (en) | 2004-01-07 | 2016-05-30 | Novartis Vaccines & Diagnostics Inc | M-csf-specific monoclonal antibody and uses thereof |
MX350383B (en) | 2004-01-09 | 2017-09-04 | Pfizer | ANTIBODIES TO MAdCAM. |
PL1729795T3 (en) | 2004-02-09 | 2016-08-31 | Human Genome Sciences Inc | Albumin fusion proteins |
US7625549B2 (en) | 2004-03-19 | 2009-12-01 | Amgen Fremont Inc. | Determining the risk of human anti-human antibodies in transgenic mice |
US20050260679A1 (en) | 2004-03-19 | 2005-11-24 | Sirid-Aimee Kellerman | Reducing the risk of human anti-human antibodies through V gene manipulation |
EP1737979B9 (en) | 2004-03-23 | 2011-09-21 | Oncotherapy Science, Inc. | Method for diagnosing non-small cell lung cancer |
US7973139B2 (en) | 2004-03-26 | 2011-07-05 | Human Genome Sciences, Inc. | Antibodies against nogo receptor |
AU2005249360B2 (en) | 2004-04-12 | 2011-07-21 | Medimmune, Llc | Anti-IL-9 antibody formulations and uses thereof |
CA2568201C (en) | 2004-05-24 | 2013-07-30 | Universitat Zu Koln | Identification of ergothioneine transporter and therapeutic uses thereof |
KR20070039911A (en) | 2004-06-01 | 2007-04-13 | 도만티스 리미티드 | Bispecific fusion antibodies with enhanced serum half-life |
ES2694123T3 (en) | 2004-06-01 | 2018-12-18 | Icahn School Of Medicine At Mount Sinai | Swine influenza virus modified by genetic engineering and uses thereof |
EP1602926A1 (en) | 2004-06-04 | 2005-12-07 | University of Geneva | Novel means and methods for the treatment of hearing loss and phantom hearing |
US8486893B2 (en) | 2004-06-24 | 2013-07-16 | Biogen Idec Ma Inc. | Treatment of conditions involving demyelination |
SI2287195T1 (en) | 2004-07-01 | 2019-08-30 | Novo Nordisk A/S | Pan-kir2dl nk-receptor antibodies and their use in diagnostik and therapy |
WO2006008639A1 (en) | 2004-07-16 | 2006-01-26 | Pfizer Products Inc. | Combination treatment for non-hematologic malignancies using an anti-igf-1r antibody |
US20080199437A1 (en) | 2004-07-22 | 2008-08-21 | Eisai Co., Ltd. | Lrp4/Corin Dopaminergic Neuron Progenitor Cell Markers |
WO2006017673A2 (en) | 2004-08-03 | 2006-02-16 | Biogen Idec Ma Inc. | Taj in neuronal function |
KR101094617B1 (en) | 2004-08-16 | 2011-12-15 | 사일런스 테라퓨틱스 아게 | Therapeutic uses of inhibitors of rtp801 |
CA2478458A1 (en) | 2004-08-20 | 2006-02-20 | Michael Panzara | Treatment of pediatric multiple sclerosis |
US20060045877A1 (en) | 2004-08-30 | 2006-03-02 | Goldmakher Viktor S | Immunoconjugates targeting syndecan-1 expressing cells and use thereof |
US20060051347A1 (en) | 2004-09-09 | 2006-03-09 | Winter Charles M | Process for concentration of antibodies and therapeutic products thereof |
WO2006034292A2 (en) | 2004-09-21 | 2006-03-30 | Medimmune, Inc. | Antibodies against and methods for producing vaccines for respiratory syncytial virus |
WO2006037604A1 (en) | 2004-10-01 | 2006-04-13 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Novel antibodies directed to the mammalian eag1 ion channel protein |
US20080026457A1 (en) | 2004-10-22 | 2008-01-31 | Kevin Wells | Ungulates with genetically modified immune systems |
US20060130157A1 (en) | 2004-10-22 | 2006-06-15 | Kevin Wells | Ungulates with genetically modified immune systems |
US20060121042A1 (en) | 2004-10-27 | 2006-06-08 | Medimmune, Inc. | Modulation of antibody specificity by tailoring the affinity to cognate antigens |
CA2587903A1 (en) | 2004-11-17 | 2006-05-26 | Amgen Fremont Inc. | Fully human monoclonal antibodies to il-13 |
CN103169965A (en) | 2004-11-19 | 2013-06-26 | 比奥根艾迪克Ma公司 | Treatment for multiple sclerosis |
GB0426146D0 (en) | 2004-11-29 | 2004-12-29 | Bioxell Spa | Therapeutic peptides and method |
NZ555464A (en) | 2004-12-02 | 2010-03-26 | Domantis Ltd | Bispecific domain antibodies targeting serum albumin and glp-1 or pyy |
JP4881874B2 (en) | 2004-12-06 | 2012-02-22 | 協和発酵キリン株式会社 | Human monoclonal antibody against influenza M2 protein, production method thereof and use thereof |
WO2006068975A2 (en) | 2004-12-20 | 2006-06-29 | Abgenix, Inc. | Binding proteins specific for human matriptase |
PT1838733E (en) | 2004-12-21 | 2011-12-13 | Medimmune Ltd | Antibodies directed to angiopoietin-2 and uses thereof |
WO2006067847A1 (en) | 2004-12-22 | 2006-06-29 | Chugai Seiyaku Kabushiki Kaisha | Method of preparing antibody by use of cell having its fucose transporter function inhibited |
KR20190110637A (en) | 2005-01-21 | 2019-09-30 | 제넨테크, 인크. | Fixed dosing of her antibodies |
WO2006081139A2 (en) | 2005-01-26 | 2006-08-03 | Abgenix, Inc. | Antibodies against interleukin-1 beta |
WO2006086242A2 (en) | 2005-02-07 | 2006-08-17 | Genenews, Inc. | Mild osteoarthritis biomarkers and uses thereof |
EP2311983A1 (en) | 2005-02-10 | 2011-04-20 | Oncotherapy Science, Inc. | Method of treating bladder cancer using siRNA |
CN102178953A (en) | 2005-02-14 | 2011-09-14 | 惠氏公司 | Interleukin-17F antibodies and other IL-17F signaling antagonists and uses therefor |
JP2008532493A (en) | 2005-02-14 | 2008-08-21 | ワイス | Characterization of the interaction between IL-17F and IL-17R |
AU2006214121B9 (en) | 2005-02-15 | 2013-02-14 | Duke University | Anti-CD19 antibodies and uses in oncology |
EP1859277A4 (en) | 2005-02-17 | 2010-03-17 | Biogen Idec Inc | Treating neurological disorders |
EP1871807B1 (en) | 2005-02-18 | 2012-11-28 | Dana-Farber Cancer Institute, Inc. | Antibodies against cxcr4 and methods of use thereof |
TWI406870B (en) | 2005-02-21 | 2013-09-01 | Chugai Pharmaceutical Co Ltd | A method of making a protein using hamster IGF-1 |
RU2404806C2 (en) | 2005-02-23 | 2010-11-27 | Дженентек, Инк. | Extension of time to progression of disease or lifetime of oncologic patients with application of her dimerisation inhibitors |
EP2251037B1 (en) | 2005-03-02 | 2015-01-14 | Biogen Idec MA Inc. | KIM-1 antibodies for treatment of TH1/TH2-mediated conditions |
JP2008531730A (en) | 2005-03-04 | 2008-08-14 | キュアーディーエム、インク. | Methods and pharmaceutical compositions for treating type I diabetes mellitus and other conditions |
PT2620450T (en) | 2005-03-08 | 2018-12-17 | Pfizer Prod Inc | Anti-ctla-4 antibody compositions |
WO2007059082A1 (en) | 2005-11-10 | 2007-05-24 | Curagen Corporation | Method of treating ovarian and renal cancer using antibodies against t cell immunoglobulin domain and mucin domain 1 (tim-1) antigen |
EP1875244B1 (en) | 2005-03-30 | 2019-01-23 | Minerva Biotechnologies Corporation | Proliferation of muc1 expressing cells |
DK1875244T3 (en) | 2005-03-30 | 2019-04-29 | Minerva Biotechnologies Corp | Proliferation of MUC1-Expressing Cells |
KR101374454B1 (en) | 2005-03-31 | 2014-03-17 | 추가이 세이야쿠 가부시키가이샤 | Methods for producing polypeptides by regulating polypeptide association |
EP1863519B1 (en) | 2005-03-31 | 2013-09-25 | The General Hospital Corporation | Modulating hgf/hgfr activity for treating lymphodema |
EP3796003A1 (en) | 2005-04-04 | 2021-03-24 | Biogen MA Inc. | Methods for evaluating an immune response to a therapeutic agent |
CA2957144C (en) | 2005-04-08 | 2020-06-02 | Chugai Seiyaku Kabushiki Kaisha | Antibody substituting for function of blood coagulation factor viii |
GT200600148A (en) | 2005-04-14 | 2006-11-22 | METHODS FOR THE TREATMENT AND PREVENTION OF FIBROSIS | |
ES2707152T3 (en) | 2005-04-15 | 2019-04-02 | Macrogenics Inc | Covalent diabodies and uses thereof |
MX2007013058A (en) | 2005-04-20 | 2008-02-22 | Amgen Fremont Inc | High affinity fully human monoclonal antibodies to interleukin-8 and epitopes for such antibodies. |
AR053067A1 (en) | 2005-04-25 | 2007-04-18 | Pfizer | ANTIBODIES AGAINST MYOSTATIN |
BRPI0608096A2 (en) | 2005-04-26 | 2009-11-10 | Pfizer | p-cadherin antibodies |
PA8672101A1 (en) | 2005-04-29 | 2006-12-07 | Centocor Inc | ANTI-IL-6 ANTIBODIES, COMPOSITIONS, METHODS AND USES |
CA2607281C (en) | 2005-05-05 | 2023-10-03 | Duke University | Anti-cd19 antibody therapy for autoimmune disease |
WO2006124269A2 (en) * | 2005-05-16 | 2006-11-23 | Amgen Fremont Inc. | Human monoclonal antibodies that bind to very late antigen-1 for the treatment of inflammation and other disorders |
EP3805245A1 (en) | 2005-05-17 | 2021-04-14 | University of Connecticut | Compositions and methods for immunomodulation in an organism |
WO2006128083A2 (en) | 2005-05-25 | 2006-11-30 | Curedm, Inc. | Human proislet peptide, derivatives and analogs thereof, and methods of using same |
HUE030701T2 (en) | 2005-05-27 | 2017-05-29 | Biogen Ma Inc | Tweak binding antibodies |
JP5068167B2 (en) | 2005-06-10 | 2012-11-07 | 中外製薬株式会社 | Stabilizer for protein preparation containing meglumine and use thereof |
CA2612378A1 (en) * | 2005-06-22 | 2007-01-04 | Genentech, Inc. | Methods and compositions for targeting ifnar2 |
WO2007002543A2 (en) | 2005-06-23 | 2007-01-04 | Medimmune, Inc. | Antibody formulations having optimized aggregation and fragmentation profiles |
EP1896073B1 (en) | 2005-06-30 | 2013-03-06 | Janssen Biotech, Inc. | Anti-il-23 antibodies, compositions, methods and uses |
KR101245462B1 (en) | 2005-07-08 | 2013-03-20 | 바이오겐 아이덱 엠에이 인코포레이티드 | Sp35 antibodies and uses thereof |
US8067153B2 (en) | 2005-07-27 | 2011-11-29 | Oncotheraphy Science, Inc. | Genes and polypeptides relating to prostate cancers |
EP1913027B1 (en) | 2005-07-28 | 2015-03-04 | Novartis AG | M-csf specific monoclonal antibody and uses thereof |
CA2618681C (en) | 2005-08-10 | 2015-10-27 | Macrogenics, Inc. | Identification and engineering of antibodies with variant fc regions and methods of using same |
WO2007019865A2 (en) | 2005-08-18 | 2007-02-22 | Genmab A/S | Therapy with cd4 binding peptides and radiation |
EP2500358A3 (en) | 2005-08-19 | 2012-10-17 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
WO2007024715A2 (en) | 2005-08-19 | 2007-03-01 | Abbott Laboratories | Dual variable domain immunoglobin and uses thereof |
US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
AU2006283725B2 (en) | 2005-08-19 | 2012-02-16 | The Trustees Of The University Of Pennsylvania | Antagonist antibodies against GDF-8 and uses in treatment of ALS and other GDF-8-associated disorders |
PL2960253T3 (en) | 2005-09-07 | 2018-11-30 | Amgen Fremont Inc. | Human monoclonal antibodies to activin receptor-like kinase-1 |
WO2007035716A2 (en) | 2005-09-16 | 2007-03-29 | Raptor Pharmaceutical Inc. | Compositions comprising receptor-associated protein (rap) variants specific for cr-containing proteins and uses thereof |
US8124738B2 (en) | 2005-09-26 | 2012-02-28 | Medarex, Inc. | Human monoclonal antibodies to CD70 |
CN101277974A (en) | 2005-09-30 | 2008-10-01 | 阿伯特有限及两合公司 | Binding domains of proteins of the repulsive guidance molecule (RGM) protein family and functional fragments thereof, and their use |
AU2006300234B2 (en) | 2005-10-14 | 2013-01-10 | Chugai Seiyaku Kabushiki Kaisha | Agents for suppressing damage to transplanted islets after islet transplantation |
CN101330930B (en) | 2005-10-21 | 2011-11-23 | 中外制药株式会社 | Therapeutic agent for heart disease |
US8249814B2 (en) | 2005-10-21 | 2012-08-21 | Genenews Inc. | Method, computer readable medium, and system for determining a probability of colorectal cancer in a test subject |
CA2624393C (en) | 2005-11-04 | 2016-01-05 | Genentech, Inc. | Use of complement pathway inhibitors to treat ocular diseases |
JP2009517340A (en) | 2005-11-04 | 2009-04-30 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | Methods for promoting neurite outgrowth and survival of dopaminergic neurons |
CA2628238A1 (en) | 2005-11-07 | 2007-05-18 | The Scripps Research Institute | Compositions and methods for controlling tissue factor signaling specificity |
JP5398987B2 (en) | 2005-11-14 | 2014-01-29 | セルミド リミテッド | Method for treating and preventing diseases based on abnormal function of regulatory T cells |
AR057582A1 (en) | 2005-11-15 | 2007-12-05 | Nat Hospital Organization | AGENTS TO DELETE INDUCTION OF CYTOTOXIC T LYMPHOCYTES |
WO2007061029A1 (en) | 2005-11-25 | 2007-05-31 | Keio University | Therapeutic agent for prostate cancer |
TWI461436B (en) | 2005-11-25 | 2014-11-21 | Kyowa Hakko Kirin Co Ltd | Human monoclonal antibody human cd134 (ox40) and methods of making and using same |
EP2567973B1 (en) | 2005-11-28 | 2014-05-14 | Zymogenetics, Inc. | IL-21 antagonists |
PT1976877E (en) | 2005-11-30 | 2014-04-29 | Abbvie Inc | Monoclonal antibodies against amyloid beta protein and uses thereof |
EP1954718B1 (en) | 2005-11-30 | 2014-09-03 | AbbVie Inc. | Anti-a globulomer antibodies, antigen-binding moieties thereof, corresponding hybridomas, nucleic acids, vectors, host cells, methods of producing said antibodies, compositions comprising said antibodies, uses of said antibodies and methods of using said antibodies |
US20090175872A1 (en) | 2005-12-02 | 2009-07-09 | Biogen Idec Ma Inc. | Treatment of Conditions Involving Demyelination |
US8466263B2 (en) | 2005-12-02 | 2013-06-18 | Dana-Farber Cancer Institute, Inc. | Carbonic anhydrase IX (G250) anitbodies |
TWI531652B (en) | 2005-12-02 | 2016-05-01 | 美國紐約大學西奈山醫學院 | Chimeric viruses presenting non-native surface proteins and uses thereof |
ES2547689T3 (en) | 2005-12-02 | 2015-10-08 | Genentech, Inc. | Compositions and methods for the treatment of diseases and disorders associated with cytokine signaling that involve antibodies that bind to IL-22 and IL-22R |
NZ568016A (en) | 2005-12-07 | 2011-12-22 | Medarex Inc | CTLA-4 antibody dosage escalation regimens |
ES2385054T3 (en) | 2005-12-13 | 2012-07-17 | Medimmune Limited | Specific binding proteins for insulin-like growth factors and uses thereof |
ES2535856T3 (en) | 2005-12-15 | 2015-05-18 | Genentech, Inc. | Methods and compositions for targeting polyubiquitin |
EP1977763A4 (en) | 2005-12-28 | 2010-06-02 | Chugai Pharmaceutical Co Ltd | Antibody-containing stabilizing preparation |
WO2007079218A2 (en) | 2005-12-30 | 2007-07-12 | Dyax Corp. | Metalloproteinase binding proteins |
AR056857A1 (en) | 2005-12-30 | 2007-10-24 | U3 Pharma Ag | DIRECTED ANTIBODIES TO HER-3 (RECEIVER OF THE HUMAN EPIDERMAL GROWTH FACTOR-3) AND ITS USES |
PL2463305T3 (en) | 2006-01-12 | 2017-02-28 | Alexion Pharmaceuticals, Inc. | Antibodies to OX-2/CD200 and uses thereof |
JP2009523807A (en) | 2006-01-18 | 2009-06-25 | ザ ジェネラル ホスピタル コーポレイション | How to increase lymphatic function |
DOP2007000015A (en) | 2006-01-20 | 2007-08-31 | Quark Biotech Inc | THERAPEUTIC USES OF RTP801 INHIBITORS |
BRPI0706750A2 (en) | 2006-01-25 | 2011-04-05 | Univ Erasmus Medical Ct | heavy chain antibody generation in transgenic animals |
AR059213A1 (en) | 2006-01-27 | 2008-03-19 | Univ Keio | THERAPEUTIC AGENTS FOR DISEASES INVOLVING COROIDAL NEOVASCULARIZATION |
PT1981902E (en) | 2006-01-27 | 2015-11-02 | Biogen Ma Inc | Nogo receptor antagonists |
WO2007092431A2 (en) | 2006-02-06 | 2007-08-16 | Rhode Island Hospital | Gpr30 estrogen receptor in breast cancers |
TW200744634A (en) | 2006-02-21 | 2007-12-16 | Wyeth Corp | Methods of using antibodies against human IL-22 |
TWI417301B (en) | 2006-02-21 | 2013-12-01 | Wyeth Corp | Antibodies against human il-22 and uses therefor |
WO2007108557A1 (en) | 2006-03-20 | 2007-09-27 | Japan Science And Technology Agency | Control of intracellular target molecule by ip3 receptor-binding protein |
JP2009529915A (en) | 2006-03-20 | 2009-08-27 | ゾーマ テクノロジー リミテッド | Human antibodies and methods specific for gastrin substances |
JP2009532033A (en) | 2006-03-31 | 2009-09-10 | ダナ ファーバー キャンサー インスティテュート,インコーポレイテッド | Methods for quantifying cell chemosensitivity |
DK3056568T3 (en) | 2006-03-31 | 2021-11-01 | Chugai Pharmaceutical Co Ltd | PROCEDURES FOR CONTROL OF THE BLOOD PHARMACOKINETICS OF ANTIBODIES |
EP2009101B1 (en) | 2006-03-31 | 2017-10-25 | Chugai Seiyaku Kabushiki Kaisha | Antibody modification method for purifying bispecific antibody |
WO2007117410A2 (en) | 2006-03-31 | 2007-10-18 | Medarex, Inc. | Transgenic animals expressing chimeric antibodies for use in preparing human antibodies |
CA2647277A1 (en) | 2006-04-05 | 2007-11-08 | Genentech, Inc. | Method for using boc/cdo to modulate hedgehog signaling |
WO2007116962A1 (en) | 2006-04-07 | 2007-10-18 | Osaka University | Muscle regeneration promoter |
KR20090029184A (en) | 2006-04-07 | 2009-03-20 | 더 가브먼트 오브 더 유나이티드 스테이츠 오브 아메리카, 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 | Antibody compositions and methods for treatment of neoplastic disease |
TW200813091A (en) | 2006-04-10 | 2008-03-16 | Amgen Fremont Inc | Targeted binding agents directed to uPAR and uses thereof |
US20100080794A1 (en) | 2006-04-14 | 2010-04-01 | Takashi Tsuji | Mutant polypeptide having effector function |
JP5496658B2 (en) | 2006-05-25 | 2014-05-21 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | How to treat a stroke |
CA2652945C (en) | 2006-05-30 | 2015-06-02 | Genentech, Inc. | Antibodies and immunoconjugates and uses therefor |
EP2032604A2 (en) | 2006-06-06 | 2009-03-11 | Genentech, Inc. | Anti-dll4 antibodies and methods using same |
WO2007142325A1 (en) | 2006-06-08 | 2007-12-13 | Chugai Seiyaku Kabushiki Kaisha | Preventive or remedy for inflammatory disease |
BRPI0713426A2 (en) | 2006-06-14 | 2012-10-09 | Macrogenics Inc | methods of treating, slowing the progression, or ameliorating one or more symptoms of a disorder, and preventing or delaying the onset of a disorder |
SI2029173T1 (en) | 2006-06-26 | 2016-12-30 | Macrogenics, Inc. | Fc riib-specific antibodies and methods of use thereof |
US7572618B2 (en) | 2006-06-30 | 2009-08-11 | Bristol-Myers Squibb Company | Polynucleotides encoding novel PCSK9 variants |
EP2471815B1 (en) | 2006-07-11 | 2016-03-30 | University Of Medicine And Dentistry Of New Jersey | Proteins, nucleic acids encoding the same and associated methods of use |
AU2007273507A1 (en) | 2006-07-13 | 2008-01-17 | Chugai Seiyaku Kabushiki Kaisha | Cell death inducer |
CN101622276B (en) | 2006-07-18 | 2015-04-22 | 赛诺菲-安万特 | Antagonist antibody against EphA2 for the treatment of cancer |
EP2047862B9 (en) | 2006-07-21 | 2013-04-10 | Chugai Seiyaku Kabushiki Kaisha | Remedy for renal disease |
AU2007348941B2 (en) | 2006-08-03 | 2011-08-04 | Medimmune Limited | Antibodies directed to alphaVbeta6 and uses thereof |
CL2007002225A1 (en) | 2006-08-03 | 2008-04-18 | Astrazeneca Ab | SPECIFIC UNION AGENT FOR A RECEIVER OF THE GROWTH FACTOR DERIVED FROM PLATES (PDGFR-ALFA); NUCLEIC ACID MOLECULA THAT CODIFIES IT; VECTOR AND CELL GUESTS THAT UNDERSTAND IT; CONJUGADO UNDERSTANDING THE AGENT; AND USE OF THE AGENT OF A |
DK2511301T3 (en) | 2006-08-04 | 2018-03-12 | Medimmune Ltd | HUMAN ANTIBODIES AGAINST ERBB 2 |
EP2057193B1 (en) | 2006-08-04 | 2013-12-18 | Novartis AG | Ephb3-specific antibody and uses thereof |
BRPI0713086A2 (en) | 2006-08-14 | 2012-10-09 | Forerunner Pharma Res Co Ltd | diagnosis and treatment of cancer using anti-desmogleìna-3 antibody |
TWI454480B (en) | 2006-08-18 | 2014-10-01 | Novartis Ag | Prlr-specific antibody and uses thereof |
MY162024A (en) | 2006-08-28 | 2017-05-31 | La Jolla Inst Allergy & Immunology | Antagonistic human light-specific human monoclonal antibodies |
EP2059533B1 (en) | 2006-08-30 | 2012-11-14 | Genentech, Inc. | Multispecific antibodies |
PL2064325T3 (en) | 2006-09-01 | 2012-05-31 | Therapeutic Human Polyclonals Inc | Enhanced expression of human or humanized immunoglobulin in non-human transgenic animals |
CA2914170C (en) | 2006-09-08 | 2018-10-30 | Abbvie Bahamas Ltd. | Interleukin-13 binding proteins |
ATE522625T1 (en) | 2006-09-12 | 2011-09-15 | Genentech Inc | METHODS AND COMPOSITIONS FOR THE DIAGNOSIS AND TREATMENT OF LUNG CANCER USING PDGFRA, KIT OR KDG GENE AS GENETIC MARKERS |
US20100297103A1 (en) | 2006-09-14 | 2010-11-25 | Medical & Biological Laboratories Co., Ltd. | Antibody having enhanced adcc activity and method for production thereof |
US9505821B2 (en) | 2006-10-03 | 2016-11-29 | Rutgers, The State University Of New Jersey | ATAP peptides, nucleic acids encoding the same and associated methods of use |
RU2537245C2 (en) | 2006-10-12 | 2014-12-27 | Чугаи Сейяку Кабусики Кайся | Diagnosing and treating malignant tumour with using anti-ereg antibody |
US7744890B2 (en) | 2006-10-12 | 2010-06-29 | Wyeth Llc | Methods and compositions with reduced opalescence |
EP2407548A1 (en) | 2006-10-16 | 2012-01-18 | MedImmune, LLC | Molecules with reduced half-lives, compositions and uses thereof |
EP1914242A1 (en) | 2006-10-19 | 2008-04-23 | Sanofi-Aventis | Novel anti-CD38 antibodies for the treatment of cancer |
AU2007311946A1 (en) | 2006-10-20 | 2008-04-24 | Forerunner Pharma Research Co., Ltd. | Anti-cancer agent comprising anti-HB-EGF antibody as active ingredient |
WO2008047925A1 (en) | 2006-10-20 | 2008-04-24 | Forerunner Pharma Research Co., Ltd. | Pharmaceutical composition comprising anti-hb-egf antibody as active ingredient |
US7846434B2 (en) | 2006-10-24 | 2010-12-07 | Trubion Pharmaceuticals, Inc. | Materials and methods for improved immunoglycoproteins |
PT2502938E (en) | 2006-10-27 | 2015-06-05 | Genentech Inc | Antibodies and immunoconjugates and uses therefor |
JP5401319B2 (en) | 2006-11-03 | 2014-01-29 | ワイス・エルエルシー | Glycolytic inhibitors in cell culture |
EP2433966A1 (en) | 2006-11-03 | 2012-03-28 | U3 Pharma GmbH | FGFR4 antibodies |
US8785400B2 (en) | 2006-11-22 | 2014-07-22 | Curedm Group Holdings, Llc | Methods and compositions relating to islet cell neogenesis |
CA2683287A1 (en) | 2006-11-27 | 2008-12-18 | Patrys Limited | Novel glycosylated peptide target in neoplastic cells |
US8455626B2 (en) | 2006-11-30 | 2013-06-04 | Abbott Laboratories | Aβ conformer selective anti-aβ globulomer monoclonal antibodies |
CN101678100A (en) | 2006-12-06 | 2010-03-24 | 米迪缪尼有限公司 | methods of treating systemic lupus erythematosus |
WO2008070780A1 (en) | 2006-12-07 | 2008-06-12 | Novartis Ag | Antagonist antibodies against ephb3 |
CA2672581A1 (en) | 2006-12-14 | 2008-06-19 | Forerunner Pharma Research Co., Ltd. | Anti-claudin 3 monoclonal antibody and treatment and diagnosis of cancer using the same |
TWI419904B (en) | 2006-12-18 | 2013-12-21 | Genentech Inc | Antagonist anti-notch3 antibodies and their use in the prevention and treatment of notch3-related diseases |
CA2673592C (en) | 2006-12-20 | 2014-03-25 | Xoma Technology Ltd. | Methods for the treatment of il-1.beta. related diseases |
EA017611B1 (en) | 2007-01-05 | 2013-01-30 | Юнивэсэти Оф Цюрих | Method for preparing a disorder-associated protein specific binding molecule or an antibody or a binding fragment or at least one immunoglobulin chain, binding said protein (variants), a binding molecule, an antibody, an immunoglobulin chain or a binding fragment thereof (variants), an antigen, a polynucleotide, vector and a host-cell, a composition comprising them and a kit and a method of diagnosing or treating neurological disorders by using said subjects (variants) |
US20100111851A1 (en) | 2007-01-05 | 2010-05-06 | The University Of Tokyo | Diagnosis and treatment of cancer by using anti-prg-3 antibody |
LT2740744T (en) | 2007-01-09 | 2018-05-10 | Biogen Ma Inc. | Sp35 antibodies and uses thereof |
US8128926B2 (en) | 2007-01-09 | 2012-03-06 | Biogen Idec Ma Inc. | Sp35 antibodies and uses thereof |
EP2839743A1 (en) | 2007-01-16 | 2015-02-25 | Abbvie Inc. | Methods for treating psoriasis |
WO2008090901A1 (en) | 2007-01-23 | 2008-07-31 | Shinshu University | Chronic rejection inhibitor |
EP3246407B1 (en) | 2007-02-09 | 2019-04-03 | Eisai R&D Management Co., Ltd. | Gaba neuron progenitor cell marker 65b13 |
CA2676766A1 (en) | 2007-02-09 | 2008-08-21 | Genentech, Inc. | Anti-robo4 antibodies and uses therefor |
US8685666B2 (en) | 2007-02-16 | 2014-04-01 | The Board Of Trustees Of Southern Illinois University | ARL-1 specific antibodies and uses thereof |
US8114606B2 (en) | 2007-02-16 | 2012-02-14 | The Board Of Trustees Of Southern Illinois University | ARL-1 specific antibodies |
WO2008103962A2 (en) | 2007-02-22 | 2008-08-28 | Genentech, Inc. | Methods for detecting inflammatory bowel disease |
US20100311767A1 (en) | 2007-02-27 | 2010-12-09 | Abbott Gmbh & Co. Kg | Method for the treatment of amyloidoses |
JP5374360B2 (en) | 2007-02-27 | 2013-12-25 | 中外製薬株式会社 | Pharmaceutical composition comprising anti-GRP78 antibody as an active ingredient |
PE20090681A1 (en) | 2007-03-02 | 2009-06-10 | Genentech Inc | PREDICTION OF RESPONSE TO A HER INHIBITOR |
CL2008000719A1 (en) | 2007-03-12 | 2008-09-05 | Univ Tokushima Chugai Seiyaku | THERAPEUTIC AGENT FOR CANCER RESISTANT TO CHEMOTHERAPEUTIC AGENTS THAT UNDERSTAND AN ANTIBODY THAT RECOGNIZES IT CLASS I AS ACTIVE INGREDIENT; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH ANTIBODY; AND METHOD TO TREAT CANCER RESISTANT TO |
EP2125888B1 (en) | 2007-03-13 | 2015-12-02 | University of Zurich | Method of providing human tumor-specific antibodies |
KR101605908B1 (en) | 2007-03-22 | 2016-03-23 | 바이오젠 엠에이 인코포레이티드 | Binding proteins, including antibodies, antibody derivatives and antibody fragments, that specifically bind cd154 and uses thereof |
US7960139B2 (en) | 2007-03-23 | 2011-06-14 | Academia Sinica | Alkynyl sugar analogs for the labeling and visualization of glycoconjugates in cells |
WO2008118324A2 (en) | 2007-03-26 | 2008-10-02 | Macrogenics, Inc. | Composition and method of treating cancer with an anti-uroplakin ib antibody |
JP5456658B2 (en) | 2007-03-30 | 2014-04-02 | メディミューン,エルエルシー | Antibody preparation |
KR20100018499A (en) | 2007-04-02 | 2010-02-17 | 암젠 프레몬트 인코포레이티드 | Anti-ige antibodies |
ES2558689T3 (en) | 2007-05-14 | 2016-02-08 | Medimmune, Llc | Methods to reduce eosinophil levels |
KR101729431B1 (en) | 2007-05-21 | 2017-04-21 | 제넨테크, 인크. | Methods and compositions for identifying and treating lupus |
JP5117765B2 (en) | 2007-05-28 | 2013-01-16 | 国立大学法人 東京大学 | Tumor diagnostic agent for PET containing anti-ROBO1 antibody |
WO2008154249A2 (en) | 2007-06-08 | 2008-12-18 | Genentech, Inc. | Gene expression markers of tumor resistance to her2 inhibitor treatment |
TWI614028B (en) | 2007-06-14 | 2018-02-11 | 百健Ma公司 | Antibody formulations |
CN107226864A (en) | 2007-06-21 | 2017-10-03 | 宏观基因有限公司 | Covalent diabodies and application thereof |
AU2008275229B2 (en) | 2007-07-09 | 2014-11-06 | Genentech, Inc. | Prevention of disulfide bond reduction during recombinant production of polypeptides |
US20100129355A1 (en) | 2007-07-26 | 2010-05-27 | Osaka University | Therapeutic agents for ocular inflammatory disease comprising interleukin 6 receptor inhibitor as active ingredient |
EP2185719B1 (en) | 2007-08-02 | 2013-11-13 | NovImmune SA | Anti-rantes antibodies and methods of use thereof |
KR101561175B1 (en) | 2007-08-20 | 2015-10-16 | 온코세라피 사이언스 가부시키가이샤 | CDH3 peptide and medicinal agent comprising the same |
ES2537323T3 (en) | 2007-08-20 | 2015-06-05 | Oncotherapy Science, Inc. | CDCA1 peptide and pharmaceutical agent comprising it |
JP5555952B2 (en) | 2007-08-20 | 2014-07-23 | オンコセラピー・サイエンス株式会社 | FOXM1 peptide and drug containing the same |
EP2615113A3 (en) | 2007-08-23 | 2013-11-13 | Amgen Inc. | Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (PCSK9) |
JOP20080381B1 (en) | 2007-08-23 | 2023-03-28 | Amgen Inc | Antigen Binding Proteins to Proprotein Convertase subtillisin Kexin type 9 (pcsk9) |
NZ583605A (en) | 2007-08-29 | 2012-10-26 | Sanofi Aventis | Humanized anti-cxcr5 antibodies, derivatives thereof and their uses |
CN101896499B (en) | 2007-08-30 | 2014-02-12 | 库尔Dm股份有限公司 | Compositions and methods of using proislet peptides and analogs thereof |
US20100239570A1 (en) | 2007-09-13 | 2010-09-23 | Roger Nitsch | Moncolonal amyloid beta (abeta) - specific antibody and uses thereof |
JP5334319B2 (en) | 2007-09-26 | 2013-11-06 | 中外製薬株式会社 | Method for modifying isoelectric point of antibody by amino acid substitution of CDR |
BRPI0817255A2 (en) | 2007-09-26 | 2017-06-06 | Amgen Inc | heparin-binding epidermal growth factor-like growth factor antigen-binding proteins. |
EP2205280B1 (en) | 2007-09-27 | 2019-09-04 | Amgen Inc. | Pharmaceutical formulations |
JP4535406B2 (en) | 2007-09-28 | 2010-09-01 | 中外製薬株式会社 | Glypican 3 antibody with improved plasma kinetics |
BRPI0817482B8 (en) | 2007-10-02 | 2021-05-25 | Chugai Pharmaceutical Co Ltd | use of an interleukin-6 (il-6) receptor antibody in the treatment of graft versus host disease (gvhd) |
EP2050764A1 (en) | 2007-10-15 | 2009-04-22 | sanofi-aventis | Novel polyvalent bispecific antibody format and uses thereof |
CN101802192A (en) | 2007-10-15 | 2010-08-11 | 中外制药株式会社 | Method for production of antibody |
AU2008312802A1 (en) | 2007-10-19 | 2009-04-23 | Immunas Pharma, Inc. | Antibody capable of specifically binding to abeta oligomer, and use thereof |
WO2009054435A1 (en) | 2007-10-24 | 2009-04-30 | Otsuka Chemical Co., Ltd. | Polypeptide having enhanced effector function |
PE20091163A1 (en) | 2007-11-01 | 2009-08-09 | Wyeth Corp | ANTIBODIES FOR GDF8 |
WO2009061818A1 (en) | 2007-11-05 | 2009-05-14 | Medimmune, Llc | Methods of treating scleroderma |
WO2009062125A1 (en) | 2007-11-07 | 2009-05-14 | Genentech, Inc. | Methods and compositions for assessing responsiveness of b-cell lymphoma to treatment with anti-cd40 antibodies |
LT2514436T (en) | 2007-11-07 | 2018-04-10 | Genentech, Inc. | Il-22 for use in treating microbial disorders |
CN101939336B (en) | 2007-11-12 | 2014-05-14 | U3制药有限公司 | AXL antibodies |
WO2009063970A1 (en) | 2007-11-14 | 2009-05-22 | Forerunner Pharma Research Co., Ltd. | Diagnosis and treatment of cancer using anti-gpr49 antibody |
US8796206B2 (en) | 2007-11-15 | 2014-08-05 | Amgen Inc. | Aqueous formulation of erythropoiesis stimulating protein stabilised by antioxidants for parenteral administration |
RU2559530C2 (en) | 2007-11-15 | 2015-08-10 | Чугаи Сейяку Кабусики Кайся | Monoclonal antibodies capable of binding with axl protein and their application |
JP5490714B2 (en) | 2007-11-28 | 2014-05-14 | メディミューン,エルエルシー | Protein preparation |
TWI580694B (en) | 2007-11-30 | 2017-05-01 | 建南德克公司 | Anti-vegf antibodies |
KR101643005B1 (en) | 2007-12-05 | 2016-07-28 | 추가이 세이야쿠 가부시키가이샤 | Anti-NR10 antibody and use thereof |
BRPI0821145B8 (en) | 2007-12-05 | 2021-05-25 | Chugai Pharmaceutical Co Ltd | use of an anti-nr10 antibody as a preventive or therapeutic agent for pruritus |
NZ586611A (en) | 2007-12-06 | 2012-09-28 | Dana Farber Cancer Inst Inc | Antibodies against influenza virus and methods of use thereof |
EP2241333A1 (en) | 2007-12-12 | 2010-10-20 | National Cancer Center | Therapeutic agent for mll leukemia and moz leukemia of which molecular target is m-csf receptor, and use thereof |
PT2391650E (en) | 2007-12-20 | 2015-01-14 | Xoma Us Llc | Methods for the treatment of gout |
ES2475201T3 (en) | 2007-12-26 | 2014-07-10 | Biotest Ag | Agents directed against CD138 and their uses |
JP2011507933A (en) | 2007-12-26 | 2011-03-10 | バイオテスト・アクチエンゲゼルシヤフト | Methods for reducing cytotoxic side effects and improving efficacy of immune complexes |
MX2010007101A (en) | 2007-12-26 | 2011-07-01 | Biotest Ag | Methods and agents for improving targeting of cd138 expressing tumor cells. |
HUE024291T2 (en) | 2007-12-26 | 2016-01-28 | Biotest Ag | Immunoconjugates targeting cd138 and uses thereof |
PE20091174A1 (en) | 2007-12-27 | 2009-08-03 | Chugai Pharmaceutical Co Ltd | LIQUID FORMULATION WITH HIGH CONCENTRATION OF ANTIBODY CONTENT |
WO2009086514A1 (en) | 2007-12-28 | 2009-07-09 | Dana-Farber Cancer Institute, Inc. | Humanized monoclonal antibodies and methods of use |
KR20100107501A (en) | 2008-01-18 | 2010-10-05 | 메디뮨 엘엘씨 | Cysteine engineered antibodies for site-specific conjugation |
WO2009094551A1 (en) | 2008-01-25 | 2009-07-30 | Amgen Inc. | Ferroportin antibodies and methods of use |
AU2009211635B2 (en) | 2008-02-08 | 2014-06-26 | Immunas Pharma, Inc. | Antibody capable of binding specifically to Abeta-oligomer, and use thereof |
BR122020023189B1 (en) | 2008-02-08 | 2022-02-01 | Astrazeneca Ab | Use of a pharmaceutical composition comprising an antibody specific for ifnar1 |
US8962803B2 (en) | 2008-02-29 | 2015-02-24 | AbbVie Deutschland GmbH & Co. KG | Antibodies against the RGM A protein and uses thereof |
AU2009225797A1 (en) | 2008-03-18 | 2009-09-24 | Abbvie Inc. | Methods for treating psoriasis |
US8557239B2 (en) | 2009-09-14 | 2013-10-15 | Abbvie Inc. | Methods for treating psoriasis using antibodies that bind to the P40 subunit of IL-12 and/or IL-23 |
US20110020368A1 (en) | 2008-03-25 | 2011-01-27 | Nancy Hynes | Treating cancer by down-regulating frizzled-4 and/or frizzled-1 |
KR102070761B1 (en) | 2008-03-31 | 2020-01-29 | 제넨테크, 인크. | Compositions and methods for treating and diagnosing asthma |
WO2009124109A1 (en) | 2008-04-04 | 2009-10-08 | The Government Of The U.S. A. As Represented By The Secretary Of The Dept. Of Health &Human Services | Human monoclonal antibodies specific for cd22 |
CL2009000647A1 (en) | 2008-04-04 | 2010-06-04 | Chugai Pharmaceutical Co Ltd | Pharmaceutical composition for treating or preventing liver cancer comprising a combination of a chemotherapeutic agent and an anti-glypican 3 antibody; agent for attenuating a side effect comprising said antibody; method of treating or preventing liver cancer of a subject. |
CA2721052C (en) | 2008-04-11 | 2023-02-21 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly |
BR122021026834B1 (en) | 2008-04-25 | 2022-11-08 | Takeda Pharmaceutical Company Limited | ISOLATED ANTIBODIES BINDING FCRN, PHARMACEUTICAL COMPOSITION COMPRISING THEMSELVES AND METHODS TO DETECT AND MODULATE FCRN |
NZ588554A (en) | 2008-04-29 | 2013-03-28 | Abbott Lab | Dual variable domain immunoglobulins and uses thereof |
EP2816059A1 (en) | 2008-05-01 | 2014-12-24 | Amgen, Inc | Anti-hepcidin antibodies and methods of use |
CA2723197C (en) | 2008-05-02 | 2017-09-19 | Seattle Genetics, Inc. | Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation |
SG188142A1 (en) | 2008-05-09 | 2013-03-28 | Abbott Gmbh & Co Kg | Antibodies to receptor of advanced glycation end products (rage) and uses thereof |
EP2304439A4 (en) | 2008-05-29 | 2012-07-04 | Nuclea Biotechnologies Llc | Anti-phospho-akt antibodies |
US9226934B2 (en) | 2008-06-02 | 2016-01-05 | The University Of Tokyo | Anti-cancer drug |
CN102112494A (en) | 2008-06-03 | 2011-06-29 | 雅培制药有限公司 | Dual variable domain immunoglobulins and uses thereof |
AR072001A1 (en) | 2008-06-03 | 2010-07-28 | Abbott Lab | IMMUNOGLOBULIN WITH DUAL VARIABLE DOMAIN AND USES OF THE SAME |
CN102256623A (en) | 2008-06-05 | 2011-11-23 | 独立行政法人国立癌症研究中心 | Neuroinvasion inhibitor |
ES2595362T3 (en) | 2008-06-16 | 2016-12-29 | Patrys Limited | LM antibodies, functional fragments, LM-1 target antigen and methods to prepare and use them |
EP2319869B1 (en) | 2008-06-20 | 2016-08-17 | National University Corporation Okayama University | ANTIBODY AGAINST OXIDIZED LDL/ß²GPI COMPLEX AND USE OF THE SAME |
US8187601B2 (en) | 2008-07-01 | 2012-05-29 | Aveo Pharmaceuticals, Inc. | Fibroblast growth factor receptor 3 (FGFR3) binding proteins |
TW201014602A (en) | 2008-07-08 | 2010-04-16 | Abbott Lab | Prostaglandin E2 binding proteins and uses thereof |
WO2010006060A2 (en) | 2008-07-08 | 2010-01-14 | Abbott Laboratories | Prostaglandin e2 dual variable domain immunoglobulins and uses thereof |
CA2729961C (en) | 2008-07-09 | 2018-05-01 | Biogen Idec Ma Inc. | Li113, li62 variant co2, anti-lingo antibodies |
US8680020B2 (en) | 2008-07-15 | 2014-03-25 | Academia Sinica | Glycan arrays on PTFE-like aluminum coated glass slides and related methods |
CA2733642A1 (en) | 2008-08-14 | 2010-02-18 | Cephalon Australia Pty Ltd | Anti-il-12/il-23 antibodies |
JP5685535B2 (en) | 2008-08-18 | 2015-03-18 | ファイザー インコーポレイティッド | Antibodies against CCR2 |
WO2010027818A2 (en) | 2008-08-25 | 2010-03-11 | Dana-Farber Cancer Institute, Inc. | Conserved hemagglutinin epitope, antibodies to the epitope, and methods of use |
AR073538A1 (en) | 2008-09-03 | 2010-11-17 | Genentech Inc | MULTI-SPECIFIC ANTIBODIES THAT SPECIFICALLY JOIN THE RECEPTOR OF THE HUMAN EPIDERMIC GROWTH FACTOR 2 (HER2) AND THE VASCULAR ENDOTELIAL GROWTH FACTOR (VEGF) |
US8163497B2 (en) | 2008-09-07 | 2012-04-24 | Glyconex Inc. | Anti-extended type I glycosphingolipid antibody, derivatives thereof and use |
CA2735900A1 (en) | 2008-09-19 | 2010-03-25 | Medimmune, Llc | Antibodies directed to dll4 and uses thereof |
EP2344180A2 (en) | 2008-09-23 | 2011-07-20 | Wyeth LLC | Methods for predicting production of activating signals by cross-linked binding proteins |
NZ592308A (en) | 2008-09-30 | 2012-11-30 | Ablexis Llc | Non-human mammals for the production of chimeric antibodies |
EP2344632B1 (en) | 2008-10-09 | 2022-12-28 | Minerva Biotechnologies Corporation | Method for inducing pluripotency in cells |
JP2012505900A (en) | 2008-10-14 | 2012-03-08 | ダイアクス コーポレーション | Use of an IGF-II / IGF-IIE binding protein for the treatment and prevention of pulmonary fibrosis associated with systemic scleroderma |
KR102100066B1 (en) | 2008-10-14 | 2020-04-10 | 제넨테크, 인크. | Immunoglobulin variants and uses thereof |
US20120251502A1 (en) | 2008-10-24 | 2012-10-04 | The Government of the US as Represented by the Secretary of the Dept. of health | Human Ebola Virus Species and Compositions and Methods Thereof |
ES2548377T3 (en) | 2008-10-27 | 2015-10-16 | Revivicor, Inc. | Immunosuppressed ungulates |
CN104740631B (en) | 2008-10-29 | 2019-04-16 | 阿布林克斯公司 | The preparation of single domain antigen-binding molecule |
US10118962B2 (en) | 2008-10-29 | 2018-11-06 | Ablynx N.V. | Methods for purification of single domain antigen binding molecules |
US8642280B2 (en) | 2008-11-07 | 2014-02-04 | Novartis Forschungsstiftung Zweigniederlassung Friedrich Miescher Institute For Biomedical Research | Teneurin and cancer |
KR20110094029A (en) | 2008-11-10 | 2011-08-19 | 알렉시온 파마슈티칼스, 인코포레이티드 | Methods and compositions for treating complement-associated disorders |
EP2191841A1 (en) | 2008-11-28 | 2010-06-02 | Sanofi-Aventis | Antitumor combinations containing antibodies recognizing specifically CD38 and vincristine |
EP2191843A1 (en) | 2008-11-28 | 2010-06-02 | Sanofi-Aventis | Antitumor combinations containing antibodies recognizing specifically CD38 and cyclophosphamide |
EP2191840A1 (en) | 2008-11-28 | 2010-06-02 | Sanofi-Aventis | Antitumor combinations containing antibodies recognizing specifically CD38 and melphalan |
EP2191842A1 (en) | 2008-11-28 | 2010-06-02 | Sanofi-Aventis | Antitumor combinations containing antibodies recognizing specifically CD38 and cytarabine |
BRPI0917592B1 (en) | 2008-12-09 | 2021-08-17 | Genentech, Inc | ANTI-PD-L1 ANTIBODY, COMPOSITION, MANUFACTURED ARTICLES AND USES OF A COMPOSITION |
AU2009335798B2 (en) | 2008-12-19 | 2014-11-27 | Macrogenics, Inc. | Covalent diabodies and uses thereof |
EP3521309A1 (en) | 2008-12-19 | 2019-08-07 | Biogen International Neuroscience GmbH | Human anti-alpha-synuclein antibodies |
JP5523346B2 (en) | 2008-12-22 | 2014-06-18 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | Method for obtaining pancreatic progenitor cells using Neph3 |
WO2010075249A2 (en) | 2008-12-22 | 2010-07-01 | Genentech, Inc. | A method for treating rheumatoid arthritis with b-cell antagonists |
BRPI0918204A2 (en) | 2008-12-23 | 2015-12-08 | Genentech Inc | igv variant pharmaceutical composition and kit |
US20120114667A1 (en) | 2008-12-23 | 2012-05-10 | Medimmune Limited | TARGETED BINDING AGENTS DIRECTED TO a5BETA1 AND USES THEREOF |
BRPI0923652A2 (en) | 2008-12-26 | 2016-10-18 | Forerunner Pharma Res Co Ltd | cancer diagnosis and treatment using anti-lgr7 antibody |
CN102341411A (en) | 2008-12-31 | 2012-02-01 | 比奥根艾迪克Ma公司 | Anti-lymphotoxin antibodies |
CA2749572A1 (en) | 2009-01-14 | 2010-07-22 | Iq Therapeutics Bv | Combination antibodies for the treatment and prevention of disease caused by bacillus anthracis and related bacteria and their toxins |
WO2010085510A1 (en) | 2009-01-20 | 2010-07-29 | Zadeh Homayoun H | Antibody mediated osseous regeneration |
WO2010087927A2 (en) | 2009-02-02 | 2010-08-05 | Medimmune, Llc | Antibodies against and methods for producing vaccines for respiratory syncytial virus |
US8309530B2 (en) | 2009-02-04 | 2012-11-13 | Washington State University | Compositions and methods for modulating ghrelin-mediated conditions |
EP2394159B1 (en) | 2009-02-04 | 2018-09-26 | Molecular Innovations | Assays for detecting prorenin, and antibodies used therein |
US20110014190A1 (en) | 2009-02-12 | 2011-01-20 | Human Genome Sciences, Inc. | Use of b lymphocyte stimulator protein antagonists to promote transplantation tolerance |
JP5836807B2 (en) | 2009-03-05 | 2015-12-24 | アッヴィ・インコーポレイテッド | IL-17 binding protein |
EP2405920A1 (en) | 2009-03-06 | 2012-01-18 | Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research | Novel therapy for anxiety |
JP2010210772A (en) | 2009-03-13 | 2010-09-24 | Dainippon Screen Mfg Co Ltd | Method of manufacturing liquid crystal display device |
TW201544123A (en) | 2009-03-20 | 2015-12-01 | Genentech Inc | Anti-HER antibodies |
CN102428103B (en) | 2009-03-24 | 2015-04-08 | 泰华生物制药美国公司 | Humanized antibodies against light and uses thereof |
CA2787099A1 (en) | 2009-03-30 | 2010-10-14 | Anice C. Lowen | Influenza virus hemagglutinin polypeptides containing stem domains, vaccines and uses thereof |
JP5795306B2 (en) | 2009-04-01 | 2015-10-14 | ジェネンテック, インコーポレイテッド | Treatment of insulin resistance disease |
US20100297127A1 (en) | 2009-04-08 | 2010-11-25 | Ghilardi Nico P | Use of il-27 antagonists to treat lupus |
EP2417984B1 (en) | 2009-04-10 | 2016-03-30 | Kyowa Hakko Kirin Co., Ltd. | Method for treatment of blood tumor using anti-tim-3 antibody |
EP2241323A1 (en) | 2009-04-14 | 2010-10-20 | Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research | Tenascin-W and brain cancers |
TWI559930B (en) | 2009-04-16 | 2016-12-01 | Abbvie Biotherapeutics Inc | Anti-tnf-α antibodies and their uses |
DK2419447T3 (en) | 2009-04-17 | 2017-09-25 | Immunas Pharma Inc | ANTIBODIES THAT SPECIFICALLY BIND TO A BETA OLIGOMER AND USE THEREOF |
WO2010121231A1 (en) | 2009-04-18 | 2010-10-21 | Genentech, Inc. | Methods for assessing responsiveness of b-cell lymphoma to treatment with anti-cd40 antibodies |
CN104558179A (en) | 2009-04-27 | 2015-04-29 | 协和发酵麒麟株式会社 | Anti-iL-3R[alpha] antibody for use in treatment of blood tumor |
EP2424891B1 (en) | 2009-04-29 | 2014-06-11 | The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. | Erg monoclonal antibodies |
WO2010126137A1 (en) | 2009-05-01 | 2010-11-04 | 国立大学法人 東京大学 | Anti-cadherin antibody |
EP2427203B1 (en) | 2009-05-05 | 2018-10-17 | Novimmune S.A. | Anti-il-17f antibodies and use thereof |
US8673314B2 (en) | 2009-05-26 | 2014-03-18 | Mount Sinai School Of Medicine | Monoclonal antibodies against influenza virus generated by cyclical administration and uses thereof |
EP2436397B1 (en) | 2009-05-29 | 2017-05-10 | Chugai Seiyaku Kabushiki Kaisha | Pharmaceutical composition containing antagonist of egf family ligand as component |
WO2010146059A2 (en) | 2009-06-16 | 2010-12-23 | F. Hoffmann-La Roche Ag | Biomarkers for igf-1r inhibitor therapy |
BRPI1012321A8 (en) | 2009-06-17 | 2016-09-27 | Abbott Biotherapeutics Corp | ANTI-VEGF ANTIBODIES AND THEIR USES |
CN102802661B (en) | 2009-06-22 | 2016-01-13 | 米迪缪尼有限公司 | For the engineered Fc district of site-specific conjugation |
CN102481380A (en) | 2009-07-09 | 2012-05-30 | 霍夫曼-拉罗奇有限公司 | In vivo tumor vasculature imaging |
WO2011006001A1 (en) | 2009-07-09 | 2011-01-13 | Genentech, Inc. | Animal model for the evaluation of adjuvant therapies of cancer |
JP6095367B2 (en) | 2009-07-13 | 2017-03-15 | ジェネンテック, インコーポレイテッド | Diagnostic methods and compositions for cancer treatment |
TW201106972A (en) | 2009-07-27 | 2011-03-01 | Genentech Inc | Combination treatments |
US9217157B2 (en) | 2009-07-27 | 2015-12-22 | Icahn School Of Medicine At Mount Sinai | Recombinant influenza viruses and uses thereof |
JP5845180B2 (en) | 2009-07-30 | 2016-01-20 | モウント シナイ スクール オフ メディシネ | Influenza viruses and their use |
TWI523661B (en) | 2009-07-31 | 2016-03-01 | Shin Maeda | Anti-IL-6 receptor antibody in the manufacture of inhibitors of metastatic inhibition of lung cancer metastasis to the liver |
WO2011014750A1 (en) | 2009-07-31 | 2011-02-03 | Genentech, Inc. | Inhibition of tumor metastasis using bv8- or g-csf-antagonists |
US20120164659A1 (en) | 2009-08-05 | 2012-06-28 | Nexigen Gmbh | Human hcv-interacting proteins and methods of use |
ES2624835T3 (en) | 2009-08-06 | 2017-07-17 | Immunas Pharma, Inc. | Antibodies that specifically bind to the A beta oligomers and use thereof |
ES2614949T3 (en) | 2009-08-06 | 2017-06-02 | Immunas Pharma, Inc. | Antibodies that specifically bind to beta A oligomers and use thereof |
US20110039300A1 (en) | 2009-08-10 | 2011-02-17 | Robert Bayer | Antibodies with enhanced adcc functions |
RU2639288C2 (en) | 2009-08-11 | 2017-12-20 | Дженентек, Инк. | Proteins production in cultural media without glutamine |
PL2464664T3 (en) | 2009-08-13 | 2016-02-29 | Crucell Holland Bv | Antibodies against human respiratory syncytial virus (rsv) and methods of use |
CA2770321A1 (en) | 2009-08-14 | 2011-02-17 | Genentech, Inc. | Biological markers for monitoring patient response to vegf antagonists |
WO2011019622A1 (en) | 2009-08-14 | 2011-02-17 | Genentech, Inc. | Cell culture methods to make antibodies with enhanced adcc function |
EP2468771A4 (en) | 2009-08-17 | 2013-06-05 | Forerunner Pharma Res Co Ltd | Pharmaceutical composition containing anti-hb-egf antibody as active ingredient |
WO2011024114A1 (en) | 2009-08-25 | 2011-03-03 | Ecole Polytechnique Federale De Lausanne (Epfl) | Targeting extracellular matrix molecules for the treatment of cancer |
EP2292266A1 (en) | 2009-08-27 | 2011-03-09 | Novartis Forschungsstiftung, Zweigniederlassung | Treating cancer by modulating copine III |
CN105131112A (en) | 2009-08-29 | 2015-12-09 | Abbvie公司 | Therapeutic dll4 binding proteins |
EP2473524A4 (en) | 2009-09-01 | 2013-05-22 | Abbott Lab | Dual variable domain immunoglobulins and uses thereof |
ES2599076T3 (en) | 2009-09-02 | 2017-01-31 | Genentech, Inc. | Smoothened mutant and methods of use thereof |
CN107385034B (en) | 2009-09-03 | 2021-08-17 | 弗·哈夫曼-拉罗切有限公司 | Methods for treating, diagnosing and monitoring rheumatoid arthritis |
EP2475996A1 (en) | 2009-09-11 | 2012-07-18 | F. Hoffmann-La Roche AG | Method to identify a patient with an increased likelihood of responding to an anti-cancer agent |
MX2012002909A (en) | 2009-09-17 | 2012-04-19 | Hoffmann La Roche | Methods and compositions for diagnostics use in cancer patients. |
WO2011036118A1 (en) | 2009-09-22 | 2011-03-31 | Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research | Treating cancer by modulating mex-3 |
TW201118166A (en) | 2009-09-24 | 2011-06-01 | Chugai Pharmaceutical Co Ltd | HLA class I-recognizing antibodies |
WO2011038301A2 (en) | 2009-09-25 | 2011-03-31 | Xoma Technology Ltd. | Screening methods |
US8926976B2 (en) | 2009-09-25 | 2015-01-06 | Xoma Technology Ltd. | Modulators |
EP2305285A1 (en) | 2009-09-29 | 2011-04-06 | Julius-Maximilians-Universität Würzburg | Means and methods for treating ischemic conditions |
PE20120998A1 (en) | 2009-09-30 | 2012-08-14 | Genentech Inc | METHODS FOR TREATING CANCER USING NOTCH ANTAGONISTS |
AR078470A1 (en) | 2009-10-02 | 2011-11-09 | Sanofi Aventis | ANTIBODIES THAT SPECIFICALLY JOIN THE EPHA2 RECEIVER |
US9096877B2 (en) | 2009-10-07 | 2015-08-04 | Macrogenics, Inc. | Fc region-containing polypeptides that exhibit improved effector function due to alterations of the extent of fucosylation, and methods for their use |
KR101953075B1 (en) | 2009-10-07 | 2019-02-27 | 제넨테크, 인크. | Methods for treating, diagnosing, and monitoring lupus |
CA2776756A1 (en) | 2009-10-11 | 2011-04-14 | Biogen Idec Ma Inc. | Anti-vla-4 related assays |
EP2488658A4 (en) | 2009-10-15 | 2013-06-19 | Abbvie Inc | Dual variable domain immunoglobulins and uses thereof |
WO2011045352A2 (en) | 2009-10-15 | 2011-04-21 | Novartis Forschungsstiftung | Spleen tyrosine kinase and brain cancers |
WO2011056494A1 (en) | 2009-10-26 | 2011-05-12 | Genentech, Inc. | Activin receptor-like kinase-1 antagonist and vegfr3 antagonist combinations |
WO2011056497A1 (en) | 2009-10-26 | 2011-05-12 | Genentech, Inc. | Activin receptor type iib compositions and methods of use |
KR101832510B1 (en) | 2009-10-26 | 2018-02-26 | 제넨테크, 인크. | Assays for detecting antibodies specific to therapeutic anti-ige antibodies and their use in anaphylaxis |
WO2011056502A1 (en) | 2009-10-26 | 2011-05-12 | Genentech, Inc. | Bone morphogenetic protein receptor type ii compositions and methods of use |
UY32979A (en) | 2009-10-28 | 2011-02-28 | Abbott Lab | IMMUNOGLOBULINS WITH DUAL VARIABLE DOMAIN AND USES OF THE SAME |
CN102753580A (en) | 2009-10-28 | 2012-10-24 | 亚培生物医疗股份有限公司 | Anti-egfr antibodies and their uses |
US20120213801A1 (en) | 2009-10-30 | 2012-08-23 | Ekaterina Gresko | Phosphorylated Twist1 and cancer |
WO2011053707A1 (en) | 2009-10-31 | 2011-05-05 | Abbott Laboratories | Antibodies to receptor for advanced glycation end products (rage) and uses thereof |
EP2496604B1 (en) | 2009-11-06 | 2017-08-23 | IDEXX Laboratories, Inc. | Canine anti-cd20 antibodies |
WO2011060015A1 (en) | 2009-11-11 | 2011-05-19 | Genentech, Inc. | Methods and compositions for detecting target proteins |
LT3351558T (en) | 2009-11-13 | 2020-06-10 | Daiichi Sankyo Europe Gmbh | Material and methods for treating or preventing her-3 associated diseases |
US9260517B2 (en) | 2009-11-17 | 2016-02-16 | Musc Foundation For Research Development | Human monoclonal antibodies to human nucleolin |
RS56469B1 (en) | 2009-11-24 | 2018-01-31 | Medimmune Ltd | Targeted binding agents against b7-h1 |
US11377485B2 (en) | 2009-12-02 | 2022-07-05 | Academia Sinica | Methods for modifying human antibodies by glycan engineering |
US10087236B2 (en) | 2009-12-02 | 2018-10-02 | Academia Sinica | Methods for modifying human antibodies by glycan engineering |
MX2012006560A (en) | 2009-12-08 | 2012-10-05 | Abbott Gmbh & Co Kg | Monoclonal antibodies against the rgm a protein for use in the treatment of retinal nerve fiber layer degeneration. |
EP2509626B1 (en) | 2009-12-11 | 2016-02-10 | F.Hoffmann-La Roche Ag | Anti-vegf-c antibodies and methods using same |
US8937159B2 (en) | 2009-12-16 | 2015-01-20 | Abbvie Biotherapeutics Inc. | Anti-HER2 antibodies and their uses |
WO2011084750A1 (en) | 2009-12-21 | 2011-07-14 | Genentech, Inc. | Antibody formulation |
CA2784385A1 (en) | 2009-12-23 | 2011-06-30 | Genentech, Inc. | Anti-bv8 antibodies and uses thereof |
CA3168591A1 (en) | 2010-01-06 | 2011-07-14 | Takeda Pharmaceutical Company Limited | Plasma kallikrein binding proteins |
CN102906115A (en) | 2010-01-11 | 2013-01-30 | 阿雷克森制药公司 | Biomarkers of immunomodulatory effects in humans treated with anti-cd200 antibodies |
TWI609698B (en) | 2010-01-20 | 2018-01-01 | Chugai Pharmaceutical Co Ltd | Stabilized antibody-containing solution preparation |
CN102712769B (en) | 2010-01-29 | 2014-12-03 | 东丽株式会社 | Polylactic acid-based resin sheet |
CN102892787B (en) | 2010-02-10 | 2015-04-29 | 富士胶片Ri制药株式会社 | Radioactive metal-labeled anti-cadherin antibody |
RU2573994C2 (en) | 2010-02-10 | 2016-01-27 | Иммьюноджен, Инк | Anti-cd20 antibodies and thereof application |
US9701723B2 (en) | 2010-02-18 | 2017-07-11 | Icahn School Of Medicine At Mount Sinai | Vaccines for use in the prophylaxis and treatment of influenza virus disease |
CA2790200A1 (en) | 2010-02-19 | 2011-08-25 | The Board Of Regents Of The University Of Oklahoma | Monoclonal antibodies that inhibit the wnt signaling pathway and methods of production and use thereof |
MY160628A (en) | 2010-03-02 | 2017-03-15 | Abbvie Inc | Therapeutic DLL4 Binding Proteins |
US10435458B2 (en) | 2010-03-04 | 2019-10-08 | Chugai Seiyaku Kabushiki Kaisha | Antibody constant region variants with reduced Fcgammar binding |
EP2542578A1 (en) | 2010-03-05 | 2013-01-09 | Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research | Smoc1, tenascin-c and brain cancers |
TWI667346B (en) | 2010-03-30 | 2019-08-01 | 中外製藥股份有限公司 | Antibodies with modified affinity to fcrn that promote antigen clearance |
CN102939103A (en) | 2010-03-30 | 2013-02-20 | 西奈山医学院 | Influenza virus vaccines and uses thereof |
EP3251503B1 (en) | 2010-03-31 | 2024-03-20 | Ablexis, LLC | Genetic engineering of mice for the production of chimeric antibodies |
WO2011130332A1 (en) | 2010-04-12 | 2011-10-20 | Academia Sinica | Glycan arrays for high throughput screening of viruses |
CA2796571C (en) | 2010-04-13 | 2019-10-29 | Celldex Therapeutics Inc. | Antibodies that bind human cd27 and uses thereof |
JP2013523182A (en) | 2010-04-15 | 2013-06-17 | アボット・ラボラトリーズ | Amyloid beta-binding protein |
ES2805873T3 (en) | 2010-04-16 | 2021-02-15 | Biogen Ma Inc | Anti-VLA-4 antibodies |
US20130034543A1 (en) | 2010-04-19 | 2013-02-07 | Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Resear | Modulating xrn1 |
WO2011133931A1 (en) | 2010-04-22 | 2011-10-27 | Genentech, Inc. | Use of il-27 antagonists for treating inflammatory bowel disease |
ES2623799T3 (en) | 2010-04-30 | 2017-07-12 | Alexion Pharmaceuticals, Inc. | Anti-C5a antibodies and methods for the use of antibodies |
IL208820A0 (en) | 2010-10-19 | 2011-01-31 | Rachel Teitelbaum | Biologic female contraceptives |
CN103068378B (en) | 2010-05-10 | 2016-07-06 | 中央研究院 | Zanamivir phosphonate ester congener with anti-influenza activity and preparation method thereof |
US20110293629A1 (en) | 2010-05-14 | 2011-12-01 | Bastid Jeremy | Methods of Treating and/or Preventing Cell Proliferation Disorders with IL-17 Antagonists |
PE20130205A1 (en) | 2010-05-14 | 2013-03-24 | Abbvie Inc | IL-1 BINDING PROTEINS |
WO2011146568A1 (en) | 2010-05-19 | 2011-11-24 | Genentech, Inc. | Predicting response to a her inhibitor |
JP6051049B2 (en) | 2010-05-28 | 2016-12-21 | 中外製薬株式会社 | Anti-tumor T cell response enhancer |
JP5904552B2 (en) | 2010-05-28 | 2016-04-13 | 国立研究開発法人国立がん研究センター | Pancreatic cancer treatment |
AU2011261396B2 (en) | 2010-06-02 | 2015-11-05 | Dana-Farber Cancer Institute, Inc. | Humanized monoclonal antibodies and methods of use |
WO2011153224A2 (en) | 2010-06-02 | 2011-12-08 | Genentech, Inc. | Diagnostic methods and compositions for treatment of cancer |
RU2613886C2 (en) | 2010-06-03 | 2017-03-21 | Дженентек, Инк. | Antibodies and immunoconjugates rendered by immuno-positron emission tomography, methods of application |
EP2580239A1 (en) | 2010-06-10 | 2013-04-17 | Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research | Treating cancer by modulating mammalian sterile 20-like kinase 3 |
AU2011268110B2 (en) | 2010-06-19 | 2016-05-19 | Memorial Sloan-Kettering Cancer Center | Anti-GD2 antibodies |
CA2803588A1 (en) | 2010-06-22 | 2011-12-29 | The Regents Of The University Of Colorado, A Body Corporate | Antibodies to the c3d fragment of complement component 3 |
JP2013530981A (en) | 2010-06-25 | 2013-08-01 | アストン ユニバーシティ | Glycoproteins with lipid mobilization properties and therapeutic uses thereof |
WO2012006500A2 (en) | 2010-07-08 | 2012-01-12 | Abbott Laboratories | Monoclonal antibodies against hepatitis c virus core protein |
NZ718973A (en) | 2010-07-09 | 2019-01-25 | Janssen Vaccines & Prevention Bv | Anti-human respiratory syncytial virus (rsv) antibodies and methods of use |
UY33492A (en) | 2010-07-09 | 2012-01-31 | Abbott Lab | IMMUNOGLOBULINS WITH DUAL VARIABLE DOMAIN AND USES OF THE SAME |
WO2012009705A1 (en) | 2010-07-15 | 2012-01-19 | Zyngenia, Inc. | Ang-2 binding complexes and uses thereof |
CN103119062A (en) | 2010-07-16 | 2013-05-22 | 埃博灵克斯股份有限公司 | Modified single domain antigen binding molecules and uses thereof |
WO2012010549A1 (en) | 2010-07-19 | 2012-01-26 | F. Hoffmann-La Roche Ag | Method to identify a patient with an increased likelihood of responding to an anti-cancer therapy |
SG187120A1 (en) | 2010-07-19 | 2013-02-28 | Hoffmann La Roche | Method to identify a patient with an increased likelihood of responding to an anti-cancer therapy |
BR112013003646B1 (en) | 2010-07-29 | 2021-09-08 | Eleven Biotherapeutics, Inc. | ISOLATED PROTEIN THAT COMPRISES A DOMAIN OF CYTOKINE OF THE INTERLEUKIN-1 (IL-1) CHIMERIC FAMILY, ITS METHOD OF PREPARATION, PHARMACEUTICAL COMPOSITION AND USES, AS WELL AS, NUCLEIC ACID, VECTOR, AND HOST CELL |
ES2667100T3 (en) | 2010-08-02 | 2018-05-09 | Macrogenics, Inc. | Covalent Diabodies and Their Uses |
EP3252072A3 (en) | 2010-08-03 | 2018-03-14 | AbbVie Inc. | Dual variable domain immunoglobulins and uses thereof |
EP2601220A2 (en) | 2010-08-06 | 2013-06-12 | U3 Pharma GmbH | Use of her3 binding agents in prostate treatment |
EP2420250A1 (en) | 2010-08-13 | 2012-02-22 | Universitätsklinikum Münster | Anti-Syndecan-4 antibodies |
EP2603524A1 (en) | 2010-08-14 | 2013-06-19 | AbbVie Inc. | Amyloid-beta binding proteins |
EP2606067B1 (en) | 2010-08-19 | 2018-02-21 | Zoetis Belgium S.A. | Anti-ngf antibodies and their use |
KR20130139884A (en) | 2010-08-26 | 2013-12-23 | 애브비 인코포레이티드 | Dual variable domain immunoglobulins and uses thereof |
WO2012025636A1 (en) | 2010-08-27 | 2012-03-01 | University Of Zurich | Method for target and drug validation in inflammatory and/or cardiovascular diseases |
WO2012028697A1 (en) | 2010-09-01 | 2012-03-08 | Eth Zürich, Institute Of Molecular Biology And Biophysics | Affinity purification system based on donor strand complementation |
EP2614080A1 (en) | 2010-09-10 | 2013-07-17 | Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research | Phosphorylated twist1 and metastasis |
EA032336B1 (en) | 2010-09-17 | 2019-05-31 | Баксалта Инкорпорейтид | Stable aqueous immunoglobulin composition and method of stabilization thereof |
DK2625197T3 (en) | 2010-10-05 | 2016-10-03 | Genentech Inc | Smoothened MUTANT AND METHODS OF USING THE SAME |
ES2686550T3 (en) | 2010-10-11 | 2018-10-18 | Biogen International Neuroscience Gmbh | Human anti-tau antibodies |
WO2012054748A2 (en) | 2010-10-22 | 2012-04-26 | Seattle Genetics, Inc. | Synergistic effects between auristatin-based antibody drug conjugates and inhibitors of the pi3k-akt mtor pathway |
EP2632481A1 (en) | 2010-10-25 | 2013-09-04 | Regents Of The University Of Minnesota | Therapeutic composition for treatment of glioblastoma |
WO2012057328A1 (en) | 2010-10-29 | 2012-05-03 | 株式会社ペルセウスプロテオミクス | Anti-cdh3 antibody having high internalizing capability |
EP2640738A1 (en) | 2010-11-15 | 2013-09-25 | Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research | Anti-fungal agents |
DK2644698T3 (en) | 2010-11-17 | 2018-01-22 | Chugai Pharmaceutical Co Ltd | MULTI-SPECIFIC ANTIGEN-BINDING MOLECULE WITH ALTERNATIVE FUNCTION TO BLOOD COAGULATION FACTOR FUNCTION VIII |
SG10201509790YA (en) | 2010-11-30 | 2015-12-30 | Chugai Pharmaceutical Co Ltd | Antigen-Binding Molecule Capable Of Binding To Plurality Of Antigen Molecules Repeatedly |
TR201815863T4 (en) | 2010-11-30 | 2018-11-21 | Chugai Pharmaceutical Co Ltd | Therapeutic agent that induces cytotoxicity. |
UA112170C2 (en) | 2010-12-10 | 2016-08-10 | Санофі | ANTI-TUMOR COMBINATION CONTAINING AN ANTIBODY SPECIFICALLY RECOGNIZING CD38 AND BORTESOMB |
EP2651979B1 (en) | 2010-12-17 | 2019-08-28 | Neurimmune Holding AG | Human anti-sod1 antibodies |
CN108939067A (en) | 2010-12-21 | 2018-12-07 | 瑟莱克斯制药公司 | Anti- palatelet-selectin antibody and its use and identification method |
SG191312A1 (en) | 2010-12-21 | 2013-07-31 | Abbvie Inc | Il-1 -alpha and -beta bispecific dual variable domain immunoglobulins and their use |
US20120275996A1 (en) | 2010-12-21 | 2012-11-01 | Abbott Laboratories | IL-1 Binding Proteins |
EA201390923A1 (en) | 2010-12-22 | 2013-12-30 | Сефалон Острэйлиа Пти Лтд. | MODIFIED ANTIBODY WITH AN IMPROVED ELEMENTATION SEMIUM PERIOD |
WO2012092539A2 (en) | 2010-12-31 | 2012-07-05 | Takeda Pharmaceutical Company Limited | Antibodies to dll4 and uses thereof |
CA2822969C (en) | 2010-12-31 | 2018-03-13 | Jay M. Short | Comprehensive monoclonal antibody generation |
US20120171195A1 (en) | 2011-01-03 | 2012-07-05 | Ravindranath Mepur H | Anti-hla-e antibodies, therapeutic immunomodulatory antibodies to human hla-e heavy chain, useful as ivig mimetics and methods of their use |
EP2665751A1 (en) | 2011-01-19 | 2013-11-27 | Bayer Intellectual Property GmbH | Binding proteins to inhibitors of coagulation factors |
WO2012102679A1 (en) | 2011-01-24 | 2012-08-02 | National University Of Singapore | Pathogenic mycobacteria-derived mannose-capped lipoarabinomannan antigen binding proteins |
WO2012103240A2 (en) | 2011-01-25 | 2012-08-02 | Eleven Biotherapeutics, Inc. | Receptor binding agents |
DK2668210T3 (en) | 2011-01-26 | 2020-08-24 | Celldex Therapeutics Inc | ANTI-KIT ANTIBODIES AND USES THEREOF |
AU2012212066A1 (en) | 2011-02-03 | 2013-08-15 | Alexion Pharmaceuticals, Inc. | Use of an anti-CD200 antibody for prolonging the survival of allografts |
WO2012104824A1 (en) | 2011-02-04 | 2012-08-09 | Ecole polytechnique fédérale de Lausanne (EPFL) | Therapeutic antibodies targeting app-c99 |
WO2012113775A1 (en) | 2011-02-21 | 2012-08-30 | University Of Zurich | Ankyrin g and modulators thereof for the treatment of neurodegenerative disorders |
MX352889B (en) | 2011-02-25 | 2017-12-13 | Chugai Pharmaceutical Co Ltd | Fcîriib-specific fc antibody. |
KR20140022815A (en) | 2011-02-28 | 2014-02-25 | 제넨테크, 인크. | Biological markers and methods for predicting response to b-cell antagonists |
AR085911A1 (en) | 2011-03-16 | 2013-11-06 | Sanofi Sa | SAFE THERAPEUTIC DOSE OF A SIMILAR PROTEIN TO AN ANTIBODY WITH VUAL REGION |
EP2500073A1 (en) | 2011-03-17 | 2012-09-19 | ChromaCon AG | Method for identification and purification of multi-specific polypeptides |
WO2012128377A1 (en) | 2011-03-18 | 2012-09-27 | 国立大学法人鹿児島大学 | Composition for treatment and diagnosis of pancreatic cancer |
US9555108B2 (en) | 2011-03-24 | 2017-01-31 | Texas Tech University System | TCR mimic antibodies as vascular targeting tools |
AU2012237287B2 (en) | 2011-03-30 | 2016-09-08 | Ablynx Nv | Methods of treating immune disorders with single domain antibodies against TNF-alpha |
AU2012233313C1 (en) | 2011-03-30 | 2017-08-03 | Chugai Seiyaku Kabushiki Kaisha | Method for altering plasma retention and immunogenicity of antigen-binding molecule |
US10059746B2 (en) | 2011-04-04 | 2018-08-28 | University Of Iowa Research Foundation | Methods of improving vaccine immunogenicity |
KR102001686B1 (en) | 2011-04-07 | 2019-07-18 | 암젠 인크 | Novel egfr binding proteins |
US9150644B2 (en) | 2011-04-12 | 2015-10-06 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Human monoclonal antibodies that bind insulin-like growth factor (IGF) I and II |
KR101970025B1 (en) | 2011-04-20 | 2019-04-17 | 메디뮨 엘엘씨 | Antibodies and other molecules that bind b7-h1 and pd-1 |
WO2012149197A2 (en) | 2011-04-27 | 2012-11-01 | Abbott Laboratories | Methods for controlling the galactosylation profile of recombinantly-expressed proteins |
JOP20200043A1 (en) | 2011-05-10 | 2017-06-16 | Amgen Inc | Methods of treating or preventing cholesterol related disorders |
WO2012158818A2 (en) | 2011-05-16 | 2012-11-22 | Fabion Pharmaceuticals, Inc. | Multi-specific fab fusion proteins and methods of use |
EP2714079B2 (en) | 2011-05-21 | 2019-08-28 | MacroGenics, Inc. | Deimmunized serum-binding domains and their use for extending serum half-life |
WO2012162561A2 (en) | 2011-05-24 | 2012-11-29 | Zyngenia, Inc. | Multivalent and monovalent multispecific complexes and their uses |
AR086543A1 (en) | 2011-05-25 | 2014-01-08 | Bg Medicine Inc | GALECTIN-3 INHIBITORS AND METHODS OF USE OF THE SAME, PHARMACEUTICAL COMPOSITION |
EP2530088A1 (en) | 2011-05-30 | 2012-12-05 | Klinikum rechts der Isar der Technischen Universität München | Means and methods for diagnosing and treating multiple sclerosis |
MX343659B (en) | 2011-06-02 | 2016-11-16 | Dyax Corp | Fc RECEPTOR BINDING PROTEINS. |
ES2894398T3 (en) | 2011-06-03 | 2022-02-14 | Xoma Technology Ltd | Specific antibodies to TGF-beta |
US9574002B2 (en) | 2011-06-06 | 2017-02-21 | Amgen Inc. | Human antigen binding proteins that bind to a complex comprising β-Klotho and an FGF receptor |
JP6305919B2 (en) | 2011-06-06 | 2018-04-04 | プロセナ バイオサイエンシーズ リミテッド | MCAM antagonists and methods of treatment |
WO2012168259A1 (en) | 2011-06-06 | 2012-12-13 | Novartis Forschungsstiftung, Zweigniederlassung | Protein tyrosine phosphatase, non-receptor type 11 (ptpn11) and triple-negative breast cancer |
US9244074B2 (en) | 2011-06-07 | 2016-01-26 | University Of Hawaii | Biomarker of asbestos exposure and mesothelioma |
US9561274B2 (en) | 2011-06-07 | 2017-02-07 | University Of Hawaii | Treatment and prevention of cancer with HMGB1 antagonists |
ES2664972T3 (en) | 2011-06-10 | 2018-04-24 | Medimmune Limited | Pseudomonas anti-Psl binding molecules and uses thereof |
US20140120555A1 (en) | 2011-06-20 | 2014-05-01 | Pierre Fabre Medicament | Anti-cxcr4 antibody with effector functions and its use for the treatment of cancer |
TR201815563T4 (en) | 2011-06-23 | 2018-11-21 | Biogen Int Neuroscience Gmbh | Anti-alpha synuclein binding molecules. |
TWI687441B (en) | 2011-06-30 | 2020-03-11 | 中外製藥股份有限公司 | Heterodimerized polypeptide |
JP2013040160A (en) | 2011-07-01 | 2013-02-28 | Genentech Inc | Use of anti-cd83 agonist antibody for treating autoimmune disease |
DE202011103324U1 (en) | 2011-07-12 | 2012-01-02 | Nekonal S.A.R.L. | Therapeutic anti-TIRC7 antibodies for use in immune and other diseases |
WO2013009521A2 (en) | 2011-07-13 | 2013-01-17 | Abbvie Inc. | Methods and compositions for treating asthma using anti-il-13 antibodies |
US9574005B2 (en) | 2011-07-19 | 2017-02-21 | Chugai Seiyaku Kabushiki Kaisha | Stable Protein-containing preparation containing argininamide or analogous compound thereof |
CN103842030B (en) | 2011-08-01 | 2018-07-31 | 霍夫曼-拉罗奇有限公司 | Use the method for PD-1 axis binding antagonists and mek inhibitor treating cancer |
WO2013017656A1 (en) | 2011-08-02 | 2013-02-07 | Medizinische Universität Wien | Antagonists of ribonucleases for treating obesity |
WO2013017691A1 (en) | 2011-08-04 | 2013-02-07 | Medizinische Universität Innsbruck | Cahgt1p inhibitors for use in the treatment of candidiasis |
CA2845536A1 (en) | 2011-08-15 | 2013-02-21 | Amplimmune, Inc. | Anti-b7-h4 antibodies and their uses |
KR20140068877A (en) | 2011-08-17 | 2014-06-09 | 제넨테크, 인크. | Inhibition of angiogenesis in refractory tumors |
WO2013027802A1 (en) | 2011-08-23 | 2013-02-28 | 中外製薬株式会社 | Novel anti-ddr1 antibody having anti-tumor activity |
JP6216317B2 (en) | 2011-09-09 | 2017-10-18 | メディミューン リミテッド | Anti-Siglec-15 antibody and use thereof |
CN104185476A (en) | 2011-09-20 | 2014-12-03 | 西奈山医学院 | Influenza virus vaccines and uses thereof |
CN103827145A (en) | 2011-09-21 | 2014-05-28 | 富士瑞必欧株式会社 | Antibody against affinity complex |
WO2013041687A1 (en) | 2011-09-23 | 2013-03-28 | Amgen Research (Munich) Gmbh | Bispecific binding molecules for 5t4 and cd3 |
EP3939996A1 (en) | 2011-09-30 | 2022-01-19 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule promoting disappearance of antigens having plurality of biological activities |
CN107287660A (en) | 2011-09-30 | 2017-10-24 | 中外制药株式会社 | Ion concentration dependence binding molecule library |
TWI580693B (en) | 2011-09-30 | 2017-05-01 | 中外製藥股份有限公司 | Antigen-binding molecule that promotes the disappearance of antigen |
TW201326209A (en) | 2011-09-30 | 2013-07-01 | Chugai Pharmaceutical Co Ltd | Therapeutic antigen-binding molecule with a FcRn-binding domain that promotes antigen clearance |
JP6352634B2 (en) | 2011-09-30 | 2018-07-04 | 中外製薬株式会社 | Antigen-binding molecules that induce immune responses to target antigens |
EP2764118A1 (en) | 2011-10-05 | 2014-08-13 | University of Bremen | Wnt4 and med12 for use in the diagnosis and treatment of tumor diseases |
AU2012319150B2 (en) | 2011-10-05 | 2017-08-17 | Genentech, Inc. | Methods of treating liver conditions using Notch2 antagonists |
EP3617313A1 (en) | 2011-10-05 | 2020-03-04 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule for promoting clearance from plasma of antigen comprising saccharide chain receptor-binding domain |
CA2852758C (en) | 2011-10-21 | 2020-12-29 | Augurex Life Sciences Corporation | Antigens derived from citrullinated 14-3-3 and uses thereof in the diagnosis of rheumatoid arthritis |
CA2853357A1 (en) | 2011-10-24 | 2013-05-02 | Abbvie Inc. | Immunobinders directed against tnf |
UY34411A (en) | 2011-10-24 | 2013-05-31 | Abbvie Inc | IMMUNO LINKERS AGAINST SCLEROSTINE |
US9272002B2 (en) | 2011-10-28 | 2016-03-01 | The Trustees Of The University Of Pennsylvania | Fully human, anti-mesothelin specific chimeric immune receptor for redirected mesothelin-expressing cell targeting |
ES2732712T3 (en) | 2011-10-31 | 2019-11-25 | Chugai Pharmaceutical Co Ltd | Antigen binding molecule that has a regulated conjugation between the heavy chain and the light chain |
KR20140084078A (en) | 2011-10-31 | 2014-07-04 | 제넨테크, 인크. | Antibody formulations |
US10598653B2 (en) | 2011-11-01 | 2020-03-24 | Bionomics Inc. | Methods of blocking cancer stem cell growth |
EP2773667A1 (en) | 2011-11-01 | 2014-09-10 | Bionomics, Inc. | Anti-gpr49 antibodies |
CA2853951A1 (en) | 2011-11-01 | 2013-05-10 | Bionomics, Inc. | Antibodies and methods of treating cancer |
US9220774B2 (en) | 2011-11-01 | 2015-12-29 | Bionomics Inc. | Methods of treating cancer by administering anti-GPR49 antibodies |
US9422351B2 (en) | 2011-11-03 | 2016-08-23 | The Trustees Of The University Of Pennsylvania | Isolated B7-H4 specific compositions and methods of use thereof |
WO2013070468A1 (en) | 2011-11-08 | 2013-05-16 | The Trustees Of The University Of Pennsylvania | Glypican-3-specific antibody and uses thereof |
EP2776565A1 (en) | 2011-11-08 | 2014-09-17 | Quark Pharmaceuticals, Inc. | Methods and compositions for treating diseases, disorders or injury of the nervous system |
EP2776838A1 (en) | 2011-11-08 | 2014-09-17 | Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research | Early diagnostic of neurodegenerative diseases |
IN2014CN04183A (en) | 2011-11-08 | 2015-07-17 | Pfizer | |
US20140314787A1 (en) | 2011-11-08 | 2014-10-23 | Novartis Forschungsstiftung, Zweigniederlassung, Friedrich Miescher Institute | Treatment for neurodegenerative diseases |
TWI679212B (en) | 2011-11-15 | 2019-12-11 | 美商安進股份有限公司 | Binding molecules for e3 of bcma and cd3 |
AP2014007638A0 (en) | 2011-11-16 | 2014-05-31 | Amgen Inc | Methods of treating epidermal growth factor deletion mutant VIII related disorders |
DK2785375T3 (en) | 2011-11-28 | 2020-10-12 | Merck Patent Gmbh | ANTI-PD-L1 ANTIBODIES AND USES THEREOF |
SG10201609301QA (en) | 2011-11-30 | 2016-12-29 | Chugai Pharmaceutical Co Ltd | Drug containing carrier into cell for forming immune complex |
CN104302324A (en) | 2011-12-08 | 2015-01-21 | 生物测试股份公司 | Uses of immunoconjugates targeting cd138 |
EP2602621A1 (en) | 2011-12-08 | 2013-06-12 | Julius-Maximilians-Universität Würzburg | LASP-1, a novel urinary marker for transitional cell carcinoma detection |
CA2855570A1 (en) | 2011-12-14 | 2013-06-20 | AbbVie Deutschland GmbH & Co. KG | Composition and method for the diagnosis and treatment of iron-related disorders |
AU2012352168C1 (en) | 2011-12-14 | 2018-01-25 | AbbVie Deutschland GmbH & Co. KG | Composition and method for the diagnosis and treatment of iron-related disorders |
CN104144946A (en) | 2011-12-19 | 2014-11-12 | 爱克索马美国有限责任公司 | Methods for treating acne |
US20150030602A1 (en) | 2011-12-23 | 2015-01-29 | Phenoquest Ag | Antibodies for the treatment and diagnosis of affective and anxiety disorders |
CA2859755C (en) | 2011-12-23 | 2021-04-20 | Pfizer Inc. | Engineered antibody constant regions for site-specific conjugation and methods and uses therefor |
TWI593705B (en) | 2011-12-28 | 2017-08-01 | Chugai Pharmaceutical Co Ltd | Humanized anti-epiregulin antibody and cancer therapeutic agent containing the antibody as an active ingredient |
WO2013098419A1 (en) | 2011-12-28 | 2013-07-04 | Immunoqure Ag | Method of providing monoclonal auto-antibodies with desired specificity |
CN104159920A (en) | 2011-12-30 | 2014-11-19 | 艾伯维公司 | Dual specific binding proteins directed against il-13 and/or il-17 |
US20140363448A1 (en) | 2012-01-02 | 2014-12-11 | Novartis Ag | Cdcp1 and breast cancer |
US10774132B2 (en) | 2012-01-09 | 2020-09-15 | The Scripps Research Instittue | Ultralong complementarity determining regions and uses thereof |
JP2015509091A (en) | 2012-01-09 | 2015-03-26 | ザ スクリプス リサーチ インスティテュート | Humanized antibody |
US20130177574A1 (en) | 2012-01-11 | 2013-07-11 | Paul I. Terasaki Foundation Laboratory | ANTI-HLA CLASS-Ib ANTIBODIES MIMIC IMMUNOREACTIVITY AND IMMUNOMODULATORY FUNCTIONS OF INTRAVENOUS IMMUNOGLOBULIN (IVIg) USEFUL AS THERAPEUTIC IVIg MIMETICS AND METHODS OF THEIR USE |
US10800847B2 (en) | 2012-01-11 | 2020-10-13 | Dr. Mepur Ravindranath | Anti-HLA class-IB antibodies mimic immunoreactivity and immunomodulatory functions of intravenous immunoglobulin (IVIG) useful as therapeutic IVIG mimetics and methods of their use |
EP2802346B1 (en) | 2012-01-13 | 2018-09-12 | F.Hoffmann-La Roche Ag | Biological markers for identifying patients for treatment with vegf antagonists |
CN104471064B (en) | 2012-01-20 | 2018-11-02 | 中华人民共和国香港特别行政区政府 | Paramyxovirus and application thereof |
RS57603B1 (en) | 2012-01-27 | 2018-11-30 | Abbvie Deutschland | Composition and method for diagnosis and treatment of diseases associated with neurite degeneration |
TW201334789A (en) | 2012-01-31 | 2013-09-01 | Genentech Inc | Anti-IgE antibodies and methods using same |
CA2863834A1 (en) | 2012-02-06 | 2013-08-15 | Inhibrx Llc | Cd47 antibodies and methods of use thereof |
SG11201404751UA (en) | 2012-02-09 | 2014-09-26 | Chugai Pharmaceutical Co Ltd | Modified fc region of antibody |
US10444241B2 (en) | 2012-02-10 | 2019-10-15 | Seattle Genetics, Inc. | Detection and treatment of CD30+ cancers |
ES2690786T3 (en) | 2012-02-15 | 2018-11-22 | Novo Nordisk A/S | Antibodies that bind peptidoglycan recognition protein 1 |
PL2814844T3 (en) | 2012-02-15 | 2017-12-29 | Novo Nordisk A/S | Antibodies that bind and block triggering receptor expressed on myeloid cells-1 (trem-1) |
US9550830B2 (en) | 2012-02-15 | 2017-01-24 | Novo Nordisk A/S | Antibodies that bind and block triggering receptor expressed on myeloid cells-1 (TREM-1) |
US10160808B2 (en) | 2012-02-16 | 2018-12-25 | Santarus, Inc. | Anti-VLA1 (CD49A) antibody pharmaceutical compositions |
RU2736349C2 (en) | 2012-02-24 | 2020-11-16 | Чугаи Сейяку Кабусики Кайся | Antigen-binding molecule to accelerate antigen disappearance through fcγriib |
JP6407726B2 (en) | 2012-03-01 | 2018-10-24 | アムゲン リサーチ (ミュンヘン) ゲーエムベーハーAMGEN Research(Munich)GmbH | Long-life polypeptide binding molecule |
MY173376A (en) | 2012-03-16 | 2020-01-21 | Regeneron Pharma | Mice that produce antigen?binding proteins with ph?dependent binding characteristics |
BR112014022855A2 (en) | 2012-03-16 | 2017-07-18 | Regeneron Pharma | genetically modified nonhuman animal, genetically modified mammal, and method for making a nonhuman animal |
US20140013456A1 (en) | 2012-03-16 | 2014-01-09 | Regeneron Pharmaceuticals, Inc. | Histidine Engineered Light Chain Antibodies and Genetically Modified Non-Human Animals for Generating the Same |
CA2865643A1 (en) | 2012-03-16 | 2013-09-19 | Regeneron Pharmaceuticals, Inc. | Histidine engineered light chain antibodies and genetically modified non-human animals for generating the same |
US9592289B2 (en) | 2012-03-26 | 2017-03-14 | Sanofi | Stable IgG4 based binding agent formulations |
CN107099581B (en) | 2012-03-27 | 2021-07-13 | 弗·哈夫曼-拉罗切有限公司 | Methods of prognosing, diagnosing and treating idiopathic pulmonary fibrosis |
RU2014136886A (en) | 2012-03-27 | 2016-05-20 | Дженентек, Инк. | DIAGNOSTIC AND TREATMENT TYPES RELATED TO HER3 INHIBITORS |
HUE037613T2 (en) | 2012-03-29 | 2018-09-28 | Novimmune Sa | Anti-tlr4 antibodies and uses thereof |
JP6280031B2 (en) | 2012-03-29 | 2018-02-14 | 中外製薬株式会社 | Anti-LAMP5 antibody and use thereof |
US20150266961A1 (en) | 2012-03-29 | 2015-09-24 | Novartis Forschungsstiftung, Zweigniederlassung, Fridrich Miescher Institute | Inhibition of interleukin-8 and/or its receptor cxcr1 in the treatment of her2/her3-overexpressing breast cancer |
JP6335875B2 (en) | 2012-03-30 | 2018-05-30 | ジェネンテック, インコーポレイテッド | Diagnostic methods and compositions for the treatment of cancer |
JP6113717B2 (en) | 2012-04-04 | 2017-04-12 | 株式会社ペルセウスプロテオミクス | Drug conjugate of anti-CDH3 (P-cadherin) antibody |
WO2013151649A1 (en) | 2012-04-04 | 2013-10-10 | Sialix Inc | Glycan-interacting compounds |
EP2836514A4 (en) | 2012-04-13 | 2015-12-30 | Childrens Medical Center | Tiki inhibitors |
US10130714B2 (en) | 2012-04-14 | 2018-11-20 | Academia Sinica | Enhanced anti-influenza agents conjugated with anti-inflammatory activity |
US9067990B2 (en) | 2013-03-14 | 2015-06-30 | Abbvie, Inc. | Protein purification using displacement chromatography |
WO2013158279A1 (en) | 2012-04-20 | 2013-10-24 | Abbvie Inc. | Protein purification methods to reduce acidic species |
US9181572B2 (en) | 2012-04-20 | 2015-11-10 | Abbvie, Inc. | Methods to modulate lysine variant distribution |
WO2013166043A1 (en) | 2012-05-02 | 2013-11-07 | Children's Hospital Medical Center | Rejuvenation of precursor cells |
US9480449B2 (en) | 2012-05-03 | 2016-11-01 | Fibrogen, Inc. | Methods for treating idiopathic pulmonary fibrosis |
EA039663B1 (en) | 2012-05-03 | 2022-02-24 | Амген Инк. | Use of an anti-pcsk9 antibody for lowering serum cholesterol ldl and treating cholesterol related disorders |
WO2013166290A1 (en) | 2012-05-04 | 2013-11-07 | Abbvie Biotherapeutics Inc. | P21 biomarker assay |
CA2871751C (en) | 2012-05-04 | 2021-08-24 | Dana-Farber Cancer Institute, Inc. | Affinity matured anti-ccr4 humanized monoclonal antibodies and methods of use |
EP2849787A4 (en) | 2012-05-14 | 2016-06-15 | Biogen Ma Inc | Lingo-2 antagonists for treatment of conditions involving motor neurons |
KR20220051197A (en) | 2012-05-17 | 2022-04-26 | 익스텐드 바이오사이언시즈, 인크. | Carriers for improved drug delivery |
WO2013176754A1 (en) | 2012-05-24 | 2013-11-28 | Abbvie Inc. | Novel purification of antibodies using hydrophobic interaction chromatography |
WO2013177386A1 (en) | 2012-05-24 | 2013-11-28 | Abbvie Biotherapeutics Inc. | Biomarkers for predicting response to tweak receptor (tweakr) agonist therapy |
US20150353630A1 (en) | 2012-05-30 | 2015-12-10 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule for eliminating aggregated antigens |
EP3795215A1 (en) | 2012-05-30 | 2021-03-24 | Chugai Seiyaku Kabushiki Kaisha | Target tissue-specific antigen-binding molecule |
SG10201603055WA (en) | 2012-05-31 | 2016-05-30 | Genentech Inc | Methods Of Treating Cancer Using PD-L1 Axis Binding Antagonists And VEGF Antagonists |
WO2013184871A1 (en) | 2012-06-06 | 2013-12-12 | Zoetis Llc | Caninized anti-ngf antibodies and methods thereof |
EP2862875B1 (en) | 2012-06-14 | 2023-09-06 | Chugai Seiyaku Kabushiki Kaisha | ANTIGEN-BINDING MOLECULE CONTAINING MODIFIED Fc REGION |
CA2876397C (en) | 2012-06-15 | 2019-08-06 | Pfizer Inc. | Improved antagonist antibodies against gdf-8 and uses therefor |
US9127053B2 (en) | 2012-06-22 | 2015-09-08 | Cytomx Therapeutics, Inc. | Anti-jagged 1/jagged 2 cross-reactive antibodies, activatable anti-jagged antibodies and methods of use thereof |
EP2866831A1 (en) | 2012-06-29 | 2015-05-06 | Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research | Treating diseases by modulating a specific isoform of mkl1 |
US10656156B2 (en) | 2012-07-05 | 2020-05-19 | Mepur Ravindranath | Diagnostic and therapeutic potential of HLA-E monospecific monoclonal IgG antibodies directed against tumor cell surface and soluble HLA-E |
EP2870242A1 (en) | 2012-07-05 | 2015-05-13 | Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research | New treatment for neurodegenerative diseases |
WO2014006115A1 (en) | 2012-07-06 | 2014-01-09 | Novartis Ag | Combination of a phosphoinositide 3-kinase inhibitor and an inhibitor of the il-8/cxcr interaction |
WO2014011955A2 (en) | 2012-07-12 | 2014-01-16 | Abbvie, Inc. | Il-1 binding proteins |
ES2786263T3 (en) | 2012-07-13 | 2020-10-09 | Univ Pennsylvania | Enhancement of T-lymphocyte CAR activity by co-introduction of a bispecific antibody |
CA2880701A1 (en) | 2012-08-18 | 2014-02-27 | Academia Sinica | Cell-permeable probes for identification and imaging of sialidases |
WO2014031762A1 (en) | 2012-08-21 | 2014-02-27 | Academia Sinica | Benzocyclooctyne compounds and uses thereof |
JP6501521B2 (en) | 2012-08-24 | 2019-04-17 | 中外製薬株式会社 | FcγRIIb-specific Fc region variant |
EP3597747B1 (en) | 2012-08-24 | 2023-03-15 | Chugai Seiyaku Kabushiki Kaisha | Mouse fcgammarii-specific fc antibody |
KR20240005129A (en) | 2012-08-31 | 2024-01-11 | 이뮤노젠 아이엔씨 | Diagnostic assays and kits for detection of folate receptor 1 |
US9561266B2 (en) | 2012-08-31 | 2017-02-07 | University Of Virginia Patent Foundation | Target peptides for immunotherapy and diagnostics |
SG11201504249XA (en) | 2012-09-02 | 2015-07-30 | Abbvie Inc | Methods to control protein heterogeneity |
US9512214B2 (en) | 2012-09-02 | 2016-12-06 | Abbvie, Inc. | Methods to control protein heterogeneity |
US10682399B2 (en) | 2012-09-05 | 2020-06-16 | The University Of Birmingham | Target peptides for colorectal cancer therapy and diagnostics |
TWI595007B (en) | 2012-09-10 | 2017-08-11 | Neotope Biosciences Ltd | Anti-mcam antibodies and associated methods of use |
EP2898327A1 (en) | 2012-09-19 | 2015-07-29 | Dana-Farber Cancer Institute, Inc. | Dynamic bh3 profiling |
EP2711016A1 (en) | 2012-09-21 | 2014-03-26 | Covagen AG | Novel IL-17A binding molecules and medical uses thereof |
WO2014051022A1 (en) | 2012-09-27 | 2014-04-03 | 中外製薬株式会社 | Fgfr3 fusion gene and pharmaceutical drug targeting same |
JP6284481B2 (en) | 2012-09-28 | 2018-02-28 | 中外製薬株式会社 | Evaluation method of blood coagulation reaction |
EP2904106A4 (en) | 2012-10-01 | 2016-05-11 | Univ Pennsylvania | Compositions and methods for targeting stromal cells for the treatment of cancer |
NO2760138T3 (en) | 2012-10-01 | 2018-08-04 | ||
AU2013326901B2 (en) | 2012-10-04 | 2018-05-31 | Dana-Farber Cancer Institute, Inc. | Human monoclonal anti-PD-L1 antibodies and methods of use |
WO2014055771A1 (en) | 2012-10-05 | 2014-04-10 | The Trustees Of The University Of Pennsylvania | Human alpha-folate receptor chimeric antigen receptor |
WO2014063205A1 (en) | 2012-10-26 | 2014-05-01 | The University Of Queensland | Use of endocytosis inhibitors and antibodies for cancer therapy |
KR20180008921A (en) | 2012-11-01 | 2018-01-24 | 애브비 인코포레이티드 | Anti-vegf/dll4 dual variable domain immunoglobulins and uses thereof |
LT2918603T (en) | 2012-11-08 | 2018-10-25 | University Of Miyazaki | Antibody capable of specifically recognizing transferrin receptor |
US20140154255A1 (en) | 2012-11-30 | 2014-06-05 | Abbvie Biotherapeutics Inc. | Anti-vegf antibodies and their uses |
EP3725807A1 (en) | 2012-12-03 | 2020-10-21 | NovImmune SA | Anti-cd47 antibodies and methods of use thereof |
UA118255C2 (en) | 2012-12-07 | 2018-12-26 | Санофі | Compositions comprising anti-cd38 antibodies and lenalidomide |
US10342869B2 (en) | 2012-12-07 | 2019-07-09 | The Regents Of The University Of California | Compositions comprising anti-CD38 antibodies and lenalidomide |
PT2928923T (en) | 2012-12-10 | 2020-03-27 | Biogen Ma Inc | Anti-blood dendritic cell antigen 2 antibodies and uses thereof |
EP2931312A4 (en) | 2012-12-13 | 2016-10-19 | Univ Virginia Patent Found | Target peptides for ovarian cancer therapy and diagnostics |
US9968670B2 (en) | 2012-12-18 | 2018-05-15 | Icahn School Of Medicine At Mount Sinai | Influenza virus vaccines and uses thereof |
CA2894879A1 (en) | 2012-12-19 | 2014-06-26 | Amplimmune, Inc. | B7-h4 specific antibodies, and compositions and methods of use thereof |
KR20150100715A (en) | 2012-12-21 | 2015-09-02 | 앰플리뮨, 인크. | Anti-h7cr antibodies |
MX2015008024A (en) | 2012-12-21 | 2016-08-08 | Biogen Int Neuroscience Gmbh | Human anti-tau antibodies. |
KR102249779B1 (en) | 2012-12-27 | 2021-05-07 | 추가이 세이야쿠 가부시키가이샤 | Heterodimerized polypeptide |
US9771413B2 (en) | 2012-12-31 | 2017-09-26 | Neurimmune Holding Ag | Recombinant human antibodies for therapy and prevention of polyomavirus-related diseases |
US10717965B2 (en) | 2013-01-10 | 2020-07-21 | Gloriana Therapeutics, Inc. | Mammalian cell culture-produced neublastin antibodies |
ES2728936T3 (en) | 2013-01-25 | 2019-10-29 | Amgen Inc | Antibodies directed against CDH19 for melanoma |
JO3519B1 (en) | 2013-01-25 | 2020-07-05 | Amgen Inc | Antibody constructs for CDH19 and CD3 |
US9834610B2 (en) | 2013-01-31 | 2017-12-05 | Thomas Jefferson University | Fusion proteins for modulating regulatory and effector T cells |
CA2900468A1 (en) | 2013-02-06 | 2014-08-14 | Inhibrx Llc | Non-platelet depleting and non-red blood cell depleting cd47 antibodies and methods of use thereof |
RU2015140573A (en) | 2013-02-25 | 2017-03-30 | Дженентек, Инк. | METHODS AND COMPOSITIONS FOR DETECTION AND TREATMENT OF DRUG-RESISTANT MUTANT RESISTANT TO MEDICINES |
EP2830651A4 (en) | 2013-03-12 | 2015-09-02 | Abbvie Inc | Human antibodies that bind human tnf-alpha and methods of preparing the same |
EP3744345B1 (en) | 2013-03-13 | 2022-02-09 | F. Hoffmann-La Roche AG | Antibody formulations |
ES2884813T3 (en) | 2013-03-13 | 2021-12-13 | Buzzard Pharmaceuticals AB | Chimeric Cytokine Formulations for Ocular Administration |
US10653779B2 (en) | 2013-03-13 | 2020-05-19 | Genentech, Inc. | Formulations with reduced oxidation |
SG10201705525VA (en) | 2013-03-13 | 2017-08-30 | Genentech Inc | Formulations with reduced oxidation |
RU2670127C2 (en) | 2013-03-13 | 2018-10-18 | Санофи | Compositions comprising antibody to cd38 and carfilzomib |
CN105209058A (en) | 2013-03-13 | 2015-12-30 | 豪夫迈·罗氏有限公司 | Formulations with reduced oxidation |
AR095398A1 (en) | 2013-03-13 | 2015-10-14 | Genentech Inc | FORMULATIONS WITH REDUCED OXIDATION |
CA2906421C (en) | 2013-03-14 | 2022-08-16 | George J. Dawson | Hcv antigen-antibody combination assay and methods and compositions for use therein |
US9017687B1 (en) | 2013-10-18 | 2015-04-28 | Abbvie, Inc. | Low acidic species compositions and methods for producing and using the same using displacement chromatography |
WO2014159242A1 (en) | 2013-03-14 | 2014-10-02 | Novartis Ag | Notch 3 mutants and uses thereof |
WO2014151878A2 (en) | 2013-03-14 | 2014-09-25 | Abbvie Inc. | Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides |
BR112015023355A8 (en) | 2013-03-14 | 2018-01-30 | Abbott Lab | hcv ns3 recombinant antigens and mutants thereof for enhanced antibody detection. |
AU2014244444A1 (en) | 2013-03-14 | 2015-09-24 | Amgen Inc. | CHRDL-1 antigen binding proteins and methods of treatment |
US9908930B2 (en) | 2013-03-14 | 2018-03-06 | Icahn School Of Medicine At Mount Sinai | Antibodies against influenza virus hemagglutinin and uses thereof |
SG11201507563SA (en) | 2013-03-14 | 2015-10-29 | Parkash Gill | Cancer treatment using antibodies that bind cell surface grp78 |
US8921526B2 (en) | 2013-03-14 | 2014-12-30 | Abbvie, Inc. | Mutated anti-TNFα antibodies and methods of their use |
MX2015012825A (en) | 2013-03-14 | 2016-06-10 | Abbott Lab | Hcv core lipid binding domain monoclonal antibodies. |
CN105451767B (en) | 2013-03-15 | 2019-10-18 | 泽恩格尼亚股份有限公司 | Multivalence and monovalent polyspecific compound and application thereof |
WO2014144292A2 (en) | 2013-03-15 | 2014-09-18 | Sanofi Pasteur Biologics , Llc | Antibodies against clostridium difficile toxins and methods of using the same |
CN105324396A (en) | 2013-03-15 | 2016-02-10 | 艾伯维公司 | Dual specific binding proteins directed against il-1 beta and il-17 |
SI2970449T1 (en) | 2013-03-15 | 2019-11-29 | Amgen Res Munich Gmbh | Single chain binding molecules comprising n-terminal abp |
AR095374A1 (en) | 2013-03-15 | 2015-10-14 | Amgen Res (Munich) Gmbh | UNION MOLECULES FOR BCMA AND CD3 |
JP6591395B2 (en) | 2013-03-15 | 2019-10-16 | ジェネンテック, インコーポレイテッド | Cell culture compositions containing antioxidants and methods for polypeptide production |
JP2016514690A (en) | 2013-03-15 | 2016-05-23 | アッヴィ バイオテクノロジー リミテッド | Anti-CD25 antibodies and their use |
EA201591806A1 (en) | 2013-03-15 | 2016-01-29 | Байоджен Ма Инк. | TREATMENT AND PREVENTION OF ACUTE RENAL FAILURE WITH THE USE OF ANTI-ALPHA-V-BETA-5 ANTIBODIES |
MX2015012551A (en) | 2013-03-15 | 2016-10-26 | Abbvie Biotechnology Ltd | Anti-cd25 antibodies and their uses. |
EP2970446A1 (en) | 2013-03-15 | 2016-01-20 | Amgen Research (Munich) GmbH | Antibody constructs for influenza m2 and cd3 |
EP2968544A4 (en) | 2013-03-15 | 2016-10-12 | Hoffmann La Roche | Cell culture media and methods of antibody production |
ES2699599T3 (en) | 2013-03-15 | 2019-02-11 | Abbvie Biotherapeutics Inc | Fc variants |
US9469686B2 (en) | 2013-03-15 | 2016-10-18 | Abbott Laboratories | Anti-GP73 monoclonal antibodies and methods of obtaining the same |
KR102207859B1 (en) | 2013-03-15 | 2021-01-27 | 메모리얼 슬로안 케터링 캔서 센터 | High affinity anti-gd2 antibodies |
CA2901358C (en) | 2013-03-15 | 2022-07-26 | Dana-Farber Cancer Institute, Inc. | Flavivirus neutralizing antibodies and methods of use thereof |
AU2014250434B2 (en) | 2013-04-02 | 2019-08-08 | Chugai Seiyaku Kabushiki Kaisha | Fc region variant |
WO2014165818A2 (en) | 2013-04-05 | 2014-10-09 | T Cell Therapeutics, Inc. | Compositions and methods for preventing and treating prostate cancer |
US20160053023A1 (en) | 2013-04-09 | 2016-02-25 | Annexon, Inc. | Methods of treatment for neuromyelitis optica |
TWI679019B (en) | 2013-04-29 | 2019-12-11 | 法商賽諾菲公司 | Anti-il-4/anti-il-13 bispecific antibody formulations |
SG10201800800YA (en) | 2013-05-06 | 2018-03-28 | Scholar Rock Inc | Compositions and methods for growth factor modulation |
US9989540B2 (en) | 2013-05-10 | 2018-06-05 | The Regents Of The University Of California | Diagnostic and monitoring system for Huntington's disease |
CA2912526C (en) | 2013-05-16 | 2021-09-14 | Kyoto University | Method for determining prognosis of cancer |
CA2913312A1 (en) | 2013-05-24 | 2014-11-27 | Medimmune, Llc | Anti-b7-h5 antibodies and their uses |
ES2891755T3 (en) | 2013-06-06 | 2022-01-31 | Pf Medicament | Anti-C10orf54 antibodies and uses thereof |
US10781259B2 (en) | 2013-06-06 | 2020-09-22 | Magenta Therapeutics, Inc. | Modified antibodies and related compounds, compositions, and methods of use |
EP3632467B1 (en) | 2013-06-07 | 2023-09-27 | Duke University | Inhibitors of complement factor h |
WO2014200018A1 (en) | 2013-06-11 | 2014-12-18 | 独立行政法人 国立精神・神経医療研究センター | Method for predicting post-therapy prognosis of relapsing-remitting multiple sclerosis (rrms) patient, and method for determining applicability of novel therapy |
US9499628B2 (en) | 2013-06-14 | 2016-11-22 | Children's Hospital Medical Center | Method of boosting the immune response in neonates |
BR112015032414A2 (en) | 2013-06-24 | 2017-11-07 | Chugai Pharmaceutical Co Ltd | therapeutic agent comprising humanized antiepyrregulin antibody as active ingredient for non-small cell lung carcinoma excluding adenocarcinoma |
WO2014210397A1 (en) | 2013-06-26 | 2014-12-31 | Academia Sinica | Rm2 antigens and use thereof |
US9981030B2 (en) | 2013-06-27 | 2018-05-29 | Academia Sinica | Glycan conjugates and use thereof |
JP6267792B2 (en) | 2013-06-28 | 2018-01-24 | アムジエン・インコーポレーテツド | Methods for treating homozygous familial hypercholesterolemia |
CA2917112C (en) | 2013-07-03 | 2022-07-05 | Immunoqure Ag | Human anti-ifn-alpha antibodies |
EP3019240B1 (en) | 2013-07-09 | 2024-03-13 | Annexon, Inc. | Anti-complement factor c1q antibodies and uses thereof |
ES2819209T3 (en) | 2013-07-16 | 2021-04-15 | Hoffmann La Roche | Cancer treatment procedures using PD-1 axis binding antagonists and TIGIT inhibitors |
JP6687520B2 (en) | 2013-07-18 | 2020-04-22 | トーラス バイオサイエンシズ リミテッド ライアビリティ カンパニー | Humanized antibody with extremely long complementarity determining regions |
WO2015017146A2 (en) | 2013-07-18 | 2015-02-05 | Fabrus, Inc. | Antibodies with ultralong complementarity determining regions |
ES2761587T3 (en) | 2013-08-07 | 2020-05-20 | Friedrich Miescher Institute For Biomedical Res | New screening method for the treatment of Friedreich's ataxia |
MX2016001573A (en) | 2013-08-07 | 2016-09-07 | Astute Medical Inc | Assays for timp2 having improved performance in biological samples. |
WO2015023851A1 (en) | 2013-08-14 | 2015-02-19 | The Governing Council Of The University Of Toronto | Antibodies against frizzled proteins and methods of use thereof |
EP3036320B2 (en) | 2013-08-19 | 2024-04-03 | Biogen MA Inc. | Control of protein glycosylation by culture medium supplementation and cell culture process parameters |
US10617755B2 (en) | 2013-08-30 | 2020-04-14 | Genentech, Inc. | Combination therapy for the treatment of glioblastoma |
US10456470B2 (en) | 2013-08-30 | 2019-10-29 | Genentech, Inc. | Diagnostic methods and compositions for treatment of glioblastoma |
WO2015035044A2 (en) | 2013-09-04 | 2015-03-12 | Abbvie Biotherapeutics Inc. | Fc VARIANTS WITH IMPROVED ANTIBODY-DEPENDENT CELL-MEDIATED CYTOTOXICITY |
CA2923579C (en) | 2013-09-06 | 2023-09-05 | Academia Sinica | Human inkt cell activation using glycolipids with altered glycosyl groups |
WO2015042249A1 (en) | 2013-09-19 | 2015-03-26 | Dana-Farber Cancer Institute, Inc. | Methods of bh3 profiling |
WO2015041310A1 (en) | 2013-09-20 | 2015-03-26 | 中外製薬株式会社 | Treatment for hemorrhagic diseases by anti-protein-c antibody |
MA38960A1 (en) | 2013-09-27 | 2017-10-31 | Genentech Inc | Anti-pdl1 antibody formulations |
JP6534615B2 (en) | 2013-09-27 | 2019-06-26 | 中外製薬株式会社 | Method for producing polypeptide heteromultimer |
WO2015051293A2 (en) | 2013-10-04 | 2015-04-09 | Abbvie, Inc. | Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins |
MX2016004579A (en) | 2013-10-10 | 2016-12-09 | Beth Israel Deaconess Medical Ct Inc | Tm4sf1 binding proteins and methods of using same. |
US9085618B2 (en) | 2013-10-18 | 2015-07-21 | Abbvie, Inc. | Low acidic species compositions and methods for producing and using the same |
US8946395B1 (en) | 2013-10-18 | 2015-02-03 | Abbvie Inc. | Purification of proteins using hydrophobic interaction chromatography |
US9181337B2 (en) | 2013-10-18 | 2015-11-10 | Abbvie, Inc. | Modulated lysine variant species compositions and methods for producing and using the same |
EP3063317B1 (en) | 2013-10-28 | 2020-06-03 | DOTS Technology Corp. | Allergen detection |
EA201690731A1 (en) | 2013-11-06 | 2016-10-31 | Астьют Медикал, Инк. | ANALYSIS OF IGFBP7, HAVING IMPROVED CHARACTERISTICS IN BIOLOGICAL SPECIMENS |
JPWO2015068847A1 (en) | 2013-11-11 | 2017-03-09 | 中外製薬株式会社 | Antigen-binding molecules comprising modified antibody variable regions |
US20150139988A1 (en) | 2013-11-15 | 2015-05-21 | Abbvie, Inc. | Glycoengineered binding protein compositions |
TWI664331B (en) | 2013-12-04 | 2019-07-01 | 日商中外製藥股份有限公司 | Antigen-binding molecules that change antigen-binding ability in response to compound concentration and its database |
JP2017502002A (en) | 2013-12-09 | 2017-01-19 | ニューヨーク・ユニバーシティ | Composition and method for phagocytic cell delivery of anti-staphylococcal agents |
US9944694B2 (en) | 2013-12-13 | 2018-04-17 | Rijksuniversiteit Groningen | Antibodies against Staphylococcus aureus and uses therof |
CA2934028A1 (en) | 2013-12-17 | 2015-06-25 | Genentech, Inc. | Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists |
CN105899535A (en) | 2013-12-17 | 2016-08-24 | 豪夫迈·罗氏有限公司 | Methods of treating cancer using pd-1 axis binding antagonists and an anti-cd20 antibody |
NZ720515A (en) | 2013-12-17 | 2022-12-23 | Genentech Inc | Methods of treating cancers using pd-1 axis binding antagonists and taxanes |
CA2931684C (en) | 2013-12-19 | 2024-02-20 | Novartis Ag | Human mesothelin chimeric antigen receptors and uses thereof |
MX2016006529A (en) | 2013-12-20 | 2016-08-03 | Genentech Inc | Dual specific antibodies. |
WO2015095809A1 (en) | 2013-12-20 | 2015-06-25 | Biogen Idec Ma Inc. | Use of perfusion seed cultures to improve biopharmaceutical fed-batch production capacity and product quality |
CN106661107B (en) | 2013-12-24 | 2021-12-24 | 杨森制药公司 | anti-VISTA antibodies and fragments |
DK3087986T3 (en) | 2013-12-27 | 2019-12-02 | Chugai Pharmaceutical Co Ltd | MUTANT FGFR GATEKEEPERGEN AND ACTIVE SUBSTANCE AIMED AT THE SAME |
SG11201605256YA (en) | 2013-12-27 | 2016-08-30 | Chugai Pharmaceutical Co Ltd | Method for purifying antibody having low isoelectric point |
EP2893939A1 (en) | 2014-01-10 | 2015-07-15 | Netris Pharma | Anti-netrin-1 antibody |
WO2016114819A1 (en) | 2015-01-16 | 2016-07-21 | Academia Sinica | Compositions and methods for treatment and detection of cancers |
US10150818B2 (en) | 2014-01-16 | 2018-12-11 | Academia Sinica | Compositions and methods for treatment and detection of cancers |
TW201620939A (en) | 2014-01-16 | 2016-06-16 | 中央研究院 | Compositions and methods for treatment and detection of cancers |
WO2015116902A1 (en) | 2014-01-31 | 2015-08-06 | Genentech, Inc. | G-protein coupled receptors in hedgehog signaling |
DK3102197T3 (en) | 2014-02-04 | 2018-11-19 | Genentech Inc | Smoothened mutant and methods for its use |
US10106623B2 (en) | 2014-02-12 | 2018-10-23 | Michael Uhlin | Bispecific antibodies for use in stem cell transplantation |
GB201403775D0 (en) | 2014-03-04 | 2014-04-16 | Kymab Ltd | Antibodies, uses & methods |
AU2015231164B2 (en) | 2014-03-19 | 2020-04-09 | Dana-Farber Cancer Institute, Inc. | Immunogenetic restriction on elicitation of antibodies |
EP3122869B2 (en) | 2014-03-24 | 2022-08-10 | Biogen MA Inc. | Methods for overcoming glutamine deprivation during mammalian cell culture |
CN111808276A (en) | 2014-03-25 | 2020-10-23 | 豪夫迈·罗氏有限公司 | Methods of preparing poloxamers for use in cell culture media |
JP6562942B2 (en) | 2014-03-27 | 2019-08-28 | アカデミア シニカAcademia Sinica | Reactive labeled compounds and uses thereof |
EP3125936B1 (en) | 2014-03-31 | 2019-05-08 | Debiopharm International SA | Fgfr fusions |
RU2016142476A (en) | 2014-03-31 | 2018-05-07 | Дженентек, Инк. | COMBINED THERAPY, INCLUDING ANTI-ANGIOGENESIS AGENTS AND AGONISTS BINDING OX40 |
CN106536556B (en) | 2014-04-04 | 2020-02-07 | 生态学有限公司 | Humanized antibodies that bind LGR5 |
KR20160145813A (en) | 2014-04-25 | 2016-12-20 | 다나-파버 캔서 인스티튜트 인크. | Middle east respiratory syndrome coronavirus neutralizing antibodies and methods of use thereof |
WO2015164364A2 (en) | 2014-04-25 | 2015-10-29 | The Brigham And Women's Hospital, Inc. | Methods to manipulate alpha-fetoprotein (afp) |
WO2015166057A1 (en) | 2014-04-30 | 2015-11-05 | Klinikum Rechts Der Isar Der Technischen Universität München | Diagnosis of multiple sclerosis |
US20170267780A1 (en) | 2014-05-16 | 2017-09-21 | Medimmune, Llc | Molecules with altered neonate fc receptor binding having enhanced therapeutic and diagnostic properties |
US10118969B2 (en) | 2014-05-27 | 2018-11-06 | Academia Sinica | Compositions and methods relating to universal glycoforms for enhanced antibody efficacy |
AU2015267045B2 (en) | 2014-05-27 | 2021-02-25 | Academia Sinica | Anti-HER2 glycoantibodies and uses thereof |
WO2015184008A1 (en) | 2014-05-27 | 2015-12-03 | Academia Sinica | Fucosidase from bacteroides and methods using the same |
JP2017518989A (en) | 2014-05-27 | 2017-07-13 | アカデミア シニカAcademia Sinica | Anti-CD20 glycoengineered antibody group and use thereof |
LT3148579T (en) | 2014-05-28 | 2021-05-25 | Agenus Inc. | Anti-gitr antibodies and methods of use thereof |
TWI732738B (en) | 2014-05-28 | 2021-07-11 | 中央研究院 | Anti-tnf-alpha glycoantibodies and uses thereof |
WO2015189816A1 (en) | 2014-06-13 | 2015-12-17 | Friedrich Miescher Institute For Biomedical Research | New treatment against influenza virus |
TWI695011B (en) | 2014-06-18 | 2020-06-01 | 美商梅爾莎納醫療公司 | Monoclonal antibodies against her2 epitope and methods of use thereof |
TW201625299A (en) | 2014-06-20 | 2016-07-16 | Chugai Pharmaceutical Co Ltd | Pharmaceutical composition for use in prevention and/or treatment of disease that develops or progresses as a result of decrease or loss of activity of blood coagulation factor viii and/or activated blood coagulation factor viii |
WO2015198202A1 (en) | 2014-06-23 | 2015-12-30 | Friedrich Miescher Institute For Biomedical Research | Methods for triggering de novo formation of heterochromatin and or epigenetic silencing with small rnas |
EP3164129A1 (en) | 2014-07-01 | 2017-05-10 | Friedrich Miescher Institute for Biomedical Research | Combination of a brafv600e inhibitor and mertk inhibitor to treat melanoma |
ES2825574T3 (en) | 2014-07-09 | 2021-05-17 | Hoffmann La Roche | PH adjustment to improve thaw recovery of cell banks |
EP3169801A1 (en) | 2014-07-14 | 2017-05-24 | F. Hoffmann-La Roche AG | Diagnostic methods and compositions for treatment of glioblastoma |
SG11201700074YA (en) | 2014-07-15 | 2017-02-27 | Genentech Inc | Compositions for treating cancer using pd-1 axis binding antagonists and mek inhibitors |
EP4332119A2 (en) | 2014-07-17 | 2024-03-06 | Novo Nordisk A/S | Site directed mutagenesis of trem-1 antibodies for decreasing viscosity |
TW201609811A (en) | 2014-07-31 | 2016-03-16 | 安美基研究(慕尼黑)公司 | Bispecific single chain antibody construct with enhanced tissue distribution |
MX2017001401A (en) | 2014-07-31 | 2017-08-07 | Amgen Res (Munich) Gmbh | Optimized cross-species specific bispecific single chain antibody constructs. |
AR101669A1 (en) | 2014-07-31 | 2017-01-04 | Amgen Res (Munich) Gmbh | ANTIBODY CONSTRUCTS FOR CDH19 AND CD3 |
EA035098B1 (en) | 2014-07-31 | 2020-04-27 | Санофи | Method of treating relapsed and/or refractory multiple myeloma |
US20170240631A1 (en) | 2014-08-08 | 2017-08-24 | Alector Llc | Anti-trem2 antibodies and methods of use thereof |
CA2958200A1 (en) | 2014-08-14 | 2016-02-18 | Novartis Ag | Treatment of cancer using a gfr alpha-4 chimeric antigen receptor |
JP6858559B2 (en) | 2014-08-20 | 2021-04-14 | 中外製薬株式会社 | Method for measuring viscosity of protein solution |
US10961298B2 (en) | 2014-08-21 | 2021-03-30 | The Government Of The United States, Represented By The Secretary Of The Army | Monoclonal antibodies for treatment of microbial infections |
SG11201701328XA (en) | 2014-09-02 | 2017-03-30 | Immunogen Inc | Methods for formulating antibody drug conjugate compositions |
CA2960712A1 (en) | 2014-09-08 | 2016-03-17 | Academia Sinica | Human inkt cell activation using glycolipids |
WO2016040767A2 (en) | 2014-09-12 | 2016-03-17 | Amgen Inc. | Chrdl-1 epitopes and antibodies |
CA2959545A1 (en) | 2014-09-15 | 2016-03-24 | Genentech, Inc. | Antibody formulations |
EP3197557A1 (en) | 2014-09-24 | 2017-08-02 | Friedrich Miescher Institute for Biomedical Research | Lats and breast cancer |
MA40764A (en) | 2014-09-26 | 2017-08-01 | Chugai Pharmaceutical Co Ltd | THERAPEUTIC AGENT INDUCING CYTOTOXICITY |
IL278941B (en) | 2014-09-30 | 2022-07-01 | Neurimmune Holding Ag | Human-derived anti-dipeptide repeats (dprs) antibody |
US10463732B2 (en) | 2014-10-03 | 2019-11-05 | Dana-Farber Cancer Institute, Inc. | Glucocorticoid-induced tumor necrosis factor receptor (GITR) antibodies and methods of use thereof |
US10675349B2 (en) | 2014-10-06 | 2020-06-09 | Dana-Farber Cancer Institute, Inc. | Humanized CC chemokine receptor 4 (CCR4) antibodies and methods of use thereof |
MA41685A (en) | 2014-10-17 | 2017-08-22 | Biogen Ma Inc | COPPER SUPPLEMENT FOR THE REGULATION OF GLYCOSYLATION IN A MAMMAL CELL CULTURE PROCESS |
WO2016065052A1 (en) | 2014-10-22 | 2016-04-28 | Extend Biosciences, Inc. | Insulin vitamin d conjugates |
US9585934B2 (en) | 2014-10-22 | 2017-03-07 | Extend Biosciences, Inc. | Therapeutic vitamin D conjugates |
US9789197B2 (en) | 2014-10-22 | 2017-10-17 | Extend Biosciences, Inc. | RNAi vitamin D conjugates |
KR102546296B1 (en) | 2014-10-31 | 2023-06-21 | 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 | Altering gene expression in modified t cells and uses thereof |
EP3212668B1 (en) | 2014-10-31 | 2020-10-14 | AbbVie Biotherapeutics Inc. | Anti-cs1 antibodies and antibody drug conjugates |
AU2015339106B2 (en) | 2014-10-31 | 2020-07-02 | The Trustees Of The University Of Pennsylvania | Compositions and methods of stimulating and expanding T cells |
MA40864A (en) | 2014-10-31 | 2017-09-05 | Biogen Ma Inc | HYPOTAURINE, GABA, BETA-ALANINE AND CHOLINE FOR THE REGULATION OF THE ACCUMULATION OF RESIDUAL BY-PRODUCTS IN MAMMAL CELL CULTURE PROCESSES |
KR20170075793A (en) | 2014-11-05 | 2017-07-03 | 제넨테크, 인크. | Methods of producing two chain proteins in bacteria |
SG11201703667SA (en) | 2014-11-05 | 2017-06-29 | Annexon Inc | Humanized anti-complement factor c1q antibodies and uses thereof |
SI3215525T1 (en) | 2014-11-05 | 2020-11-30 | Genentech, Inc. | Methods of producing two chain proteins in bacteria |
CN107073126A (en) | 2014-11-06 | 2017-08-18 | 豪夫迈·罗氏有限公司 | Combination treatment comprising OX40 combinations activator and TIGIT inhibitor |
WO2016073157A1 (en) | 2014-11-06 | 2016-05-12 | Genentech, Inc. | Anti-ang2 antibodies and methods of use thereof |
US9879087B2 (en) | 2014-11-12 | 2018-01-30 | Siamab Therapeutics, Inc. | Glycan-interacting compounds and methods of use |
CA2967595A1 (en) | 2014-11-12 | 2016-05-19 | Siamab Therapeutics, Inc. | Glycan-interacting compounds and methods of use |
BR112017010198A2 (en) | 2014-11-17 | 2017-12-26 | Genentech Inc | combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists |
JP6857603B2 (en) | 2014-11-18 | 2021-04-14 | ヤンセン ファーマシューティカ エヌ.ベー. | Anti-CD147 antibody, method and use |
BR112017010268B1 (en) | 2014-11-19 | 2024-01-16 | P & M Venge Ab | BINDING AGENT, DIAGNOSTIC COMPOSITION, DIAGNOSTIC KIT, METHOD OF DIAGNOSING A BACTERIAL INFECTION OR OF DIFFERENTIATION BETWEEN A BACTERIAL INFECTION AND A VIRAL INFECTION, METHODS FOR RULED OUT A BACTERIAL OR VIRAL INFECTION IN AN INDIVIDUAL, METHODS FOR CONSIDERING AN INFECTION BACTERIAL ACTION OR VIRAL IN AN INDIVIDUAL, METHOD FOR DISTINGUISHING BETWEEN A BACTERIAL OR MIXED INFECTION AND A VIRAL INFECTION IN AN INDIVIDUAL, METHOD FOR RULING OUT AN INFECTIOUS DISEASE, METHOD FOR IDENTIFYING THE TYPE OF INFECTION AND DEVICE FOR DIAGNOSING BACTERIAL INFECTIONS |
WO2016081808A1 (en) | 2014-11-20 | 2016-05-26 | The Regents Of The University Of California | Compositions and methods related to hematologic recovery |
EP3220900B1 (en) | 2014-11-21 | 2020-09-23 | University of Maryland, Baltimore | Targeted structure-specific particulate delivery systems |
EP3227337A1 (en) | 2014-12-05 | 2017-10-11 | F. Hoffmann-La Roche AG | Methods and compositions for treating cancer using pd-1 axis antagonists and hpk1 antagonists |
ES2934940T3 (en) | 2014-12-11 | 2023-02-28 | Pf Medicament | Anti-C10orf54 antibodies and uses thereof |
US10093733B2 (en) | 2014-12-11 | 2018-10-09 | Abbvie Inc. | LRP-8 binding dual variable domain immunoglobulin proteins |
ES2870983T3 (en) | 2014-12-19 | 2021-10-28 | Univ Nantes | Anti-IL-34 antibodies |
ES2862701T3 (en) | 2014-12-22 | 2021-10-07 | Univ Rockefeller | Anti-MERTK Agonist Antibodies and Uses Thereof |
JP2018504400A (en) | 2015-01-08 | 2018-02-15 | バイオジェン・エムエイ・インコーポレイテッドBiogen MA Inc. | LINGO-1 antagonist and use for treatment of demyelinating disorders |
CN107530423B (en) | 2015-01-14 | 2022-04-05 | 布里格姆及妇女医院股份有限公司 | Treatment of cancer with anti-LAP monoclonal antibodies |
US10495645B2 (en) | 2015-01-16 | 2019-12-03 | Academia Sinica | Cancer markers and methods of use thereof |
US9975965B2 (en) | 2015-01-16 | 2018-05-22 | Academia Sinica | Compositions and methods for treatment and detection of cancers |
CA2974699A1 (en) | 2015-01-23 | 2016-07-28 | Icahn School Of Medicine At Mount Sinai | Influenza virus vaccination regimens |
AU2016209056B2 (en) | 2015-01-24 | 2021-01-28 | Academia Sinica | Cancer markers and methods of use thereof |
JP6779887B2 (en) | 2015-01-24 | 2020-11-04 | アカデミア シニカAcademia Sinica | New glycan conjugate and how to use it |
JP2018506275A (en) | 2015-01-28 | 2018-03-08 | ジェネンテック, インコーポレイテッド | Gene expression markers and treatment of multiple sclerosis |
KR102620346B1 (en) | 2015-01-30 | 2024-01-02 | 아카데미아 시니카 | Compositions and Methods Related to Universal Glycoforms for Enhanced Antibody Efficacy |
US10828353B2 (en) | 2015-01-31 | 2020-11-10 | The Trustees Of The University Of Pennsylvania | Compositions and methods for T cell delivery of therapeutic molecules |
JP2018512597A (en) | 2015-02-04 | 2018-05-17 | ジェネンテック, インコーポレイテッド | Mutant smoothened and method of using the same |
US9969800B2 (en) | 2015-02-05 | 2018-05-15 | Chugai Seiyaku Kabushiki Kaisha | IL-8 antibodies |
AU2016219534B2 (en) | 2015-02-09 | 2021-07-01 | Massachusetts Institute Of Technology | Multi-specific antibodies with affinity for human A33 antigen and dota metal complex and uses thereof |
US10800846B2 (en) | 2015-02-26 | 2020-10-13 | Merck Patent Gmbh | PD-1/PD-L1 inhibitors for the treatment of cancer |
AU2016224409B2 (en) | 2015-02-27 | 2021-01-28 | Chugai Seiyaku Kabushiki Kaisha | Composition for treating IL-6-related diseases |
US10711067B2 (en) | 2015-03-03 | 2020-07-14 | Xoma (Us) Llc | Treatment of post-prandial hyperinsulinemia and hypoglycemia after bariatric surgery |
MX2017011194A (en) | 2015-03-03 | 2018-04-10 | Kymab Ltd | Antibodies, uses & methods. |
CN107406493B (en) | 2015-03-06 | 2021-08-13 | 康诺贝林伦瑙有限公司 | Modified von willebrand factor with improved half-life |
EP3271387B1 (en) | 2015-03-16 | 2023-12-06 | Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) | Trispecific binding molecules for treating hbv infection and associated conditions |
KR102618312B1 (en) | 2015-03-17 | 2023-12-28 | 메모리얼 슬로안 케터링 캔서 센터 | Anti-MUC16 antibody and use thereof |
EP3271397B1 (en) | 2015-03-18 | 2021-03-03 | The Johns Hopkins University | Inhibitory monoclonal antibody targeting potassium channel kcnk9 |
US20180074077A1 (en) | 2015-03-25 | 2018-03-15 | Alexion Pharmaceuticals, Inc. | A method for measuring the protease activity of factor d of the alternative complement pathway |
EP3274468B1 (en) | 2015-03-25 | 2019-02-20 | Alexion Pharmaceuticals, Inc. | A method for measuring the protease activity of c3 and c5 convertase of the alternative complement pathway |
JP6901400B2 (en) | 2015-04-03 | 2021-07-14 | ゾーマ テクノロジー リミテッド | Cancer treatment using TGF-β and PD-1 inhibitors |
US10849992B1 (en) | 2015-04-07 | 2020-12-01 | Alector Llc | Methods of screening for sortilin binding antagonists |
DK3280441T3 (en) | 2015-04-07 | 2021-11-15 | Alector Llc | ANTI-SORTILINE ANTIBODIES AND PROCEDURES FOR USE |
KR20170133507A (en) | 2015-04-08 | 2017-12-05 | 다나-파버 캔서 인스티튜트 인크. | Humanized influenza monoclonal antibodies and methods for their use |
DK3283524T3 (en) | 2015-04-17 | 2023-05-30 | Amgen Res Munich Gmbh | BISPECIFIC ANTIBODY CONSTRUCTIONS AGAINST CDH3 and CD3 |
KR102057767B1 (en) | 2015-04-17 | 2019-12-19 | 에프. 호프만-라 로슈 아게 | Combination Therapy of Coagulation Factors and Multispecific Antibodies |
US9901574B2 (en) | 2015-04-20 | 2018-02-27 | Tolero Pharmaceuticals, Inc. | Predicting response to alvocidib by mitochondrial profiling |
CA2983022C (en) | 2015-04-27 | 2023-03-07 | Dana-Farber Cancer Institute, Inc. | High throughput bh3 profiling: a rapid and scalable technology to bh3 profile on low numbers of cells |
KR20170138556A (en) | 2015-05-01 | 2017-12-15 | 다나-파버 캔서 인스티튜트 인크. | Methods for mediating cytokine expression using anti-CCR4 antibodies |
MY189692A (en) | 2015-05-07 | 2022-02-26 | Memorial Sloan Kettering Cancer Center | Anti-ox40 antibodies and methods of use thereof |
JP6963508B2 (en) | 2015-05-11 | 2021-11-10 | ジェネンテック, インコーポレイテッド | Compositions and Methods for Treating Lupus Nephritis |
JP7048319B2 (en) | 2015-05-12 | 2022-04-05 | ジェネンテック, インコーポレイテッド | Treatment and diagnosis methods for cancer |
CA2985816A1 (en) | 2015-05-15 | 2016-11-24 | The General Hospital Corporation | Antagonistic anti-tumor necrosis factor receptor superfamily antibodies |
EP3298021B1 (en) | 2015-05-18 | 2019-05-01 | Tolero Pharmaceuticals, Inc. | Alvocidib prodrugs having increased bioavailability |
CN107921126A (en) | 2015-05-22 | 2018-04-17 | 转化药物开发有限责任公司 | The composition and its application method of benzamide and reactive compound |
CN113603784A (en) | 2015-05-29 | 2021-11-05 | 艾吉纳斯公司 | anti-CTLA-4 antibodies and methods of use thereof |
JP7144935B2 (en) | 2015-05-29 | 2022-09-30 | ジェネンテック, インコーポレイテッド | Therapeutic and diagnostic methods for cancer |
JP6518917B2 (en) | 2015-05-29 | 2019-05-29 | アッヴィ・インコーポレイテッド | Anti-CD40 antibody and use thereof |
WO2016191811A1 (en) | 2015-06-03 | 2016-12-08 | The University Of Queensland | Mobilizing agents and uses therefor |
SG10201912085WA (en) | 2015-06-12 | 2020-02-27 | Alector Llc | Anti-cd33 antibodies and methods of use thereof |
US11174313B2 (en) | 2015-06-12 | 2021-11-16 | Alector Llc | Anti-CD33 antibodies and methods of use thereof |
TW201710286A (en) | 2015-06-15 | 2017-03-16 | 艾伯維有限公司 | Binding proteins against VEGF, PDGF, and/or their receptors |
CA2989586A1 (en) | 2015-06-16 | 2016-12-22 | Pfizer, Inc. | Pd-l1 antagonist combination treatments |
EP3310815A1 (en) | 2015-06-17 | 2018-04-25 | F. Hoffmann-La Roche AG | Methods of treating locally advanced or metastatic breast cancers using pd-1 axis binding antagonists and taxanes |
CN107922497B (en) | 2015-06-24 | 2022-04-12 | 詹森药业有限公司 | anti-VISTA antibodies and fragments |
CA2989936A1 (en) | 2015-06-29 | 2017-01-05 | Genentech, Inc. | Type ii anti-cd20 antibody for use in organ transplantation |
TWI796283B (en) | 2015-07-31 | 2023-03-21 | 德商安美基研究(慕尼黑)公司 | Antibody constructs for msln and cd3 |
TW202346349A (en) | 2015-07-31 | 2023-12-01 | 德商安美基研究(慕尼黑)公司 | Antibody constructs for dll3 and cd3 |
TWI744242B (en) | 2015-07-31 | 2021-11-01 | 德商安美基研究(慕尼黑)公司 | Antibody constructs for egfrviii and cd3 |
TWI829617B (en) | 2015-07-31 | 2024-01-21 | 德商安美基研究(慕尼黑)公司 | Antibody constructs for flt3 and cd3 |
TWI717375B (en) | 2015-07-31 | 2021-02-01 | 德商安美基研究(慕尼黑)公司 | Antibody constructs for cd70 and cd3 |
EP3331510A4 (en) | 2015-08-03 | 2019-04-03 | Tolero Pharmaceuticals, Inc. | Combination therapies for treatment of cancer |
TW202340452A (en) | 2015-08-04 | 2023-10-16 | 美商再生元醫藥公司 | Taurine supplemented cell culture medium and methods of use |
JP2018532693A (en) | 2015-08-06 | 2018-11-08 | ゾーマ (ユーエス) リミテッド ライアビリティ カンパニー | Antibody fragments against the insulin receptor and their use to treat hypoglycemia |
MA45352A (en) | 2015-08-07 | 2018-06-13 | Univ Birmingham | IDENTIFICATION OF GLYCOPEPTIDES ASSOCIATED WITH CATEGORY I HCM AS TARGETS FOR CANCER IMMUNOTHERAPY |
CN105384825B (en) | 2015-08-11 | 2018-06-01 | 南京传奇生物科技有限公司 | A kind of bispecific chimeric antigen receptor and its application based on single domain antibody |
CA2995838A1 (en) | 2015-08-19 | 2017-02-23 | Rutgers, The State University Of New Jersey | Novel methods of generating antibodies |
BR112018001956A2 (en) | 2015-08-20 | 2018-09-11 | Hoffmann La Roche | ? analyte measurement method and kit? |
KR20180054639A (en) | 2015-08-28 | 2018-05-24 | 알렉터 엘엘씨 | Anti-SIGLEC-7 Antibodies and Methods of Use Thereof |
BR112018003186A2 (en) | 2015-09-01 | 2018-09-25 | Agenus Inc. | anti-pd-1 antibodies and their methods of use |
US10935544B2 (en) | 2015-09-04 | 2021-03-02 | Obi Pharma, Inc. | Glycan arrays and method of use |
JP6266164B2 (en) | 2015-09-18 | 2018-01-31 | 中外製薬株式会社 | Antibodies that bind to IL-8 and uses thereof |
US20180282415A1 (en) | 2015-09-30 | 2018-10-04 | Merck Patent Gmbh | Combination of a PD-1 Axis Binding Antagonist and an ALK Inhibitor for Treating ALK-Negative Cancer |
CN117069841A (en) | 2015-10-06 | 2023-11-17 | 艾利妥 | anti-TREM 2 antibodies and methods of use thereof |
WO2017072669A1 (en) | 2015-10-28 | 2017-05-04 | Friedrich Miescher Institute For Biomedical Research | Tenascin-w and biliary tract cancers |
EP3368575A2 (en) | 2015-10-29 | 2018-09-05 | Alector LLC | Anti-siglec-9 antibodies and methods of use thereof |
AR106543A1 (en) | 2015-11-02 | 2018-01-24 | Netris Pharma | NTN1 NEUTRALIZING AGENT COMBINATION THERAPY WITH DRUGS THAT INHIBIT EPIGENTICAL CONTROL |
EP3909984A1 (en) | 2015-11-03 | 2021-11-17 | Merck Patent GmbH | Affinity matured c-met antibodies |
KR20180088381A (en) | 2015-11-12 | 2018-08-03 | 시아맙 쎄라퓨틱스, 인코포레이티드 | Glycan-interacting compounds and methods of use |
JP6931329B2 (en) | 2015-11-18 | 2021-09-01 | 中外製薬株式会社 | Combination therapy using T cell redirection antigen-binding molecule for cells with immunosuppressive function |
US11649293B2 (en) | 2015-11-18 | 2023-05-16 | Chugai Seiyaku Kabushiki Kaisha | Method for enhancing humoral immune response |
RS65120B1 (en) | 2015-11-25 | 2024-02-29 | Immunogen Inc | Pharmaceutical formulations and methods of use thereof |
WO2017095805A1 (en) | 2015-11-30 | 2017-06-08 | Abbvie Inc. | ANTI-huLRRC15 ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE |
CA3006610A1 (en) | 2015-11-30 | 2017-06-08 | Abbvie Inc. | Anti-hulrrc15 antibody drug conjugates and methods for their use |
WO2017096017A1 (en) | 2015-12-02 | 2017-06-08 | Stsciences, Inc. | Antibodies specific to glycosylated btla (b- and t- lymphocyte attenuator) |
JP7090545B2 (en) | 2015-12-02 | 2022-06-24 | ストキューブ アンド シーオー., インコーポレイテッド | Antibodies and molecules that immunospecifically bind to BTN1A1 and their therapeutic use |
EP3184544A1 (en) | 2015-12-23 | 2017-06-28 | Julius-Maximilians-Universität Würzburg | Glycoprotein v inhibitors for use as coagulants |
EP3395835B1 (en) | 2015-12-25 | 2021-02-03 | Chugai Seiyaku Kabushiki Kaisha | Antibody having enhanced activity, and method for modifying same |
WO2017117304A1 (en) | 2015-12-30 | 2017-07-06 | Genentech, Inc. | Use of tryptophan derivatives for protein formulations |
CN115400220A (en) | 2015-12-30 | 2022-11-29 | 豪夫迈·罗氏有限公司 | Preparation for reducing degradation of polysorbate |
KR102197478B1 (en) | 2015-12-31 | 2021-01-04 | 프로가스트린 에 캔서스 에스.에이 알.엘. | Compositions and methods for detecting and treating esophageal cancer |
EP3397965A1 (en) | 2015-12-31 | 2018-11-07 | Syncerus S.à R.l. | Compositions and methods for assessing the risk of cancer occurrence |
SG11201805141QA (en) | 2015-12-31 | 2018-07-30 | Progastrine Et Cancers S A R L | Compositions and methods for detecting and treating gastric cancer |
CA3194356A1 (en) | 2015-12-31 | 2017-07-06 | Progastrine Et Cancers S.A R.L. | Compositions and methods for detecting and treating ovarian cancer |
US11103589B2 (en) | 2016-01-08 | 2021-08-31 | Apg Therapeutics, Inc. | Polyethylenimine (PEI)-polypeptide conjugates and methods of use thereof |
ES2837428T3 (en) | 2016-01-08 | 2021-06-30 | Hoffmann La Roche | CEA-Positive Cancer Treatment Procedures Using PD-1 Axis Binding Antagonists and Anti-CEA / Anti-CD3 Bispecific Antibodies |
EA039859B1 (en) | 2016-02-03 | 2022-03-21 | Эмджен Рисерч (Мюник) Гмбх | Bispecific antibody constructs binding egfrviii and cd3 |
MX2018009386A (en) | 2016-02-03 | 2018-11-09 | Amgen Res Munich Gmbh | Psma and cd3 bispecific t cell engaging antibody constructs. |
KR20180103084A (en) | 2016-02-03 | 2018-09-18 | 암젠 리서치 (뮌헨) 게엠베하 | BCMA and CD3 bispecific T cell engrafting antibody constructs |
JP2019509721A (en) | 2016-02-04 | 2019-04-11 | キュリス,インコーポレイテッド | Mutant smoothened and method of using the same |
CN108885210B (en) | 2016-02-05 | 2022-07-19 | 纳诺韦尔生物科学有限公司 | Detection of exosomes with surface markers |
EP3413910A1 (en) | 2016-02-12 | 2018-12-19 | Janssen Pharmaceutica NV | Anti-vista (b7h5) antibodies |
JP6821693B2 (en) | 2016-02-29 | 2021-01-27 | ジェネンテック, インコーポレイテッド | Treatment and diagnosis for cancer |
US11472877B2 (en) | 2016-03-04 | 2022-10-18 | Alector Llc | Anti-TREM1 antibodies and methods of use thereof |
JP7157981B2 (en) | 2016-03-07 | 2022-10-21 | チャールストンファーマ, エルエルシー | anti-nucleolin antibody |
CN109195996A (en) | 2016-03-08 | 2019-01-11 | 中央研究院 | The modularity synthetic method of N- glycan and its array |
AU2017233658B2 (en) | 2016-03-14 | 2023-09-21 | Chugai Seiyaku Kabushiki Kaisha | Cell injury inducing therapeutic drug for use in cancer therapy |
CN109310885B (en) | 2016-03-15 | 2022-05-31 | 梅尔莎纳医疗公司 | NaPi2b targeting antibody-drug conjugates and methods of use thereof |
ES2904286T3 (en) | 2016-03-15 | 2022-04-04 | Chugai Pharmaceutical Co Ltd | Cancer Treatment Methods Using PD-1 Axis Binding Antagonists and Anti-GPC3 Antibodies |
CN109476756B (en) | 2016-03-15 | 2022-05-31 | 埃泰美德(香港)有限公司 | Multi-specificity Fab fusion protein and application thereof |
CN108884156B (en) | 2016-03-17 | 2021-10-01 | 努玛创新有限公司 | anti-TNF alpha antibodies and functional fragments thereof |
LT3219727T (en) | 2016-03-17 | 2021-02-10 | Tillotts Pharma Ag | Anti-tnf alpha-antibodies and functional fragments thereof |
WO2017158084A1 (en) | 2016-03-17 | 2017-09-21 | Numab Innovation Ag | ANTI-TNFα-ANTIBODIES AND FUNCTIONAL FRAGMENTS THEREOF |
HUE052773T2 (en) | 2016-03-17 | 2021-05-28 | Tillotts Pharma Ag | Anti-tnf alpha-antibodies and functional fragments thereof |
US10774140B2 (en) | 2016-03-17 | 2020-09-15 | Numab Therapeutics AG | Anti-TNFα-antibodies and functional fragments thereof |
CA3018081A1 (en) | 2016-03-22 | 2017-09-28 | Bionomics Limited | Administration of an anti-lgr5 monoclonal antibody |
WO2017165683A1 (en) | 2016-03-23 | 2017-09-28 | Novartis Ag | Cell secreted minibodies and uses thereof |
CN109311995A (en) | 2016-03-29 | 2019-02-05 | 台湾浩鼎生技股份有限公司 | Antibody, pharmaceutical composition and method |
CN109071653A (en) | 2016-03-29 | 2018-12-21 | 詹森生物科技公司 | Psoriasis is treated with the increased anti-antibody administration of IL12 and/or -23 interval |
US10980894B2 (en) | 2016-03-29 | 2021-04-20 | Obi Pharma, Inc. | Antibodies, pharmaceutical compositions and methods |
WO2017175058A1 (en) | 2016-04-07 | 2017-10-12 | Janssen Pharmaceutica Nv | Anti-vista antibodies and fragments, uses thereof, and methods of identifying same |
WO2017181079A2 (en) | 2016-04-15 | 2017-10-19 | Genentech, Inc. | Methods for monitoring and treating cancer |
KR20190003958A (en) | 2016-04-15 | 2019-01-10 | 제넨테크, 인크. | Treatment and monitoring of cancer |
JOP20170091B1 (en) | 2016-04-19 | 2021-08-17 | Amgen Res Munich Gmbh | Administration of a bispecific construct binding to CD33 and CD3 for use in a method for the treatment of myeloid leukemia |
BR112018071683A2 (en) | 2016-04-22 | 2019-02-19 | Obi Pharma, Inc. | method for treating breast cancer, method for treating a tumor in a patient, method for treating an individual suffering from cancer by immunotherapy, method for inducing / improving an immune response in an individual, method for improving obi-822 induced vaccine by immune response in an individual in need thereof, method for identifying a patient suitable for cancer therapy, and method for determining a patient's cancer treatment prognosis or drug response |
KR20230124093A (en) | 2016-05-10 | 2023-08-24 | 제넨테크, 인크. | Methods of decreasing trisulfide bonds during recombinant production of polypeptides |
TW201808336A (en) | 2016-05-11 | 2018-03-16 | 賽諾菲公司 | Treatment regimen using anti-MUC1 maytansinoid immunoconjugate antibody for the treatment of tumors |
TWI808055B (en) | 2016-05-11 | 2023-07-11 | 美商滬亞生物國際有限公司 | Combination therapies of hdac inhibitors and pd-1 inhibitors |
TWI794171B (en) | 2016-05-11 | 2023-03-01 | 美商滬亞生物國際有限公司 | Combination therapies of hdac inhibitors and pd-l1 inhibitors |
EP4233909A3 (en) | 2016-05-17 | 2023-09-20 | AbbVie Biotherapeutics Inc. | Anti-cmet antibody drug conjugates and methods for their use |
CN116333130A (en) | 2016-05-24 | 2023-06-27 | 英斯梅德股份有限公司 | Antibodies and methods of making the same |
CA3025391A1 (en) | 2016-05-26 | 2017-11-30 | Merck Patent Gmbh | Pd-1 / pd-l1 inhibitors for cancer treatment |
EP3464362B1 (en) | 2016-05-27 | 2020-12-09 | AbbVie Biotherapeutics Inc. | Anti-4-1bb antibodies and their uses |
CN109476750B (en) | 2016-05-27 | 2022-02-01 | 艾伯维生物制药股份有限公司 | anti-CD 40 antibodies and uses thereof |
TWI781934B (en) | 2016-05-27 | 2022-11-01 | 美商艾吉納斯公司 | Anti-tim-3 antibodies and methods of use thereof |
KR20190079713A (en) | 2016-06-13 | 2019-07-05 | 아이-맵 | Anti-pd-l1 antibodies and uses thereof |
BR112018075032A2 (en) | 2016-06-15 | 2019-03-26 | Icahn School Of Medicine At Mount Sinai | influenza virus hemagglutinin proteins and their use |
KR20190039937A (en) | 2016-07-08 | 2019-04-16 | 스태튼 바이오테크놀로지 비.브이. | Anti-ApoC3 antibodies and methods of use thereof |
JP2018035137A (en) | 2016-07-13 | 2018-03-08 | マブイミューン ダイアグノスティックス エイジーMabimmune Diagnostics Ag | Novel anti-fibroblast activated protein (FAP) binding agent and use thereof |
WO2018014260A1 (en) | 2016-07-20 | 2018-01-25 | Nanjing Legend Biotech Co., Ltd. | Multispecific antigen binding proteins and methods of use thereof |
IL296127A (en) | 2016-07-22 | 2022-11-01 | Dana Farber Cancer Inst Inc | Glucocorticoid-induced tumor necrosis factor receptor (gitr) antibodies and methods of use thereof |
WO2018022479A1 (en) | 2016-07-25 | 2018-02-01 | Biogen Ma Inc. | Anti-hspa5 (grp78) antibodies and uses thereof |
KR20230117482A (en) | 2016-07-27 | 2023-08-08 | 오비아이 파머 인코퍼레이티드 | Immunogenic/therapeutic glycan compositions and uses thereof |
KR102528998B1 (en) | 2016-07-29 | 2023-05-03 | 오비아이 파머 인코퍼레이티드 | Human Antibodies, Pharmaceutical Compositions and Methods |
NL2017267B1 (en) | 2016-07-29 | 2018-02-01 | Aduro Biotech Holdings Europe B V | Anti-pd-1 antibodies |
CN109803680A (en) | 2016-08-01 | 2019-05-24 | 佐马美国有限公司 | (PTH1R) antibody of parathyroid hormone receptor 1 and its purposes |
NL2017270B1 (en) | 2016-08-02 | 2018-02-09 | Aduro Biotech Holdings Europe B V | New anti-hCTLA-4 antibodies |
CN109476748B (en) | 2016-08-08 | 2023-05-23 | 豪夫迈·罗氏有限公司 | Methods for treatment and diagnosis of cancer |
AU2017311585A1 (en) | 2016-08-12 | 2019-02-28 | Genentech, Inc. | Combination therapy with a MEK inhibitor, a PD-1 axis inhibitor, and a VEGF inhibitor |
CA3034057A1 (en) | 2016-08-22 | 2018-03-01 | CHO Pharma Inc. | Antibodies, binding fragments, and methods of use |
US10870694B2 (en) | 2016-09-02 | 2020-12-22 | Dana Farber Cancer Institute, Inc. | Composition and methods of treating B cell disorders |
EP3509633A1 (en) | 2016-09-06 | 2019-07-17 | Dana-Farber Cancer Institute, Inc. | Methods of treating or preventing zika virus infection |
WO2018049083A1 (en) | 2016-09-07 | 2018-03-15 | The Regents Of The University Of California | Antibodies to oxidation-specific epitopes |
WO2018049261A1 (en) | 2016-09-09 | 2018-03-15 | Icellhealth Consulting Llc | Oncolytic virus expressing immune checkpoint modulators |
PE20191102A1 (en) | 2016-09-14 | 2019-08-23 | Abbvie Biotherapeutics Inc | ANTI-PD-1 ANTIBODIES AND THEIR USES |
PE20190633A1 (en) | 2016-09-19 | 2019-04-26 | I Mab | ANTI-GM-CSF ANTIBODIES AND USES OF THE SAME |
JOP20190009A1 (en) | 2016-09-21 | 2019-01-27 | Alx Oncology Inc | Antibodies against signal-regulatory protein alpha and methods of use |
RU2759334C2 (en) | 2016-09-21 | 2021-11-12 | Нексткьюр, Инк. | Antibodies against siglec-15 and their application methods |
US10858428B2 (en) | 2016-09-28 | 2020-12-08 | Xoma (Us) Llc | Antibodies that bind interleukin-2 and uses thereof |
WO2018064299A1 (en) | 2016-09-29 | 2018-04-05 | Genentech, Inc. | Combination therapy with a mek inhibitor, a pd-1 axis inhibitor, and a taxane |
JP2020500152A (en) | 2016-09-30 | 2020-01-09 | ヤンセン バイオテツク,インコーポレーテツド | Safe and effective method of treating psoriasis with anti-IL23 specific antibody |
JP2019535015A (en) | 2016-10-03 | 2019-12-05 | アボット・ラボラトリーズAbbott Laboratories | Improved method for assessing GFAP status in patient samples |
IL265762B2 (en) | 2016-10-06 | 2024-04-01 | Merck Patent Gmbh | Dosing regimen of avelumab for the treatment of cancer |
EP3523451A1 (en) | 2016-10-06 | 2019-08-14 | Genentech, Inc. | Therapeutic and diagnostic methods for cancer |
WO2018068201A1 (en) | 2016-10-11 | 2018-04-19 | Nanjing Legend Biotech Co., Ltd. | Single-domain antibodies and variants thereof against ctla-4 |
TW202246349A (en) | 2016-10-11 | 2022-12-01 | 美商艾吉納斯公司 | Anti-lag-3 antibodies and methods of use thereof |
WO2018081531A2 (en) | 2016-10-28 | 2018-05-03 | Ariad Pharmaceuticals, Inc. | Methods for human t-cell activation |
AU2017348365A1 (en) | 2016-10-28 | 2019-05-23 | Astute Medical, Inc. | Use of antibodies to TIMP-2 for the improvement of renal function |
RU2019114863A (en) | 2016-11-02 | 2020-12-03 | Иммуноджен, Инк. | COMBINED TREATMENT WITH ANTIBODY-DRUG CONJUGATES AND PARP INHIBITORS |
US11779604B2 (en) | 2016-11-03 | 2023-10-10 | Kymab Limited | Antibodies, combinations comprising antibodies, biomarkers, uses and methods |
AU2017353936A1 (en) | 2016-11-04 | 2019-05-02 | Novimmune Sa | Anti-CD19 antibodies and methods of use thereof |
WO2018083538A1 (en) | 2016-11-07 | 2018-05-11 | Neuracle Scienc3 Co., Ltd. | Anti-family with sequence similarity 19, member a5 antibodies and method of use thereof |
MX2019005661A (en) | 2016-11-16 | 2019-10-07 | Janssen Biotech Inc | Method of treating psoriasis with anti-il-23 specific antibody. |
EP3541847A4 (en) | 2016-11-17 | 2020-07-08 | Seattle Genetics, Inc. | Glycan-interacting compounds and methods of use |
WO2018094275A1 (en) | 2016-11-18 | 2018-05-24 | Tolero Pharmaceuticals, Inc. | Alvocidib prodrugs and their use as protein kinase inhibitors |
KR20190077103A (en) | 2016-11-21 | 2019-07-02 | 오비아이 파머 인코퍼레이티드 | Conjugated biological molecules, pharmaceutical compositions and methods |
JP7080234B2 (en) | 2016-11-23 | 2022-06-03 | トランスレイショナル・ドラッグ・ディベロップメント・エルエルシー | Benzamide and active compound compositions and methods of use |
TW202235438A (en) | 2016-11-28 | 2022-09-16 | 日商中外製藥股份有限公司 | Ligand-binding molecule having adjustable ligand binding activity |
MD3551660T2 (en) | 2016-12-07 | 2024-03-31 | Agenus Inc | Anti-CTLA-4 antibodies and methods of use thereof |
BR112019011582A2 (en) | 2016-12-07 | 2019-10-22 | Agenus Inc. | antibodies and their methods of use |
TWI734879B (en) | 2016-12-15 | 2021-08-01 | 美商艾伯維生物醫療股份有限公司 | Anti-ox40 antibodies and their uses |
EP3362471B1 (en) | 2016-12-19 | 2021-11-17 | Sumitomo Dainippon Pharma Oncology, Inc. | Profiling peptides and methods for sensitivity profiling |
EP3562842A1 (en) | 2016-12-27 | 2019-11-06 | H. Hoffnabb-La Roche Ag | Novel biotin-specific monoclonal antibody and use thereof |
BR112019010915A2 (en) | 2016-12-27 | 2019-10-01 | Hoffmann La Roche | monoclonal antibody, methods for measuring an analyte in a sample and for producing an antibody, use of an antibody, immunoassay and immunogen test kit |
KR102448439B1 (en) | 2016-12-27 | 2022-09-27 | 에프. 호프만-라 로슈 아게 | Novel biotin-specific monoclonal antibodies and uses thereof |
EP3565837B1 (en) | 2017-01-05 | 2024-04-10 | Netris Pharma | Combined treatment with netrin-1 interfering drug and immune checkpoint inhibitors drugs |
US11773182B2 (en) | 2017-01-05 | 2023-10-03 | The Johns Hopkins University | Development of new monoclonal antibodies recognizing human prostate-specific membrane antigen (PSMA) |
JP7275030B2 (en) | 2017-01-20 | 2023-05-17 | タユー ファシャ バイオテック メディカル グループ カンパニー, リミテッド | ANTI-PD-1 ANTIBODY AND USES THEREOF |
KR102156199B1 (en) | 2017-01-24 | 2020-09-17 | 아이-맵 바이오파마 유에스 리미티드 | Anti-cd73 antibodies and uses thereof |
WO2018140510A1 (en) | 2017-01-25 | 2018-08-02 | Biogen Ma Inc. | Compositions and methods for treatment of stroke and other cns disorders |
EP3574012A1 (en) | 2017-01-27 | 2019-12-04 | Memorial Sloan Kettering Cancer Center | Bispecific her2 and cd3 binding molecules |
MX2019008989A (en) | 2017-01-30 | 2019-10-09 | Janssen Biotech Inc | Anti-tnf antibodies, compositions, and methods for the treatment of active psoriatic arthritis. |
JOP20190189A1 (en) | 2017-02-02 | 2019-08-01 | Amgen Res Munich Gmbh | Low ph pharmaceutical composition comprising t cell engaging antibody constructs |
EP3577460B1 (en) | 2017-02-02 | 2021-01-20 | Roche Diagnostics GmbH | Immunoassay using at least two pegylated analyte-specific binding agents |
CN110418652A (en) | 2017-02-07 | 2019-11-05 | 詹森生物科技公司 | For treating the anti-TNF antibodies, composition and method of activity ankylosing spondylitis |
CN108456251A (en) | 2017-02-21 | 2018-08-28 | 上海君实生物医药科技股份有限公司 | Anti- PD-L1 antibody and its application |
MX2019010295A (en) | 2017-03-01 | 2019-11-21 | Genentech Inc | Diagnostic and therapeutic methods for cancer. |
MA47812A (en) | 2017-03-03 | 2021-04-14 | Seagen Inc | COMPOUNDS INTERACTING WITH GLYCAN AND METHODS OF USE |
TWI808963B (en) | 2017-03-22 | 2023-07-21 | 法商賽諾菲公司 | Treatment of lupus using humanized anti-cxcr5 antibodies |
JP7346300B2 (en) | 2017-03-23 | 2023-09-19 | アボット・ラボラトリーズ | Methods for aiding in the diagnosis and determination of the extent of traumatic brain injury in human subjects using the early biomarker ubiquitin carboxy-terminal hydrolase L1 |
WO2018174274A1 (en) | 2017-03-24 | 2018-09-27 | 全薬工業株式会社 | ANTI-IgM/B CELL SURFACE ANTIGEN BISPECIFIC ANTIBODY |
ES2904939T3 (en) | 2017-03-30 | 2022-04-06 | Progastrine Et Cancers S A R L | Compositions and methods for detecting and treating prostate cancer using a progastrin-binding molecule |
SG11201908888VA (en) | 2017-03-30 | 2019-10-30 | Progastrine Et Cancers S A R L | Compositions and methods for treating lung cancer |
CN110494161A (en) | 2017-03-30 | 2019-11-22 | 默克专利股份有限公司 | The combination of anti-PD-L1 antibody and DNA-PK inhibitor for treating cancer |
TW201836636A (en) | 2017-03-31 | 2018-10-16 | 公立大學法人奈良縣立醫科大學 | Medicinal composition usable for preventing and/or treating blood coagulation factor ix abnormality, comprising multispecific antigen binding molecule replacing function of blood coagulation factor viii |
US10722589B2 (en) | 2017-04-03 | 2020-07-28 | Covagen Ag | FGFR3 binding molecules |
WO2018187453A1 (en) | 2017-04-05 | 2018-10-11 | Astute Medical, Inc. | Assays for timp2 having improved performance in biological samples |
EP3606555A4 (en) | 2017-04-07 | 2021-08-04 | Icahn School of Medicine at Mount Sinai | Anti-influenza b virus neuraminidase antibodies and uses thereof |
TW201841942A (en) | 2017-04-13 | 2018-12-01 | 美商艾吉納斯公司 | Anti-CD137 antibodies and methods of use thereof |
US10877048B2 (en) | 2017-04-15 | 2020-12-29 | Abbott Laboratories | Methods for aiding in the hyperacute diagnosis and determination of traumatic brain injury in a human subject using early biomarkers |
AU2018255938A1 (en) | 2017-04-21 | 2019-10-31 | Staten Biotechnology B.V. | Anti-ApoC3 antibodies and methods of use thereof |
JP2020517271A (en) | 2017-04-22 | 2020-06-18 | イミュノミック セラピューティックス, インコーポレイテッドImmunomic Therapeutics, Inc. | Improved LAMP construct |
WO2018196782A1 (en) | 2017-04-27 | 2018-11-01 | The University Of Hong Kong | Use of hcn inhibitors for treatment of cancer |
EP3617316A4 (en) | 2017-04-27 | 2020-12-23 | Chugai Seiyaku Kabushiki Kaisha | Coagulation factor ix with improved pharmacokinetics |
WO2018200823A1 (en) | 2017-04-28 | 2018-11-01 | Abbott Laboratories | Methods for aiding in the hyperacute diagnosis and determination of traumatic brain injury using early biomarkers on at least two samples from the same human subject |
RS64576B1 (en) | 2017-05-01 | 2023-10-31 | Agenus Inc | Anti-tigit antibodies and methods of use thereof |
WO2018203545A1 (en) | 2017-05-02 | 2018-11-08 | 国立研究開発法人国立精神・神経医療研究センター | Method for predicting and evaluating therapeutic effect in diseases related to il-6 and neutrophils |
JP7222915B2 (en) | 2017-05-02 | 2023-02-15 | イミュノミック セラピューティックス, インコーポレイテッド | Improved LAMP constructs containing cancer antigens |
UY37726A (en) | 2017-05-05 | 2018-11-30 | Amgen Inc | PHARMACEUTICAL COMPOSITION THAT INCLUDES BISPECTIFIC ANTIBODY CONSTRUCTIONS FOR IMPROVED STORAGE AND ADMINISTRATION |
US10865238B1 (en) | 2017-05-05 | 2020-12-15 | Duke University | Complement factor H antibodies |
JOP20190256A1 (en) | 2017-05-12 | 2019-10-28 | Icahn School Med Mount Sinai | Newcastle disease viruses and uses thereof |
US11359014B2 (en) | 2017-05-16 | 2022-06-14 | Alector Llc | Anti-siglec-5 antibodies and methods of use thereof |
US10914729B2 (en) | 2017-05-22 | 2021-02-09 | The Trustees Of Princeton University | Methods for detecting protein binding sequences and tagging nucleic acids |
EP3630830A1 (en) | 2017-05-23 | 2020-04-08 | Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) | Novel cd73 antibody, preparation and uses thereof |
AU2018272054A1 (en) | 2017-05-25 | 2019-09-26 | Abbott Laboratories | Methods for aiding in the determination of whether to perform imaging on a human subject who has sustained or may have sustained an injury to the head using early biomarkers |
US11260117B2 (en) | 2017-05-26 | 2022-03-01 | Novimmune Sa | Anti-CD47 x anti-mesothelin antibodies and methods of use thereof |
BR112019025313A2 (en) | 2017-05-30 | 2020-06-23 | Abbott Laboratories | METHODS FOR ASSISTANCE IN DIAGNOSIS AND EVALUATION OF A LIGHT TRAUMATIC BRAIN INJURY IN A HUMAN INDIVIDUAL USING HEART TROPONIN I |
KR20200015602A (en) | 2017-05-31 | 2020-02-12 | 주식회사 에스티큐브앤컴퍼니 | Antibodies and molecules immunospecifically binding to BTN1A1 and therapeutic uses thereof |
CN111051346A (en) | 2017-05-31 | 2020-04-21 | 斯特库伯株式会社 | Methods of treating cancer using antibodies and molecules that immunospecifically bind to BTN1a1 |
WO2018226671A1 (en) | 2017-06-06 | 2018-12-13 | Stcube & Co., Inc. | Methods of treating cancer using antibodies and molecules that bind to btn1a1 or btn1a1-ligands |
WO2019000223A1 (en) | 2017-06-27 | 2019-01-03 | Nanjing Legend Biotech Co., Ltd. | Chimeric antibody immune effctor cell engagers and methods of use thereof |
SG11202000298VA (en) | 2017-07-14 | 2020-02-27 | Pfizer | Antibodies to madcam |
AU2018304458B2 (en) | 2017-07-21 | 2021-12-09 | Foundation Medicine, Inc. | Therapeutic and diagnostic methods for cancer |
US20210032364A1 (en) | 2017-07-27 | 2021-02-04 | Nomocan Pharmaceuticals Llc | Antibodies to m(h)dm2/4 and their use in diagnosing and treating cancer |
MD3601358T2 (en) | 2017-08-03 | 2023-10-31 | Alector Llc | Anti-TREM2 antibodies and methods of use thereof |
EP3589658A1 (en) | 2017-08-03 | 2020-01-08 | Alector LLC | Anti-cd33 antibodies and methods of use thereof |
JP2020537632A (en) | 2017-08-21 | 2020-12-24 | アダジーン インコーポレイテッド | Dynamic human heavy chain antibody library |
BR112020003459A2 (en) | 2017-08-21 | 2020-08-25 | Adagene Inc. | libraries, non-human animal, phage, antibody light chain, antibodies, methods for preparing a library, for producing an antibody library and for generating a bispecific antibody and kit |
KR20200045520A (en) | 2017-09-07 | 2020-05-04 | 오거스타 유니버시티 리서치 인스티튜트, 인크. | Antibodies to programmed cell death protein 1 |
US11497756B2 (en) | 2017-09-12 | 2022-11-15 | Sumitomo Pharma Oncology, Inc. | Treatment regimen for cancers that are insensitive to BCL-2 inhibitors using the MCL-1 inhibitor alvocidib |
JP7382922B2 (en) | 2017-09-20 | 2023-11-17 | 中外製薬株式会社 | Dosing regimen for combination therapy using PD-1 system binding antagonists and GPC3 targeting agents |
EP3684801A1 (en) | 2017-09-22 | 2020-07-29 | H. Hoffnabb-La Roche Ag | Multivalent mono- or bispecific recombinant antibodies for analytic purpose |
TW201922780A (en) | 2017-09-25 | 2019-06-16 | 美商健生生物科技公司 | Safe and effective method of treating Lupus with anti-IL12/IL23 antibody |
WO2019075090A1 (en) | 2017-10-10 | 2019-04-18 | Tilos Therapeutics, Inc. | Anti-lap antibodies and uses thereof |
CA3078974A1 (en) | 2017-10-12 | 2019-04-18 | Immunowake Inc. | Vegfr-antibody light chain fusion protein |
US11692037B2 (en) | 2017-10-20 | 2023-07-04 | Hyogo College Of Medicine | Anti-IL-6 receptor antibody-containing medicinal composition for preventing post-surgical adhesion |
US11826414B2 (en) | 2017-10-23 | 2023-11-28 | Cz Biohub Sf, Llc | Measurement of afucosylated IgG Fc glycans and related vaccination methods |
US11897969B2 (en) | 2017-10-26 | 2024-02-13 | The Regents Of The University Of California | Inhibition of oxidation-specific epitopes to treat ischemic reperfusion injury |
CA3080103A1 (en) | 2017-10-31 | 2019-05-09 | Staten Biotechnology B.V. | Anti-apoc3 antibodies and methods of use thereof |
WO2019089594A1 (en) | 2017-10-31 | 2019-05-09 | Immunogen, Inc. | Combination treatment with antibody-drug conjugates and cytarabine |
MX2020004567A (en) | 2017-11-06 | 2020-08-13 | Genentech Inc | Diagnostic and therapeutic methods for cancer. |
JP7165193B2 (en) | 2017-11-27 | 2022-11-02 | パーデュー、ファーマ、リミテッド、パートナーシップ | Humanized antibody targeting human tissue factor |
RU2020120556A (en) | 2017-11-28 | 2021-12-29 | Чугаи Сейяку Кабусики Кайся | LIGAND-BINDING MOLECULE WITH REGULATED LIGAND-BINDING ACTIVITY |
EP3720879B1 (en) | 2017-12-05 | 2022-05-11 | Progastrine et Cancers S.à r.l. | Combination therapy between anti-progastrin antibody and immunotherapy to treat cancer |
AU2018378804A1 (en) | 2017-12-06 | 2020-06-11 | Ensoma, Inc. | Dosing regimens for the mobilization of hematopoietic stem and progenitor cells |
CA3067055A1 (en) | 2017-12-09 | 2019-06-13 | Abbott Laboratories | Methods for aiding in diagnosing and evaluating a traumatic brain injury in a human subject using a combination of gfap and uch-l1 |
CN111094983A (en) | 2017-12-09 | 2020-05-01 | 雅培实验室 | Methods of using Glial Fibrillary Acidic Protein (GFAP) and/or ubiquitin carboxy-terminal hydrolase L1(UCH-L1) to aid in the diagnosis and evaluation of patients who have suffered orthopedic injury and who have suffered or may have suffered a head injury such as mild Traumatic Brain Injury (TBI) |
EP3724229A1 (en) | 2017-12-11 | 2020-10-21 | Amgen Inc. | Continuous manufacturing process for bispecific antibody products |
EP3710484B1 (en) | 2017-12-20 | 2023-10-25 | Harbour Biomed (Shanghai) Co., Ltd | Antibodies binding ctla-4 and uses thereof |
KR20200104886A (en) | 2017-12-28 | 2020-09-04 | 난징 레전드 바이오테크 씨오., 엘티디. | Antibodies and variants against PD-L1 |
TWI817974B (en) | 2017-12-28 | 2023-10-11 | 日商中外製藥股份有限公司 | Cytotoxicity-inducing therapeutic agent |
EP3732202A4 (en) | 2017-12-28 | 2022-06-15 | Nanjing Legend Biotech Co., Ltd. | Single-domain antibodies and variants thereof against tigit |
WO2019133902A2 (en) | 2017-12-28 | 2019-07-04 | Astute Medical, Inc. | Antibodies and assays for ccl14 |
UY38041A (en) | 2017-12-29 | 2019-06-28 | Amgen Inc | CONSTRUCTION OF BIESPECFIC ANTIBODY DIRECTED TO MUC17 AND CD3 |
WO2019137541A1 (en) | 2018-01-15 | 2019-07-18 | Nanjing Legend Biotech Co., Ltd. | Single-domain antibodies and variants thereof against pd-1 |
BR112020013405A2 (en) | 2018-01-25 | 2020-12-01 | Acm Biolabs Pte Ltd. | polymerosomes comprising a soluble encapsulated antigen, as well as methods of its manufacture and use |
WO2019145537A1 (en) | 2018-01-26 | 2019-08-01 | Ecs-Progastrin Sa | Combination of progastrin detection with other cancer biomarkers in cancer diagnosis |
US20210363238A1 (en) | 2018-01-31 | 2021-11-25 | Motokazu Kato | Therapeutic agent for asthma containing il-6 inhibitor |
US20200399376A1 (en) | 2018-02-26 | 2020-12-24 | Genentech, Inc. | Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies |
CN112368579A (en) | 2018-02-27 | 2021-02-12 | Ecs前胃泌素股份有限公司 | Progastrin as biomarker for immunotherapy |
US20210002373A1 (en) | 2018-03-01 | 2021-01-07 | Nextcure, Inc. | KLRG1 Binding Compositions and Methods of Use Thereof |
NL2020520B1 (en) | 2018-03-02 | 2019-09-12 | Labo Bio Medical Invest B V | Multispecific binding molecules for the prevention, treatment and diagnosis of neurodegenerative disorders |
EP3762015A4 (en) | 2018-03-05 | 2022-04-27 | Janssen Biotech, Inc. | Methods of treating crohn's disease with anti-il23 specific antibody |
EP3765499A1 (en) | 2018-03-12 | 2021-01-20 | Zoetis Services LLC | Anti-ngf antibodies and methods thereof |
US11203646B2 (en) | 2018-03-14 | 2021-12-21 | Novimmune Sa | Anti-CD3 epsilon antibodies and methods of use thereof |
US11485782B2 (en) | 2018-03-14 | 2022-11-01 | Beijing Xuanyi Pharmasciences Co., Ltd. | Anti-claudin 18.2 antibodies |
PE20201265A1 (en) | 2018-03-21 | 2020-11-19 | Alx Oncology Inc | ANTIBODIES AGAINST SIGNAL REGULATORY ALPHA PROTEIN AND METHODS OF USE |
WO2019180272A1 (en) | 2018-03-23 | 2019-09-26 | Fundación Instituto De Investigación Sanitaria De Santiago De Compostela | Anti-leptin affinity reagents for use in the treatment of obesity and other leptin-resistance associated diseases |
CA3091733A1 (en) | 2018-03-26 | 2019-10-03 | Glycanostics S.R.O. | Means and methods for glycoprofiling of a protein |
CN111886254B (en) | 2018-03-30 | 2023-12-08 | 南京传奇生物科技有限公司 | Single domain antibodies against LAG-3 and uses thereof |
TWI790370B (en) | 2018-04-02 | 2023-01-21 | 美商必治妥美雅史谷比公司 | Anti-trem-1 antibodies and uses thereof |
EP3773739A1 (en) | 2018-04-12 | 2021-02-17 | MediaPharma S.r.l. | Lgals3bp antibody-drug-conjugate and its use for the treatment of cancer |
AU2019256383A1 (en) | 2018-04-17 | 2020-11-26 | Celldex Therapeutics, Inc. | Anti-CD27 and anti-PD-L1 antibodies and bispecific constructs |
WO2019207159A1 (en) | 2018-04-27 | 2019-10-31 | Fondazione Ebri Rita Levi-Montalcini | Antibody directed against a tau-derived neurotoxic peptide and uses thereof |
TW202014201A (en) | 2018-05-04 | 2020-04-16 | 德商馬克專利公司 | COMBINED INHIBITION OF PD-1/PD-L1, TGFβ AND DNA-PK FOR THE TREATMENT OF CANCER |
JP2021523138A (en) | 2018-05-11 | 2021-09-02 | ヤンセン バイオテツク,インコーポレーテツド | How to treat depression with IL-23 antibody |
US20210261647A1 (en) | 2018-05-15 | 2021-08-26 | Immunomic Therapeutics, Inc | Lamp constructs comprising allergens |
WO2019222130A1 (en) | 2018-05-15 | 2019-11-21 | Immunogen, Inc. | Combination treatment with antibody-drug conjugates and flt3 inhibitors |
TW202005628A (en) | 2018-05-21 | 2020-02-01 | 日商中外製藥股份有限公司 | Lyophilized formulation sealed in glass vial |
UA128113C2 (en) | 2018-05-25 | 2024-04-10 | ЕЛЕКТОР ЕлЕлСі | Anti-sirpa antibodies and methods of use thereof |
US20210364412A1 (en) | 2018-06-01 | 2021-11-25 | NanoView Biosciences, Inc. | Compositions, systems, and methods for enhanced label-free and fluorescence - based detection of nanoparticles |
AU2019282264A1 (en) | 2018-06-05 | 2020-11-26 | Amgen Inc. | Modulating antibody dependent cellular phagocytosis |
WO2019236965A1 (en) | 2018-06-08 | 2019-12-12 | Alector Llc | Anti-siglec-7 antibodies and methods of use thereof |
SG11202012706PA (en) | 2018-06-21 | 2021-01-28 | Yumanity Therapeutics Inc | Compositions and methods for the treatment and prevention of neurological disorders |
BR112020026384A2 (en) | 2018-06-23 | 2021-03-30 | Genentech, Inc. | METHODS FOR TREATING AN INDIVIDUAL WITH LUNG CANCER AND FOR TREATING AN INDIVIDUAL WITH SMALL CELL LUNG CANCER, KITS, ANTIBODY ANTI-PD-L1 AND COMPOSITION |
US11203645B2 (en) | 2018-06-27 | 2021-12-21 | Obi Pharma, Inc. | Glycosynthase variants for glycoprotein engineering and methods of use |
US11884729B2 (en) | 2018-06-29 | 2024-01-30 | ApitBio, Inc | Anti-L1CAM antibodies and uses thereof |
LT3618928T (en) | 2018-07-13 | 2023-04-11 | Alector Llc | Anti-sortilin antibodies and methods of use thereof |
CA3104147A1 (en) | 2018-07-18 | 2020-01-23 | Genentech, Inc. | Methods of treating lung cancer with a pd-1 axis binding antagonist, an antimetabolite, and a platinum agent |
JP2021530697A (en) | 2018-07-18 | 2021-11-11 | ヤンセン バイオテツク,インコーポレーテツド | Sustained response predictor after treatment with anti-IL23 specific antibody |
MX2021000786A (en) | 2018-07-20 | 2021-06-15 | Pf Medicament | Receptor for vista. |
EP3830123A1 (en) | 2018-07-27 | 2021-06-09 | Alector LLC | Anti-siglec-5 antibodies and methods of use thereof |
WO2020025532A1 (en) | 2018-07-30 | 2020-02-06 | Amgen Research (Munich) Gmbh | Prolonged administration of a bispecific antibody construct binding to cd33 and cd3 |
CA3107192A1 (en) | 2018-08-03 | 2020-02-06 | Amgen Research (Munich) Gmbh | Antibody constructs for cldn18.2 and cd3 |
BR112021002130A2 (en) | 2018-08-08 | 2021-05-04 | Genentech, Inc. | liquid formulation, article of manufacture or kit and method for reducing oxidation of a polypeptide |
EP3843757B1 (en) | 2018-08-27 | 2024-04-24 | Affimed GmbH | Cryopreserved nk cells preloaded with an antibody construct |
US20220033511A1 (en) | 2018-09-11 | 2022-02-03 | Amgen Inc. | Methods of modulating antibody-dependent cell-mediated cytotoxicity |
WO2020053325A1 (en) | 2018-09-12 | 2020-03-19 | Acm Biolabs Pte Ltd | Polymersomes comprising a covalently bound antigen as well as methods of making and uses thereof |
WO2020061060A1 (en) | 2018-09-19 | 2020-03-26 | Genentech, Inc. | Therapeutic and diagnostic methods for bladder cancer |
EP4249917A3 (en) | 2018-09-21 | 2023-11-08 | F. Hoffmann-La Roche AG | Diagnostic methods for triple-negative breast cancer |
BR112021005467A2 (en) | 2018-09-24 | 2021-06-22 | Janssen Biotech, Inc. | safe and effective method to treat ulcerative colitis with anti-il12/il23 antibody |
EP3856251A1 (en) | 2018-09-26 | 2021-08-04 | Merck Patent GmbH | Combination of a pd-1 antagonist, an atr inhibitor and a platinating agent for the treatment of cancer |
CN112703204A (en) | 2018-09-28 | 2021-04-23 | 安进公司 | Antibodies to soluble BCMA |
AU2019352017A1 (en) | 2018-10-03 | 2021-05-06 | Staten Biotechnology B.V. | Antibodies specific for human and cynomolgus ApoC3 and methods of use thereof |
US11130802B2 (en) | 2018-10-10 | 2021-09-28 | Tilos Therapeutics, Inc. | Anti-lap antibody variants |
CA3114802A1 (en) | 2018-10-11 | 2020-04-16 | Amgen Inc. | Downstream processing of bispecific antibody constructs |
CN113164447A (en) | 2018-10-15 | 2021-07-23 | 默克专利股份公司 | Combination therapy with DNA alkylating agents and ATR inhibitors |
EP3867646A1 (en) | 2018-10-18 | 2021-08-25 | F. Hoffmann-La Roche AG | Diagnostic and therapeutic methods for sarcomatoid kidney cancer |
WO2020086408A1 (en) | 2018-10-26 | 2020-04-30 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | A high-yield perfusion-based transient gene expression bioprocess |
WO2020092455A2 (en) | 2018-10-29 | 2020-05-07 | The Broad Institute, Inc. | Car t cell transcriptional atlas |
US20200140533A1 (en) | 2018-11-02 | 2020-05-07 | Annexon, Inc. | Compositions and methods for treating brain injury |
EP3877407A1 (en) | 2018-11-05 | 2021-09-15 | F. Hoffmann-La Roche AG | Methods of producing two chain proteins in prokaryotic host cells |
WO2020099533A1 (en) | 2018-11-16 | 2020-05-22 | F. Hoffmann-La Roche Ag | Streptavidin-coated solid phases with a member of a binding pair |
CN113395979A (en) | 2018-11-20 | 2021-09-14 | 詹森生物科技公司 | Safe and effective methods for treating psoriasis with anti-IL-23 specific antibodies |
CN113490499A (en) | 2018-12-04 | 2021-10-08 | 大日本住友制药肿瘤公司 | CDK9 inhibitors and polymorphs thereof as active agents for the treatment of cancer |
WO2020118011A1 (en) | 2018-12-06 | 2020-06-11 | Alexion Pharmaceuticals, Inc. | Anti-alk2 antibodies and uses thereof |
US20220026445A1 (en) | 2018-12-07 | 2022-01-27 | Georgia Tech Research Corporation | Antibodies that bind to natively folded myocilin |
MA54562A (en) | 2018-12-18 | 2021-10-27 | Janssen Biotech Inc | SAFE AND EFFECTIVE METHOD OF TREATING LUPUS WITH AN ANTI-IL12/IL23 ANTIBODY |
TW202043272A (en) | 2019-01-14 | 2020-12-01 | 美商建南德克公司 | Methods of treating cancer with a pd-1 axis binding antagonist and an rna vaccine |
AU2020208828A1 (en) | 2019-01-15 | 2021-08-05 | Janssen Biotech, Inc. | Anti-TNF antibody compositions and methods for the treatment of juvenile idiopathic arthritis |
EA202192038A1 (en) | 2019-01-23 | 2021-10-05 | Янссен Байотек, Инк. | ANTIBODY COMPOSITIONS TO TNF FOR USE IN METHODS FOR TREATMENT OF PSORIATIC ARTHRITIS |
MX2021008561A (en) | 2019-01-23 | 2021-08-19 | Genentech Inc | Methods of producing multimeric proteins in eukaryotic host cells. |
CN113329770A (en) | 2019-01-24 | 2021-08-31 | 中外制药株式会社 | Novel cancer antigen and antibody against said antigen |
EP3917515A1 (en) | 2019-01-29 | 2021-12-08 | Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) | Treating the causative agent in adhesiogenesis |
AU2019427766A1 (en) | 2019-01-30 | 2021-09-16 | Nomocan Pharmaceuticals Llc | Antibodies to M(H)DM2/4 and their use in diagnosing and treating cancer |
CN113396230A (en) | 2019-02-08 | 2021-09-14 | 豪夫迈·罗氏有限公司 | Methods of diagnosis and treatment of cancer |
SG11202108560RA (en) | 2019-02-13 | 2021-09-29 | Brigham & Womens Hospital Inc | Anti-peripheral lymph node addressin antibodies and uses thereof |
CN112703013B (en) | 2019-02-22 | 2022-09-30 | 武汉友芝友生物制药股份有限公司 | CD3 antigen binding fragment and application thereof |
MA55080A (en) | 2019-02-26 | 2022-01-05 | Inspirna Inc | HIGH AFFINITY ANTI-MERTK ANTIBODIES AND ASSOCIATED USES |
JP2022521773A (en) | 2019-02-27 | 2022-04-12 | ジェネンテック, インコーポレイテッド | Dosing for treatment with anti-TIGIT antibody and anti-CD20 antibody or anti-CD38 antibody |
WO2020175689A1 (en) | 2019-02-28 | 2020-09-03 | 学校法人順天堂 | Antibody capable of binding to truncated mutant calreticulin, and diagnostic, prophylactic or therapeutic drug for myeloproliferative neoplasms |
CA3133381A1 (en) | 2019-03-14 | 2020-09-17 | Janssen Biotech, Inc. | Manufacturing methods for producing anti-tnf antibody compositions |
EP3938391A1 (en) | 2019-03-14 | 2022-01-19 | Janssen Biotech, Inc. | Methods for producing anti-tnf antibody compositions |
EA202192508A1 (en) | 2019-03-14 | 2022-03-29 | Янссен Байотек, Инк. | METHODS FOR OBTAINING COMPOSITIONS OF ANTIBODIES TO TNF |
CA3133395A1 (en) | 2019-03-14 | 2020-09-17 | Janssen Biotech, Inc. | Manufacturing methods for producing anti-il12/il23 antibody compositions |
MX2021011196A (en) | 2019-03-15 | 2021-10-22 | Cartesian Therapeutics Inc | Anti-bcma chimeric antigen receptors. |
KR20210141583A (en) | 2019-03-18 | 2021-11-23 | 얀센 바이오테크 인코포레이티드 | Methods of Treating Psoriasis in Children Using Anti-IL-12/IL-23 Antibodies |
US20220153875A1 (en) | 2019-03-19 | 2022-05-19 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule containing antigen-binding domain of which binding activity to antigen is changed depending on mta, and library for obtaining said antigen-binding domain |
WO2020191326A1 (en) | 2019-03-20 | 2020-09-24 | Sumitomo Dainippon Pharma Oncology, Inc. | Treatment of acute myeloid leukemia (aml) with venetoclax failure |
EP3947471A4 (en) | 2019-03-27 | 2023-03-15 | The Trustees of The University of Pennsylvania | Tn-muc1 chimeric antigen receptor (car) t cell therapy |
CN113874392A (en) | 2019-03-28 | 2021-12-31 | 丹尼斯科美国公司 | Engineered antibodies |
US20220213140A1 (en) | 2019-04-10 | 2022-07-07 | Chugai Seiyaku Kabushiki Kaisha | Method for purifying fc region-modified antibody |
US20220204608A1 (en) | 2019-04-17 | 2022-06-30 | Hiroshima University | Therapeutic agent for urological cancer which is characterized by being administered with il-6 inhibitor and ccr2 inhibitor in combination |
EP3958908A1 (en) | 2019-04-24 | 2022-03-02 | Heidelberg Pharma Research GmbH | Amatoxin antibody-drug conjugates and uses thereof |
EP3962947A2 (en) | 2019-05-03 | 2022-03-09 | F. Hoffmann-La Roche AG | Methods of treating cancer with an anti-pd-l1 antibody |
US20200369759A1 (en) | 2019-05-23 | 2020-11-26 | Fibrogen, Inc. | Methods of treatment of muscular dystrophies |
US11780911B2 (en) | 2019-05-23 | 2023-10-10 | Janssen Biotech, Inc. | Method of treating inflammatory bowel disease with a combination therapy of antibodies to IL-23 and TNF alpha |
KR20220029593A (en) | 2019-06-03 | 2022-03-08 | 얀센 바이오테크 인코포레이티드 | Anti-TNF antibody compositions, and methods for the treatment of psoriatic arthritis |
JP2022535534A (en) | 2019-06-03 | 2022-08-09 | ヤンセン バイオテツク,インコーポレーテツド | Anti-TNF Antibodies, Compositions and Methods for Treating Active Ankylosing Spondylitis |
BR112021023735A2 (en) | 2019-06-05 | 2022-01-04 | Chugai Pharmaceutical Co Ltd | Antibody cleavage site binding molecule |
TW202045711A (en) | 2019-06-13 | 2020-12-16 | 美商安進公司 | Automated biomass-based perfusion control in the manufacturing of biologics |
CA3148591A1 (en) | 2019-07-26 | 2021-02-04 | Amgen Inc. | Anti-il13 antigen binding proteins |
WO2021028752A1 (en) | 2019-08-15 | 2021-02-18 | Janssen Biotech, Inc. | Anti-tfn antibodies for treating type i diabetes |
JP2022545741A (en) | 2019-08-30 | 2022-10-28 | アジェナス インコーポレイテッド | ANTI-CD96 ANTIBODY AND METHODS OF USE THEREOF |
JP2022547850A (en) | 2019-09-03 | 2022-11-16 | バイオ - テラ ソリューションズ、リミテッド | Anti-TIGIT immune inhibitor and application |
TW202124439A (en) | 2019-09-04 | 2021-07-01 | 美商建南德克公司 | Cd8 binding agents and uses thereof |
MX2022002981A (en) | 2019-09-10 | 2022-04-06 | Amgen Inc | Purification method for bispecific antigen-binding polypeptides with enhanced protein l capture dynamic binding capacity. |
TW202118512A (en) | 2019-09-12 | 2021-05-16 | 美商建南德克公司 | Compositions and methods of treating lupus nephritis |
US20220411511A1 (en) | 2019-09-26 | 2022-12-29 | Stcube & Co. | Antibodies specific to glycosylated ctla-4 and methods of use thereof |
JP2022548978A (en) | 2019-09-27 | 2022-11-22 | ジェネンテック, インコーポレイテッド | Dosing for Treatment with Drugs Anti-TIGIT and Anti-PD-L1 Antagonist Antibodies |
WO2021072277A1 (en) | 2019-10-09 | 2021-04-15 | Stcube & Co. | Antibodies specific to glycosylated lag3 and methods of use thereof |
CN114641306A (en) | 2019-10-18 | 2022-06-17 | 免疫治疗有限公司 | Improved LAMP constructs comprising cancer antigens |
CA3154413A1 (en) | 2019-11-01 | 2021-05-06 | Yan Lan | Combined inhibition of pd-1, tgf.beta. and atm together with radiotherapy for the treatment of cancer |
WO2021087406A1 (en) | 2019-11-01 | 2021-05-06 | Magenta Therapeutics, Inc. | Dosing regimens for the mobilization of hematopoietic stem and progentor cells |
BR112022008295A2 (en) | 2019-11-05 | 2022-07-26 | Merck Patent Gmbh | COMBINED INHIBITION OF PD-1, TGFBETA AND TIGIT FOR THE TREATMENT OF CANCER |
MX2022005400A (en) | 2019-11-06 | 2022-05-24 | Genentech Inc | Diagnostic and therapeutic methods for treatment of hematologic cancers. |
AU2020381536A1 (en) | 2019-11-13 | 2022-04-21 | Amgen Inc. | Method for reduced aggregate formation in downstream processing of bispecific antigen-binding molecules |
EP3825330A1 (en) | 2019-11-19 | 2021-05-26 | International-Drug-Development-Biotech | Anti-cd117 antibodies and methods of use thereof |
KR20220110537A (en) | 2019-12-05 | 2022-08-08 | 알렉터 엘엘씨 | How to Use Anti-TREM2 Antibodies |
US11897950B2 (en) | 2019-12-06 | 2024-02-13 | Augusta University Research Institute, Inc. | Osteopontin monoclonal antibodies |
WO2021118930A2 (en) | 2019-12-09 | 2021-06-17 | Genentech, Inc. | Anti-pd-l1 antibody formulations |
EP4073119A1 (en) | 2019-12-12 | 2022-10-19 | Alector LLC | Methods of use of anti-cd33 antibodies |
MX2022007688A (en) | 2019-12-20 | 2022-07-19 | Amgen Inc | Mesothelin-targeted cd40 agonistic multispecific antibody constructs for the treatment of solid tumors. |
KR20220119467A (en) | 2019-12-27 | 2022-08-29 | 아피메트 게엠베하 | Methods of making the bispecific FCYRIII X CD30 antibody construct |
CA3164037A1 (en) | 2020-01-08 | 2021-07-15 | Synthis Therapeutics, Inc. | Alk5 inhibitor conjugates and uses thereof |
US20230093169A1 (en) | 2020-01-22 | 2023-03-23 | Amgen Research (Munch) Gmbh | Combinations of antibody constructs and inhibitors of cytokine release syndrome and uses thereof |
WO2021194481A1 (en) | 2020-03-24 | 2021-09-30 | Genentech, Inc. | Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies |
WO2022050954A1 (en) | 2020-09-04 | 2022-03-10 | Genentech, Inc. | Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies |
CN116650628A (en) | 2020-01-31 | 2023-08-29 | 基因泰克公司 | Method for inducing neoepitope specific T cells with PD-1 axis binding antagonists and RNA vaccines |
CN113248611A (en) | 2020-02-13 | 2021-08-13 | 湖南华康恒健生物技术有限公司 | anti-BCMA antibody, pharmaceutical composition and application thereof |
US20230159637A1 (en) | 2020-02-24 | 2023-05-25 | Alector Llc | Methods of use of anti-trem2 antibodies |
WO2021177980A1 (en) | 2020-03-06 | 2021-09-10 | Genentech, Inc. | Combination therapy for cancer comprising pd-1 axis binding antagonist and il6 antagonist |
EP4114860A1 (en) | 2020-03-06 | 2023-01-11 | Go Therapeutics, Inc. | Anti-glyco-cd44 antibodies and their uses |
JP2023517889A (en) | 2020-03-10 | 2023-04-27 | マサチューセッツ インスティテュート オブ テクノロジー | Compositions and methods for immunotherapy of NPM1c-positive cancers |
EP4118113A1 (en) | 2020-03-12 | 2023-01-18 | Amgen Inc. | Method for treatment and prophylaxis of crs in patients comprising a combination of bispecifc antibodies binding to cds x cancer cell and tnfalpha or il-6 inhibitor |
WO2021188851A1 (en) | 2020-03-19 | 2021-09-23 | Amgen Inc. | Antibodies against mucin 17 and uses thereof |
CN115335082A (en) | 2020-03-27 | 2022-11-11 | 光爱科技公司 | Medicinal product for killing tumor cells |
WO2021202473A2 (en) | 2020-03-30 | 2021-10-07 | Danisco Us Inc | Engineered antibodies |
CN115362171A (en) | 2020-03-31 | 2022-11-18 | 百奥泰生物制药股份有限公司 | Antibody for treating coronavirus, fusion protein and application thereof |
MX2022012182A (en) | 2020-04-03 | 2022-12-08 | Alector Llc | Methods of use of anti-trem2 antibodies. |
CN115698717A (en) | 2020-04-03 | 2023-02-03 | 基因泰克公司 | Methods of treatment and diagnosis of cancer |
CN115379858A (en) | 2020-04-06 | 2022-11-22 | 光爱科技公司 | Medicinal product for killing tumor cells |
EP4132971A1 (en) | 2020-04-09 | 2023-02-15 | Merck Sharp & Dohme LLC | Affinity matured anti-lap antibodies and uses thereof |
EP4136459A1 (en) | 2020-04-13 | 2023-02-22 | Abbott Laboratories | Methods, complexes and kits for detecting or determining an amount of a ss-coronavirus antibody in a sample |
WO2021209458A1 (en) | 2020-04-14 | 2021-10-21 | Ares Trading S.A. | Combination treatment of cancer |
JP2023106635A (en) | 2020-04-17 | 2023-08-02 | 中外製薬株式会社 | Bispecific antigen binding molecules and compositions related thereto, uses, kits and methods for producing compositions |
JP2023523145A (en) | 2020-04-27 | 2023-06-02 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | Isotype-independent antibody against lipoprotein (a) |
AU2021263754A1 (en) | 2020-04-27 | 2022-12-01 | Ensoma, Inc. | Methods and compositions for transducing hematopoietic stem and progenitor cells in vivo |
WO2021222167A1 (en) | 2020-04-28 | 2021-11-04 | Genentech, Inc. | Methods and compositions for non-small cell lung cancer immunotherapy |
AU2021275049A1 (en) | 2020-05-19 | 2022-12-22 | Amgen Inc. | MAGEB2 binding constructs |
KR20230014719A (en) | 2020-05-22 | 2023-01-30 | 추가이 세이야쿠 가부시키가이샤 | Antibodies that neutralize substances with coagulation factor VIII (F.VIII) alternative activity |
EP3915641A1 (en) | 2020-05-27 | 2021-12-01 | International-Drug-Development-Biotech | Anti-cd5 antibodies and methods of use thereof |
JP2023527972A (en) | 2020-05-29 | 2023-07-03 | アムジエン・インコーポレーテツド | Reduced Adverse Effect Administration of Bispecific Constructs that Bind CD33 and CD3 |
US20230235080A1 (en) | 2020-06-03 | 2023-07-27 | Bionecure Therapeutics, Inc. | Trophoblast cell-surface antigen-2 (trop-2) antibodies |
WO2021249969A1 (en) | 2020-06-10 | 2021-12-16 | Merck Patent Gmbh | Combination product for the treatment of cancer diseases |
KR20230025691A (en) | 2020-06-16 | 2023-02-22 | 제넨테크, 인크. | Methods and compositions for treating triple negative breast cancer |
WO2021257124A1 (en) | 2020-06-18 | 2021-12-23 | Genentech, Inc. | Treatment with anti-tigit antibodies and pd-1 axis binding antagonists |
JPWO2021261546A1 (en) | 2020-06-24 | 2021-12-30 | ||
WO2022006562A1 (en) | 2020-07-03 | 2022-01-06 | Dana-Farber Cancer Institute, Inc. | Multispecific coronavirus antibodies |
US20230322867A1 (en) | 2020-07-24 | 2023-10-12 | Amgen Inc. | Immunogens derived from sars-cov2 spike protein |
CN116194473A (en) | 2020-07-28 | 2023-05-30 | 中外制药株式会社 | Needled prefilled syringe formulation with needle shield comprising a new engineered antibody |
CA3190649A1 (en) | 2020-07-31 | 2022-02-03 | Chugai Seiyaku Kabushiki Kaisha | Pharmaceutical composition comprising cell expressing chimeric receptor |
AU2021316017A1 (en) | 2020-07-31 | 2023-02-16 | F. Hoffmann-La Roche Ag | Anti-integrin beta7 antibody formulations and devices |
JP2023536602A (en) | 2020-08-03 | 2023-08-28 | ジェネンテック, インコーポレイテッド | Diagnostic and therapeutic methods for lymphoma |
US20220043000A1 (en) | 2020-08-04 | 2022-02-10 | Abbott Laboratories | Methods and kits for detecting sars-cov-2 protein in a sample |
US20230287126A1 (en) | 2020-08-07 | 2023-09-14 | Bio-Thera Solutions, Ltd. | Anti-pd-l1 antibody and use thereof |
WO2022036146A1 (en) | 2020-08-12 | 2022-02-17 | Genentech, Inc. | Diagnostic and therapeutic methods for cancer |
CN114106173A (en) | 2020-08-26 | 2022-03-01 | 上海泰槿生物技术有限公司 | anti-OX 40 antibodies, pharmaceutical compositions and uses thereof |
CA3192768A1 (en) | 2020-08-27 | 2022-03-03 | Juntendo Educational Foundation | Anti-cleaved mutant calr-cd3 bispecific antibody and pharmaceutical composition |
JP2023539279A (en) | 2020-08-31 | 2023-09-13 | ジェネンテック, インコーポレイテッド | Method for producing antibodies |
EP4208197A1 (en) | 2020-09-04 | 2023-07-12 | Rutgers, The State University of New Jersey | Sars-cov-2 vaccines and antibodies |
US20230372484A1 (en) | 2020-09-14 | 2023-11-23 | Vor Biopharma Inc. | Chimeric antigen receptors for treatment of cancer |
IL300314A (en) | 2020-10-08 | 2023-04-01 | Affimed Gmbh | Trispecific binders |
US20230382978A1 (en) | 2020-10-15 | 2023-11-30 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Antibody specific for sars-cov-2 receptor binding domain and therapeutic methods |
WO2022087274A1 (en) | 2020-10-21 | 2022-04-28 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Antibodies that neutralize type-i interferon (ifn) activity |
WO2022093981A1 (en) | 2020-10-28 | 2022-05-05 | Genentech, Inc. | Combination therapy comprising ptpn22 inhibitors and pd-l1 binding antagonists |
US20230406909A1 (en) | 2020-11-02 | 2023-12-21 | Roche Diagnostics Operations, Inc. | Sars-cov-2 nucleocapsid antibodies |
WO2022090529A1 (en) | 2020-11-02 | 2022-05-05 | Ares Trading S.A. | Combination treatment of cancer |
EP4237001A1 (en) | 2020-11-02 | 2023-09-06 | Ares Trading S.A. | Combination treatment of cancer |
KR20230098335A (en) | 2020-11-06 | 2023-07-03 | 암젠 인크 | Antigen binding domains with reduced clipping ratio |
CN116635421A (en) | 2020-11-06 | 2023-08-22 | 安进公司 | Polypeptide constructs that bind CD3 |
UY39508A (en) | 2020-11-06 | 2022-05-31 | Amgen Res Munich Gmbh | BSPECIFIC ANTIGEN-BINDING MOLECULES WITH MULTIPLE TARGETS OF ENHANCED SELECTIVITY |
BR112023008629A2 (en) | 2020-11-06 | 2023-10-03 | Amgen Inc | POLYPEPTIDE CONSTRUCTS THAT SELECTIVELY BIND CLDN6 AND CD3 |
WO2022095970A1 (en) | 2020-11-06 | 2022-05-12 | 百奥泰生物制药股份有限公司 | Bispecific antibody and use thereof |
CN114478770A (en) | 2020-11-12 | 2022-05-13 | 迈威(上海)生物科技股份有限公司 | Antibodies and methods of making same |
CA3198161A1 (en) | 2020-12-01 | 2022-06-09 | Beth MCQUISTON | Use of one or more biomarkers to determine traumatic brain injury (tbi) in a subject having received a head computerized tomography scan that is negative for a tbi |
WO2023102384A1 (en) | 2021-11-30 | 2023-06-08 | Abbott Laboratories | Use of one or more biomarkers to determine traumatic brain injury (tbi) in a subject having received a head computerized tomography scan that is negative for a tbi |
WO2022140797A1 (en) | 2020-12-23 | 2022-06-30 | Immunowake Inc. | Immunocytokines and uses thereof |
EP4271998A1 (en) | 2020-12-30 | 2023-11-08 | Abbott Laboratories | Methods for determining sars-cov-2 antigen and anti-sars-cov-2 antibody in a sample |
JP2024512324A (en) | 2021-03-05 | 2024-03-19 | ジーオー セラピューティクス,インコーポレイテッド | Anti-glycoCD44 antibodies and their uses |
IL305758A (en) | 2021-03-10 | 2023-11-01 | Immunowake Inc | Immunomodulatory molecules and uses thereof |
EP4305062A1 (en) | 2021-03-12 | 2024-01-17 | Janssen Biotech, Inc. | Method of treating psoriatic arthritis patients with inadequate response to tnf therapy with anti-il23 specific antibody |
IL305802A (en) | 2021-03-12 | 2023-11-01 | Janssen Biotech Inc | Safe and effective method of treating psoriatic arthritis with anti-il23 specific antibody |
JPWO2022191306A1 (en) | 2021-03-12 | 2022-09-15 | ||
WO2022198192A1 (en) | 2021-03-15 | 2022-09-22 | Genentech, Inc. | Compositions and methods of treating lupus nephritis |
WO2022197776A1 (en) | 2021-03-16 | 2022-09-22 | Magenta Therapeutics, Inc. | Dosing regimens for hematopoietic stem cell mobilization for stem cell transplants in multiple myeloma patients |
JP2024511137A (en) | 2021-03-22 | 2024-03-12 | ノビミューン エスアー | Bispecific antibodies targeting CD47 and PD-L1 and methods of use thereof |
JP2024512574A (en) | 2021-03-22 | 2024-03-19 | ノビミューン エスアー | Bispecific antibodies targeting CD47 and PD-L1 and methods of use thereof |
JP2024514530A (en) | 2021-04-02 | 2024-04-02 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | Antibodies against truncated CDCP1 and uses thereof |
CA3215594A1 (en) | 2021-04-02 | 2022-10-06 | Agnieszka KIELCZEWSKA | Mageb2 binding constructs |
CN117202897A (en) | 2021-04-09 | 2023-12-08 | 基因泰克公司 | Combination therapy using RAF inhibitors and PD-1 axis inhibitors |
AU2022258552A1 (en) | 2021-04-12 | 2023-10-19 | Acm Biolabs Pte Ltd | Polymersomes comprising a soluble encapsulated polynucleotide and an ionizable lipid as well as methods of making and uses thereof |
EP4333900A2 (en) | 2021-05-03 | 2024-03-13 | Merck Patent GmbH | Her2 targeting fc antigen binding fragment-drug conjugates |
TW202307007A (en) | 2021-05-04 | 2023-02-16 | 美商再生元醫藥公司 | Multispecific fgf21 receptor agonists and their uses |
EP4334354A1 (en) | 2021-05-06 | 2024-03-13 | Dana-Farber Cancer Institute, Inc. | Antibodies against alk and methods of use thereof |
CN117279947A (en) | 2021-05-06 | 2023-12-22 | 安进研发(慕尼黑)股份有限公司 | Antigen binding molecules targeting CD20 and CD22 for use in proliferative diseases |
CA3216320A1 (en) | 2021-05-18 | 2022-11-24 | Abbott Laboratories | Methods of evaluating brain injury in a pediatric subject |
AU2022280341A1 (en) | 2021-05-25 | 2024-01-04 | Merck Patent Gmbh | Egfr targeting fc antigen binding fragment-drug conjugates |
WO2022258622A1 (en) | 2021-06-07 | 2022-12-15 | Ares Trading S.A. | Combination treatment of cancer |
WO2022263357A1 (en) | 2021-06-14 | 2022-12-22 | Argenx Iip Bv | Anti-il-9 antibodies and methods of use thereof |
CA3222291A1 (en) | 2021-06-14 | 2022-12-22 | Jaime MARINO | Methods of diagnosing or aiding in diagnosis of brain injury caused by acoustic energy, electromagnetic energy, an over pressurization wave, and/or blast wind |
KR20240034215A (en) | 2021-07-09 | 2024-03-13 | 얀센 바이오테크 인코포레이티드 | Manufacturing Methods for Producing Anti-IL12/IL23 Antibody Compositions |
WO2023281463A1 (en) | 2021-07-09 | 2023-01-12 | Janssen Biotech, Inc. | Manufacturing methods for producing anti-tnf antibody compositions |
US20230040065A1 (en) | 2021-07-09 | 2023-02-09 | Janssen Biotech, Inc. | Manufacturing Methods for Producing Anti-TNF Antibody Compositions |
WO2023010118A1 (en) | 2021-07-29 | 2023-02-02 | Vor Biopharma Inc. | Nfat-responsive reporter systems for assessing chimeric antigen receptor activation and methods of making and using the same |
WO2023007023A1 (en) | 2021-07-30 | 2023-02-02 | Affimed Gmbh | Duplexbodies |
CA3228178A1 (en) | 2021-08-05 | 2023-02-09 | Go Therapeutics, Inc. | Anti-glyco-muc4 antibodies and their uses |
IL310535A (en) | 2021-08-10 | 2024-03-01 | Byomass Inc | Anti-gdf15 antibodies, compositions and uses thereof |
WO2023023491A1 (en) | 2021-08-16 | 2023-02-23 | Hemogenyx Pharmaceuticals Llc | Anti-flt3 antibodies, cars, car t cells and methods of use |
IL310861A (en) | 2021-08-17 | 2024-04-01 | Hemogenyx Pharmaceuticals Llc | Bispecific anti-flt3/cd3 antibodies and methods of use |
AU2022339759A1 (en) | 2021-08-31 | 2024-03-07 | Abbott Laboratories | Methods and systems of diagnosing brain injury |
AU2022339667A1 (en) | 2021-09-03 | 2024-04-11 | Go Therapeutics, Inc. | Anti-glyco-cmet antibodies and their uses |
WO2023034571A1 (en) | 2021-09-03 | 2023-03-09 | Go Therapeutics, Inc. | Anti-glyco-lamp1 antibodies and their uses |
WO2023056268A1 (en) | 2021-09-30 | 2023-04-06 | Abbott Laboratories | Methods and systems of diagnosing brain injury |
WO2023057871A1 (en) | 2021-10-04 | 2023-04-13 | Novartis Ag | Surfactant stabilizers |
TW202333781A (en) | 2021-10-08 | 2023-09-01 | 日商中外製藥股份有限公司 | Anti-hla-dq2.5 antibody formulation |
WO2023069421A1 (en) | 2021-10-18 | 2023-04-27 | Byomass Inc. | Anti-activin a antibodies, compositions and uses thereof |
WO2023072904A1 (en) | 2021-10-26 | 2023-05-04 | F. Hoffmann-La Roche Ag | Monoclonal antibodies specific for sars-cov-2 rbd |
WO2023073615A1 (en) | 2021-10-29 | 2023-05-04 | Janssen Biotech, Inc. | Methods of treating crohn's disease with anti-il23 specific antibody |
CA3233696A1 (en) | 2021-11-03 | 2023-05-11 | Joachim Koch | Bispecific cd16a binders |
WO2023079493A1 (en) | 2021-11-03 | 2023-05-11 | Affimed Gmbh | Bispecific cd16a binders |
WO2023081471A1 (en) | 2021-11-05 | 2023-05-11 | Dana-Farber Cancer Institute, Inc. | Human broadly crossreactive influenza monoclonal antibodies and methods of use thereof |
WO2023081898A1 (en) | 2021-11-08 | 2023-05-11 | Alector Llc | Soluble cd33 as a biomarker for anti-cd33 efficacy |
US20230151087A1 (en) | 2021-11-15 | 2023-05-18 | Janssen Biotech, Inc. | Methods of Treating Crohn's Disease with Anti-IL23 Specific Antibody |
US20230159633A1 (en) | 2021-11-23 | 2023-05-25 | Janssen Biotech, Inc. | Method of Treating Ulcerative Colitis with Anti-IL23 Specific Antibody |
WO2023097024A1 (en) | 2021-11-24 | 2023-06-01 | Dana-Farber Cancer Institute, Inc. | Antibodies against ctla-4 and methods of use thereof |
WO2023114544A1 (en) | 2021-12-17 | 2023-06-22 | Dana-Farber Cancer Institute, Inc. | Antibodies and uses thereof |
WO2023111168A1 (en) | 2021-12-17 | 2023-06-22 | F. Hoffmann-La Roche Ag | A novel antibody for detection of amyloid beta 42 (aβ42) |
WO2023114543A2 (en) | 2021-12-17 | 2023-06-22 | Dana-Farber Cancer Institute, Inc. | Platform for antibody discovery |
WO2023114978A1 (en) | 2021-12-17 | 2023-06-22 | Abbott Laboratories | Systems and methods for determining uch-l1, gfap, and other biomarkers in blood samples |
WO2023122213A1 (en) | 2021-12-22 | 2023-06-29 | Byomass Inc. | Targeting gdf15-gfral pathway cross-reference to related applications |
US20230213536A1 (en) | 2021-12-28 | 2023-07-06 | Abbott Laboratories | Use of biomarkers to determine sub-acute traumatic brain injury (tbi) in a subject having received a head computerized tomography (ct) scan that is negative for a tbi or no head ct scan |
WO2023147107A1 (en) | 2022-01-31 | 2023-08-03 | Byomass Inc. | Myeloproliferative conditions |
WO2023150652A1 (en) | 2022-02-04 | 2023-08-10 | Abbott Laboratories | Lateral flow methods, assays, and devices for detecting the presence or measuring the amount of ubiquitin carboxy-terminal hydrolase l1 and/or glial fibrillary acidic protein in a sample |
WO2023164516A1 (en) | 2022-02-23 | 2023-08-31 | Alector Llc | Methods of use of anti-trem2 antibodies |
WO2023169896A1 (en) | 2022-03-09 | 2023-09-14 | Astrazeneca Ab | BINDING MOLECULES AGAINST FRα |
WO2023170216A1 (en) | 2022-03-11 | 2023-09-14 | Astrazeneca Ab | A SCORING METHOD FOR AN ANTI-FRα ANTIBODY-DRUG CONJUGATE THERAPY |
WO2023178357A1 (en) | 2022-03-18 | 2023-09-21 | Evolveimmune Therapeutics, Inc. | Bispecific antibody fusion molecules and methods of use thereof |
EP4245772A1 (en) | 2022-03-18 | 2023-09-20 | Netris Pharma | Anti-netrin-1 antibody to treat liver inflammation |
EP4249509A1 (en) | 2022-03-22 | 2023-09-27 | Netris Pharma | Anti-netrin-1 antibody against arthritis-associated pain |
WO2023186968A1 (en) | 2022-03-29 | 2023-10-05 | Netris Pharma | Novel mcl-1 inhibitor and combination of mcl-1 and a bh3 mimetic, such as a bcl-2 inhibitor |
WO2023187707A1 (en) | 2022-03-30 | 2023-10-05 | Janssen Biotech, Inc. | Method of treating mild to moderate psoriasis with il-23 specific antibody |
US20230355792A1 (en) | 2022-04-07 | 2023-11-09 | Heidelberg Pharma Research Gmbh | Methods of improving the therapeutic index |
WO2023201201A1 (en) | 2022-04-10 | 2023-10-19 | Immunomic Therapeutics, Inc. | Bicistronic lamp constructs comprising immune response enhancing genes and methods of use thereof |
WO2023215498A2 (en) | 2022-05-05 | 2023-11-09 | Modernatx, Inc. | Compositions and methods for cd28 antagonism |
TW202346368A (en) | 2022-05-12 | 2023-12-01 | 德商安美基研究(慕尼黑)公司 | Multichain multitargeting bispecific antigen-binding molecules of increased selectivity |
WO2023223265A1 (en) | 2022-05-18 | 2023-11-23 | Janssen Biotech, Inc. | Method for evaluating and treating psoriatic arthritis with il23 antibody |
WO2023235415A1 (en) | 2022-06-01 | 2023-12-07 | Genentech, Inc. | Method to identify a patient with an increased likelihood of chemotherapy-induced peripheral neuropathy |
WO2023240124A1 (en) | 2022-06-07 | 2023-12-14 | Regeneron Pharmaceuticals, Inc. | Pseudotyped viral particles for targeting tcr-expressing cells |
WO2023240109A1 (en) | 2022-06-07 | 2023-12-14 | Regeneron Pharmaceuticals, Inc. | Multispecific molecules for modulating t-cell activity, and uses thereof |
WO2023240058A2 (en) | 2022-06-07 | 2023-12-14 | Genentech, Inc. | Prognostic and therapeutic methods for cancer |
WO2024006876A1 (en) | 2022-06-29 | 2024-01-04 | Abbott Laboratories | Magnetic point-of-care systems and assays for determining gfap in biological samples |
WO2024015953A1 (en) | 2022-07-15 | 2024-01-18 | Danisco Us Inc. | Methods for producing monoclonal antibodies |
WO2024039670A1 (en) | 2022-08-15 | 2024-02-22 | Dana-Farber Cancer Institute, Inc. | Antibodies against cldn4 and methods of use thereof |
WO2024039672A2 (en) | 2022-08-15 | 2024-02-22 | Dana-Farber Cancer Institute, Inc. | Antibodies against msln and methods of use thereof |
US20240092859A1 (en) | 2022-08-18 | 2024-03-21 | Immunocore Ltd | T cell receptors and fusion proteins thereof |
WO2024059675A2 (en) | 2022-09-14 | 2024-03-21 | Amgen Inc. | Bispecific molecule stabilizing composition |
WO2024059708A1 (en) | 2022-09-15 | 2024-03-21 | Abbott Laboratories | Biomarkers and methods for differentiating between mild and supermild traumatic brain injury |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1994002602A1 (en) * | 1992-07-24 | 1994-02-03 | Cell Genesys, Inc. | Generation of xenogeneic antibodies |
WO1994025585A1 (en) * | 1993-04-26 | 1994-11-10 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
WO1996033735A1 (en) * | 1995-04-27 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5204244A (en) * | 1987-10-27 | 1993-04-20 | Oncogen | Production of chimeric antibodies by homologous recombination |
WO1991000906A1 (en) * | 1989-07-12 | 1991-01-24 | Genetics Institute, Inc. | Chimeric and transgenic animals capable of producing human antibodies |
-
1995
- 1995-04-28 CA CA002219486A patent/CA2219486A1/en not_active Abandoned
- 1995-04-28 WO PCT/US1995/005500 patent/WO1996034096A1/en not_active Application Discontinuation
- 1995-04-28 AU AU24668/95A patent/AU2466895A/en not_active Abandoned
- 1995-04-28 EP EP95918935A patent/EP0823941A4/en not_active Withdrawn
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1994002602A1 (en) * | 1992-07-24 | 1994-02-03 | Cell Genesys, Inc. | Generation of xenogeneic antibodies |
WO1994025585A1 (en) * | 1993-04-26 | 1994-11-10 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
WO1996033735A1 (en) * | 1995-04-27 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
Non-Patent Citations (2)
Title |
---|
JAKOBOVITS A ET AL: "PRODUCTION OF ANTIGEN-SPECIFIC HUMAN ANTIBODIES FROM MICE ENGINEERED WITH HUMAN HEAVY AND LIGHT CHAIN YACS", ANNALS OF THE NEW YORK ACADEMY OF SCIENCES,US,NEW YORK ACADEMY OF SCIENCES, NEW YORK, NY, vol. 764, 29 September 1995 (1995-09-29), pages 525 - 535, XP002067728, ISSN: 0077-8923 * |
See also references of WO9634096A1 * |
Also Published As
Publication number | Publication date |
---|---|
AU2466895A (en) | 1996-11-18 |
WO1996034096A1 (en) | 1996-10-31 |
CA2219486A1 (en) | 1996-10-31 |
EP0823941A1 (en) | 1998-02-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0823941A4 (en) | Human antibodies derived from immunized xenomice | |
IL136335A0 (en) | Monoclonal human natural antibodies | |
PL311926A1 (en) | Anti-alphav-integrinic monoclonal antibodies | |
IL128406A0 (en) | Monoclonal antibodies | |
IL104620A (en) | Humanized monoclonal antibodies against human interleukin-5 | |
HK1015282A1 (en) | High affinity human monoclonal antibodies specificfor rsv f-protein. | |
AU1462300A (en) | Human pan-hcv human monoclonal antibodies | |
ZA979599B (en) | Humanized anti-CD11a antibodies | |
AU5365296A (en) | Human monoclonal antibody against lung carcinoma | |
AP2001002213A0 (en) | Human monoclonal antibodies to ctla-4 | |
IL130864A0 (en) | Monoclonal antibodies to human cd6 | |
IL108199A0 (en) | Monoclonal antibodies against the human il-4 receptor and hybridomas producing the same | |
EP0809806A4 (en) | Monoclonal antibodies for human osteogenic cell surface antigens | |
ZA962280B (en) | RAGE tumor rejection antigens | |
AU6702998A (en) | Anti-alphabeta3 humanized monoclonal antibodies | |
HUP9800613A3 (en) | Humanized antibody against human fas-antigene | |
EP0977590A4 (en) | Human monoclonal antibodies | |
AU5021796A (en) | Recombinant human anti-lewis b antibodies | |
HUP9601394A1 (en) | Two-function brassiere | |
IL102088A0 (en) | Me20:monoclonal antibodies and antigen for human melanoma | |
ZA941645B (en) | Antibodies specifically reactive against human prostate specific antigen. | |
GB9718911D0 (en) | Monoclonal antibodies | |
AU1809695A (en) | Tumor associated monoclonal antibody 123av16 | |
AU2828795A (en) | Monoclonal antibodies for the reduction of anti-xenogeneic immune responses | |
AU4775899A (en) | Human monoclonal antibodies against the tumor antigen uk114 and lymphocyte cellsand hybridomas for their production |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 19971128 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20010806 |
|
AK | Designated contracting states |
Kind code of ref document: A4 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE |
|
RIC1 | Information provided on ipc code assigned before grant |
Free format text: 7C 12N 15/00 A, 7C 07K 16/00 B |
|
17Q | First examination report despatched |
Effective date: 20020205 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20030308 |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: WD Ref document number: 1009153 Country of ref document: HK |